Methods and compositions comprising prokaryotic argonaute and pna

The use of PNP editors, combining PNAs and prokaryotic Argonaute proteins, addresses the limitations of current genome editing technologies by enabling precise and efficient DNA modification at physiological temperatures, overcoming specificity and delivery challenges, and allowing editing of organellar genomes.

WO2024241203A1PCT designated stage expired Publication Date: 2024-11-28KING ABDULLAH UNIV OF SCI & TECH
View PDF 36 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/054908
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-20
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current genome editing technologies, such as CRISPR, face challenges with specificity, cargo delivery, and editing organellar genomes, and prokaryotic Argonaute proteins have limited activity at physiological temperatures and efficiency on various DNA sequences, hindering their application in gene editing.

Method used

The development of compositions combining peptide nucleic acids (PNAs) with DNA-targeting nucleic acids and prokaryotic Argonaute proteins, forming PNP editors, which enable site-specific DNA modification by binding to predetermined target regions through non-covalent interactions, allowing for precise editing of various DNA sequences, including organellar genomes.

Benefits of technology

The PNP editors achieve site-specific and efficient DNA modification at physiological temperatures, overcoming the limitations of existing technologies by providing high specificity and flexibility in targeting any DNA sequence, including those in mitochondria and chloroplasts, with reduced off-target activities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000026_0001
    Figure IMGF000026_0001
  • Figure IMGF000027_0001
    Figure IMGF000027_0001
  • Figure IMGF000028_0001
    Figure IMGF000028_0001
Patent Text Reader

Abstract

Compositions and methods are provided, for site-specific modification of a target DNA. Compositions, herein "PNP editors" for targeted DNA modification, (a) include site- directed modifying polypeptides, in some forms with nuclease activity, and in other forms without nuclease activity; (b) DNA-targeting RNA or DNA, herein, guide oligonucleotides and (c) a selected PNA. The DNA-targeting RNA or DNA and its site-directed modifying polypeptide (i.e., site-directed polypeptide) form a complex (i.e., bind via non-covalent interactions). The DNA-targeting RNA or DNA provides target specificity to the complex by comprising a nucleotide sequence that is complementary to a sequence of a target DNA. The site-directed modifying polypeptide of the complex provides the site-specific activity. Methods for site-specific modification of a target DNA and / or a polypeptide associated with the target DNA includes contacting the target nucleic acid with the disclosed compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] METHODS AND COMPOSITIONS COMPRISING PROKARYOTIC ARGONAUTE AND PNA

[0002] CROSS-REFERENCE TO RELATED APPLICATION

[0003] The present application claims priority to G.B. Patent Application No. 2307563.3, filed May 19, 2023, the contents of which are hereby incorporated by reference in their entirety.

[0004] FIELD OF THE INVENTION

[0005] The disclosed invention is generally in the field of gene editing.

[0006] BACKGROUND OF THE INVENTION

[0007] Harnessing natural molecular mechanisms to develop powerful genome editing tools has enabled key applications in functional gene analysis, biotechnology and gene therapy (Anzalone, Koblan, and Liu 2020; H. Wang, La Russa, and Qi 2016). Zinc finger nucleases (ZFN), transcription activators-like effector nucleases (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR) have been used for genome editing applications in diverse eukaryotic species (Bibi ova et al. 2001). Each of these platforms suffers from challenges that limit its clinical applications; namely, specificity, cargo delivery of the reagents, and editing organellar genomes are limitations in these technologies (Boch et al. 2009). For example, CRISPR systems are quite efficient but suffer from off-target activities and enormous delivery challenges due to the size of the Cas proteins. There is a pressing need to develop alternative gene-editing technologies that overcome these challenges. Although CRISPR-Cas systems have revolutionized our ability to precisely modify the genome sequence, there still remains a considerable need to develop tools that can be delivered efficiently to target cells, including the editing of organellar genomes, and carry no off-target activities, and possess design flexibility that are not limited by the target sequence requirement, for example the requirement of PAM sequence for CRISPR enzymes.

[0008] Argonaute proteins exist in all domains of life (Meister 2013; Swarts, Makarova, et al. 2014). In eukaryotes, eukaryotic Argonaute (eAgo) proteins bind small non-coding RNAs and utilize them to guide the cleavage of complementary. Prokaryotic Argonaute (pAgo) proteins function as an innate immune system in bacterial and archaeal species to fend off invasive genetic elements from phages and conjugative plasmids.

[0009] The lack of knowledge on how pAgo proteins unwind and bind DNA targets limited the use and development of these proteins as programmable DNA scissors for in vitro and in vivo applications. There have been immense efforts to harness and develop pAgo proteins for diverse DNA manipulations with the goal of developing these proteins as programmable DNA editors for genome editing applications. It was shown that CbAgo, KmAgo and LrAgo can be programmed with DNA guides and cut ssDNA and dsDNA sequences (Kuzmenko et al. 2019; Zheng et al. 2022; Hegge et al. 2019). However, these mesophilic pAgo proteins showed very low activity at 37°C and with low efficiency and efficient cleavage activities were shown only at 55°C and at AT -rich regions on supercoiled DNA substrates (Kuzmenko et al. 2019). The lack of pAgo activities at physiological temperatures and on any DNA sequence precluded their translational applications in gene editing and biotechnology.

[0010] There exist a need for improved compositions and methods that allow for gene editing.

[0011] It is an object of the present invention to provide compositions for in vivo and in vitro gene editing.

[0012] It is still an object of the present invention to provide methods for in vivo and in vitro gene editing.

[0013] BRIEF SUMMARY OF THE INVENTION

[0014] Compositions including a peptide nucleic (PNA) in combination with DNA-targeting nucleic acids that comprises a targeting sequence and, together with a DNA nuclease, provides for site-specific modification of a target DNA.

[0015] Features of the present disclosure include compositions, herein “PNP editors” for targeted DNA modification that (a) include site-directed modifying polypeptides, in some forms with nuclease activity, and in other forms without nuclease activity; (b) DNA-targeting RNA or DNA, herein, guide oligonucleotides and (c) a selected PNA. The DNA-targeting RNA or DNA and its site-directed modifying polypeptide (i.e., site-directed polypeptide) form a complex (i.e., bind via non-covalent interactions). The DNA-targeting RNA or DNA provides target specificity to the complex by comprising a nucleotide sequence that is complementary to a sequence of a target DNA. The site-directed modifying polypeptide of the complex provides the site-specific activity. In other words, the site-directed modifying polypeptide is guided to a target DNA sequence (e.g. a target sequence in a chromosomal nucleic acid; a target sequence in an extrachromosomal nucleic acid, e.g. an episomal nucleic acid, a minicircle, etc.; a target sequence in a mitochondrial nucleic acid; a target sequence in a chloroplast nucleic acid; a target sequence in a plasmid; etc.) by virtue of its association with the protein-binding segment of the DNA-targeting RNA.

[0016] In some forms the site-directed modifying polypeptide is Argo with nuclease activity or fusions thereof, and one or more guide oligonucleotides specific for the Argo and complementary to the target sequence, region or site. In some forms, T7E1, such as mutated, catalytically inactive T7E1 fused to FokI monomer or a Cas protein is used in place of the Argo protein. FIG. 18A-F.

[0017] The PNP editors bind to a predetermined target region referred to herein as the “target sequence,” “target region,” or “target site.” The target sequence can be within the coding DNA sequence of the gene or within an intron. The target sequence can also be within DNA sequences which regulate expression of the target gene, including promoter or enhancer sequences or sites that regulate RNA splicing. .

[0018] In some forms, the compositions include a selection of PNA and Argo for PNA assisted Ago-mediated DNA modification.

[0019] In some forms, the compositions include a selection of PNA and Argo fusion protein, specifically, FokI-(d)pAgo fusion protein-mediated DNA modification.

[0020] In some forms, the compositions include a selection of PNA and Argo, for PNA assisted Argo base editing. The components include in this system are Argo fusion with Adenosine base editor (ABE), (d)pAgo-ABE, and with Cytosine Base Editor (CBE), (d)pAgo- ABE.

[0021] In some forms, the compositions include a selection of PNA and Argo fusion protein, specifically, T7E1 nuclease-(d)pAgo fusion protein-mediated DNA modification. Here the Argo protein will be dead (d) version.

[0022] In some forms, the compositions include a selection of PNA and Argo fusion protein, specifically, FokI-(d)pAgo fusion protein-mediated DNA modification.

[0023] In some forms, the compositions include a selection of 2PNA and T7E1 nuclease fusion protein, specifically, (d) T7E1 nuclease-Fokl fusion protein-mediated DNA modification. The T7E1 nuclease domain is preferably, catalytically inactive.

[0024] In some forms, the compositions include a selection of PNA and a CRISPR / Cas nuclease for PNA assisted CRISPR / Cas nuclease-mediated DNA modification.

[0025] Methods for site-specific modification of a target DNA and / or a polypeptide associated with the target DNA The method includes contacting the target nucleic acid with the disclosed compositions as disclosed further below and exemplified herein.

[0026] Additional advantages of the disclosed methods and compositions will be set forth in part in the description which follows, and in part will be understood from the description, or can be learned by practice of the disclosed method and compositions. The advantages of the disclosed method and compositions will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed.

[0027] BRIEF DESCRIPTION OF THE DRAWINGS

[0028] The accompanying drawings illustrate several embodiments of the disclosed method and compositions and together with the description, serve to explain the principles of the disclosed method and compositions.

[0029] FIGs. 1A-1G. PNA invasion and pAgo cleavage of dsDNA. FIG. 1A is a structural comparison of DNA and yPNA molecules. FIG. IB is a schematic representation of yPNA invasion into linear dsDNA. FIG. 1C is a blot showing different yPNA molecules (yPNAl, yPNA2, yPNA3, and yPNA4) invasion into specific dsDNA target and mobility shift assay. PCR amplicons (50 nM final) containing target regions specific for each yPNA were invaded over night with 2 mM of yPNA and resolved on native 6% TBE polyacrylamide gel. FIG. ID is a schematic of the PNP concept overview. The ability of yPNA to specifically invade target dsDNA can be exploited to facilitate the guide DNA loaded pAgo mediated cleavage of any form of DNA by cleaving the displaced strand opposite to yPNA invasion site to generate DSB. FIG. IE is a scheme of pAgo mediated cleavage of yPNAl / yPNA3 invaded target region in pMRS-yPNAl / yPNA3 plasmid; SEQ ID NO: 352-357. FIG. IF is a collection of gel images showing the pAgo mediated cleavage of yPNAl / yPNA3 invaded circular dsDNA. Upper and lower gels represent CbAgo and KmAgo cleavage, respectively. yPNAl / yPNA3 were used to invade a high GC-content target regions (75% and 55% respectively) cloned in pMRS-yPNAl / yPNA3 plasmid in close proximity to SacI site. Invaded target was incubated with a pair of pAgo proteins loaded with gDNAs at 37°C for 1 hour. The bands corresponding to anticipated cleavage products were observed only in the reaction containing invaded plasmid and both the gDNAs (Lane 7). Both the pAgo proteins did not show any cleavage in noninvaded circular plasmid targets (Lanes 2-5), and invaded target but with no-guides and one guide (Lanes 8-10). Only plasmids (non-invaded and invaded) (Lanes 1 and 6), SacI / BsrGI restricted (non-invaded and invaded) (Lanes 11 and 12), and SacI linearized (non-invaded and invaded) (Lanes 13 and 14) samples used as different size controls. FIG. 1G is a collection of gel images showing the pAgo mediated cleavage of yPNAl / yPNA3 invaded target region in linear dsDNA. Upper and lower gels represent CbAgo and KmAgo cleavage, respectively. yPNAl / yPNA3 were used to invade a high GC-content target regions (75% and 55% respectively) in BsrGI linearized pMRS-yPNAl / yPNA3 plasmid in close proximity to SacI site. Invaded linearized plasmid was incubated with a pair of gDNA-loaded pAgos at 37°C for 1 hour, thus demonstrating the ability of pAgos to cleave high GC content, linearized plasmid dsDNA. The bands corresponding to expected cleavage products were observed in the reaction containing invaded linear plasmid and both the gDNAs (Lane 7). Both the pAgo proteins did not show any cleavage in non-invaded linear plasmid targets (Lanes 2-5), invaded target but with no-guides and one guide (Lanes 8-10), non-specific guides (Lane 11), and non-specific PNA invasion (Lane 12). Only linear plasmids (non-invaded and invaded) (Lanes 1 and 6), and Sad restricted (Lane 13) samples used as size controls. Lane M represents the 1Kb plus DNA ladder. FIG. 1H (reproduced from Brodyagin, et al., J. Org. Chem., 17: 1641-1688 (2021) PNA binding modes: (A) PNA-dsDNA 1: 1 triplex; (B) PNA-DNA-PNA strand-invasion triplex; (C) the Hoogsteen and Watson-Crick parts are linked together in a bis-PNA; (D) shortening the Hoogsteen part and extending the Watson-Crick part of the bis-PNA creates a tail-clamp PNA (tcPNA); (E) and (F) single and double invasion using only Watson-Crick hydrogen bonding; (G) Janus-wedge triple helix.

[0030] FIGs 2A and 2B show GC content assays on circular and linear dsDNA. FIG. 2A shows GC content assay on circular plasmid. Upper and lower gels represent CbAgo and KmAgo cleavage, respectively. Non-invaded pMRS-yPNAl / yPNA3 circular plasmid was incubated with pairs of pAgo proteins loaded with guides targeting regions with GC content of 13, 22, 27, 31, 35, 50, and 75% (Lanes 1-7) at 37°C for Ih. The same plasmid was then invaded by yPNAl and yPNA3 at regions with 55% and 75% GC content, respectively, and incubated with respective pAgo-guide complexes at 37°C for Ih (Lane 8). Plasmids were treated with SacI or BsrGI depending on the position of the target region relative to the restriction enzyme site. Non-invaded pAgo cleavage (Lane 9) and SacI / BsrGI restricted (Lane 10) samples are included as control reactions. FIG. 2B show GC content assay on linearized plasmid. Upper and lower gels represent CbAgo and KmAgo cleavage, respectively. Linearized, non-invaded pMRS plasmid was incubated with pairs of pAgo proteins loaded with guides targeting regions with GC content of 13, 22, 27, 31, 35, 50, and 75% (Lanes 1-7) at 37°C for Ih. Linearized plasmid was then invaded by yPNAl and yPNA3 at regions with 55% and 75% GC content, respectively, and incubated with respective pAgo targeting complexes at 37°C for Ih (Lane 8). Non-invaded pAgo cleavage (Lane 9) and SacI restricted (Lane 10) samples used as control reactions. Expected cleavage product sizes are mentioned on top of each lane on both the gels corresponding to its GC content. Lane M represents the 1Kb plus DNA ladder. FIGs. 3A and 3B show multiplexed cleavage of circular plasmid containing two target sites with two pairs of yPNAs and pAgo-guide complexes. FIG. 3A is a schematic representation of two different target regions in pMRS-yPNAl / yPNA3-EMXl-yPNAl / EMXl- yPNA2 multiplexing plasmid. Target region 1 contains yPNAl / yPNA3 binding sequence and Target region 2 contains EMXl-yPNAl / EMXl-yPNA2 binding sequence. Both the target regions separated by 820bp DNA sequence (SEQ ID NO: 352-357, and SEQ ID NO: 358 - 363). FIG. 3B is a collection of gel images showing the multiplex cleavage of circular plasmid with two pairs pAgo-guide complexes. Upper and lower gels represent CbAgo and KmAgo cleavage, respectively. The plasmid was initially invaded with two pairs of yPNA molecules (yPNAl / yPNA3 and EMXl-yPNAl / EMXl-yPNA2) and incubated with guide DNA loaded pAgo proteins for Ihr at 37°C. Non-invaded and invaded plasmids were incubated with both pairs of protein-guide complexes (Lanes 1 and 6, respectively), only one pair guides (2-3 and 6-7, respectively), and no guides (Lanes 4 and 8, respectively). Cleavage products corresponding to a double cut were observed only in invaded plasmid when using both pairs of pAgo targeting complexes (Lane 5). Sacl / Agel restricted (non-invaded) (Lanes 9), and SacI linearised (non-invaded) (Lanes 10) samples used as different size controls. Lane M represents the 1Kb plus DNA ladder.

[0031] FIGs. 4A-4E shows spacer assay on BsrGI linearized plasmids containing yPNAl / yPNA3 binding regions in different orientations and different lengths of spacers. FIG. 4A is a schematic showing the yPNAl / yPNA3 binding regions with guides facing outward (SEFQ ID NOs: 352, 353, 355 and 356. FIG. 4B is a schematic representing the yPNAl / yPNA3 binding regions with guides facing inward. RE1 and RE2 shows the position of SacI I different target plasmids 9SEQ ID NO: 358, 359, 360 and 363). FIG. 4C is a table showing the different spacer sequences, lengths (1, 3, 5, 6, 10 (SEQ ID NO: 364), 15 SEQ ID NO: 365), 20 (SEQ ID NO: 366), 30-bp (SEQ ID NO: 367)) of spacer and the position of SacI on the target plasmid. FIG. 4D are two gel images showing the pAgo (Upper - CbAgo and lower - KmAgo) cleavage of yPNAl / yPNA3 invaded DNA targets (guides facing outward) containing varying spacer lengths between the two PNA invasions. All the plasmids were linearized using BsrGI and invaded overnight with yPNAl / yPNA3 and cleaved with a pair of guide DNA loaded pAgo proteins (Lanes 1-8). SacI / BsrGI restricted (non-invaded) (Lane 9) sample used as size control. FIG. 4E are two gel images of pAgo (Upper - CbAgo and lower - KmAgo) cleavage of yPNAl / yPNA3 invaded DNA targets (guides facing inward) containing different spacer lengths between the two PNA invasions. All the plasmids were linearized using BsrGI and invaded overnight with yPNAl / yPNA3 and cleaved with a pair of guide DNA loaded pAgo proteins (Lanes 1-8). SacI / BsrGI restricted (non-invaded) (Lane 9) sample used as size control. Lane M represents the 1Kb plus DNA ladder.

[0032] FIGs. 5A and 5B show assays testing the effect of guide type and length on pAgo cleavage efficiency of yPNAl / yPNA3 invaded BsrGI linear DNA. FIG. 5A are two gel images showing the pAgo mediated cleavage (Upper gel - CbAgo and lower gel - KmAgo) of yPNAl / yPNA3 invaded linear DNA target employing different types of guides. Linearized pMRS-yPNAl / yPNA3 plasmid, non-invaded and yPNAl / yPNA3 invaded were incubated with pAgo proteins loaded with 5 ’-hydroxylated DNA guides (5 ’-OH DNA guides) (Lane 1 and 6; respectively), phosphorothioated guides (PT guides) (Lane 2 and 7; respectively), 5’- phosphorylated RNA guides (RNA guides) (Lane 3 and 8; respectively), 5 ’-phosphorylated DNA guides (5’P-DNA guides) (Lane 4 and 9; respectively), and no guides (Lane 5 and 10; respectively). SacI restricted (non-invaded) (Lane 11) sample used as size control. FIG. 5B are two gel images showing the effect of guide length on cleavage efficiency of yPNAl / yPNA3 invaded BsrGI linearized plasmid DNA. yPNAl / yPNA3 Invaded plasmid was incubated with pAgo (Upper gel - CbAgo and lower gel - KmAgo) preloaded with guide DNAs of 10, 12, 14, 16, 18, 20-nt lengths, and non-specific guides (Lanes 1-7). Non-invaded plasmid with 16-nt guides and SacI restricted (non-invaded) (Lane 11) samples were included as control reactions. Lane M represents the 1Kb plus DNA ladder.

[0033] FIGs. 6A-6E show determination of optimum temperature for PNA invasion, pAgo cleavage and identification of pAgo cleavage site. FIG. 6A are two gel images showing pAgo activity at different temperature conditions. In order to test the ability of pAgos to cleave the invaded target at a range of temperatures, linearized plasmid containing EMX1- yPNAl / EMXl-yPNA2 binding regions was invaded with EMXl-yPNAl / EMXl-yPNA2 at 37°C overnight. Next, the target was incubated with a pair of pAgo (Upper gel - CbAgo and lower gel - KmAgo) proteins targeting the displaced ssDNA region at a range of 20, 25, 30, 27, 40, and 45°C temperatures for Ihr (Lanes 1-6). FIG. 6B are two gel picture showing EMXl-yPNAl / EMXl-yPNA2 invasion at different temperatures. In order to test the ability of yPNA to invade the target at a range of temperatures, linearized plasmid was invaded with EMXl-yPNAl / EMXl-yPNA2 at a range of temperatures 20, 25, 30, 27, 40, and 45°C overnight. Next, the target was incubated with a pair of pAgo (Upper gel - CbAgo and lower gel - KmAgo) proteins targeting the displaced ssDNA region at 37°C for 1 hours (Lanes 1-6). FIG. 6C are two gel pictures showing EMXl-yPNAl / EMXl-yPNA2 invasion and pAgo activity at different temperatures. Both the invasion step and pAgo cleavage were performed under the same varying temperature (20, 25, 30, 27, 40, and 45°C) conditions. The invasion step was performed overnight, followed by the pAgo (Upper gel - CbAgo and lower gel - KmAgo) cleavage assay for Ih (Lanes 1-6). In all the gels (A, B, and C), reactions of EMX1- yPNAl / EMXl-yPNA2 invaded and non-invaded template cleavage with pAgo (Upper gel - CbAgo and lower gel - KmAgo) proteins at 37°C were included (Lanes 7 and 8, respectively), and Agel restricted (non-invaded) (Lanes 9) samples as control reactions. Lane M represents the 1Kb plus DNA ladder. FIG. 6D is a schematic showing EMXl-yPNAl / EMXl-yPNA2 invaded and pAgo-guide complex binding sites and primers orientation for sanger sequencing (SEQ ID NO: 358-363). FIG. 6E are graphs showing pAgo cleavage site on EMX1- yPNAl / EMXl-yPNA2 invaded Agel linearized dsDNA. Confirmation of pAgo (CbAgo - top panel and KmAgo - bottom panel) cleavage site was performed on invaded pMRS-EMXl- yPNAl / EMXl-yPNA2 and BsrGI linearized plasmid. Following the cleavage assay, the bands corresponding to cleavage products were purified from the Agarose gel and sanger sequenced. The cleavage site was identified by read termination position. Asterisks denote the sequencing artifact “A” (Adenosine).

[0034] FIGs. 7A-7C show the effect of guide mismatches at different position on pAgo cleavage efficiency of BsrGI linearized plasmid DNA. FIG. 7A is a table showing the different regions in the guide DNA molecule. FIG. 7B is a table showing the different mismatched guide 1 and 2, highlighted the region, type, and number of mismatched nucleotides (SEQ ID NO: 368-383). FIG. 7C are two gel images showing the pAgo cleavage of yPNAl / yPNA3 invaded BsrGI linearized pMRS-yPNAl / yPNA3 plasmid using different mismatched guides. Invaded plasmid was incubated with CbAgo (upper gel) and KmAgo (lower gel) preloaded with different guide DNA containing 1 or 2-nt mismatches at different positions in the pAgo guide architecture for Ihr at 37°C (Lanes 1-8). Reactions of yPNAl / yPNA3 invaded samples with specific guides and non-specific guides were included (Lanes 9 and 10, respectively). Non-invaded but with specific guides (Lane 11), and Sad restricted (non-invaded) (Lanes 12) samples are included as control reactions. Lane M represents the 1Kb plus DNA ladder.

[0035] FIGs. 8A and 8B show efficiency of different combinations of yPNAs invasion and pAgo cleavage on circular plasmid. FIG. 8A is a schematic of pUC19 plasmid containing the different target regions. Target regions for binding yPNAl + yPNA2, yPNA3 + yPNA4, yPNA2 + yPNA4 and yPNAl + yPNA3 were cloned into separate pUC19 vectors at ECoRI and BamHI restriction sites. These plasmids were employed for testing the efficiencies. FIG. 8B is a gel image showing the pAgo (Upper gel - CbAgo and lower gel - Km Ago) cleavage of yPNAl / yPNA2 (Lane 1), yPNA3 / yPNA4 (Lane 2), yPNA2 / yPNA4 (Lane 3), and yPNAl / yPNA3 (Lane 4) invaded pUC19 target plasmids using the corresponding guide combinations. All the invaded samples were incubated with pAgo proteins for Ihr at 37°C and treated with XmnI restriction enzyme for 30min at 37°C following proteinaseK treatment ang resolved on 0.9% Agarose gel. SacI / XmnI restricted (non-invaded) (Lane 5) sample used as size control. Lane M represents the 1Kb plus DNA ladder.

[0036] FIGs. 9A-9D shows cleavage of different lengths of yPNAl / yPNA3 invaded BsrGI linearized target. FIG.9A is a schematic showing the invasions of different lengths of yPNAl / yPNA3 and the guide DNA lengths. Sketch 1, 2, 3 and 4 are target DNA invaded with 10-nt, 14-nt, 16-nt, and 20-nt long yPNAl / yPNA3 molecules, respectively and corresponding 16-nt long guide DNA binding (SEQ ID NO: 384-391). FIG. 9B is a gel image showing the pAgo (Upper gel - CbAgo and lower gel - KmAgo) cleavage of 10-nt (Lane 1), 14-nt (Lane 2), 16-nt (Lane 3), and 20-nt (Lane 4) long yPNAl / yPNA3 invaded target DNA using the 16-nt long guide DNA molecules. Non-invaded target cleavage with pAgo (Lane 5) and SacI restricted (non-invaded) (Lane 6) samples included as controls. FIG. 9C is a schematic showing the invasions of different lengths of yPNAl / yPNA3 and the corresponding lengths of guide DNA molecules. Sketch 1, 2, 3 and 4 are target DNA invaded with 10-nt, 14-nt, 16-nt, and 20-nt long yPNAl / yPNA3 molecules, respectively and corresponding 10-nt, 14-nt, 16-nt, and 20-nt length guide DNA binding, respectively (SEQ ID NO: 384-391). FIG. 9D is a gel image showing the pAgo (Upper gel - CbAgo and lower gel - KmAgo) cleavage of 10-nt, 14- nt, 16-nt, and 20-nt long yPNAl / yPNA3 invaded target DNA using the 10-nt (Lane 1), 14-nt (Lane 2), 16-nt (Lane 3), and 20-nt (Lane 4) long guide DNA molecules, respectively. Noninvaded target cleavage with pAgo (Lane 5) and SacI restricted (non-invaded) (Lane 6) samples included as controls. Lane M represents the 1Kb plus DNA ladder.

[0037] FIGs. 10A-10C show pAgo mediated cleavage of ytcPNA invaded linear dsDNA. FIG. 10A is a mobility shift assay of ytcPNAl and ytcPNA2 invaded DNA on 2% Agarose gel. Lane 1 and 4 are ytcPNAl and ytcPNA2 invaded DNA respectively, lane 2 and 5 are noninvaded DNA, and Lane 3 and 4 are only ytcPNAl and ytcPNA2 respectively. FIG. 10B is a schematic of pAgo mediated cleavage of ytcPNAl and ytcPNA2 invaded target region in pMRS-ytcPNA / ytcPNA2 plasmid. ytcPNA / ytcPNAZ are Cy5 and Cy3 labelled respectively (SEQ ID NO: 392-397). FIG. 10C are two gel images showing the pAgo (Upper gel - CbAgo and lower gel - KmAgo) mediated cleavage of ytcPNA / ytcPNA2 invaded BsrGI linear target. Lane 7 is the pAgo with both guides, Lanes 8 and 9 are pAgo cleavage of invaded target but with one guide, Lane 10 is without guides, Lanes 1-5 are non-invaded target cleavage with different guide combinations and pAgo proteins. pAgo cleavage with non-specific guides (Lane 11), and SacI restricted (non-invaded) (Lane 12) samples included as controls. Lane M represents the 1Kb plus DNA ladder.

[0038] FIGs. 11A and 11B show pAgo mediated targeting of flanking regions, invaded strands on circular pUC19 plasmid. FIG. 11A is a Schematic representation of yPNAl and yPNA3 invaded pUC19 target region. Highlighted the different guide binding regions in different colored text and numbers (SEQ ID NO: 398-403). FIG. 11B is a gel image showing the pAgo and different pairs of guides mediated targeting of single or two PNA invaded targets. Lane 1 is the yPNA3 invaded plasmid with a pair of pAgo proteins loaded with a guide targeting the yPNA3 displaced ssDNA region and a guide targeting the right flanking, noninvaded region in immediate proximity to the invaded region. Lane 2 is the yPNAl invaded plasmid was incubated with a pair of pAgo proteins loaded with a guide targeting the yPNAl displaced ssDNA region and a guide targeting the left flanking, non-invaded region in immediate proximity to the invaded region. Lane 3 is the yPNAl and yPNA3 invaded plasmid was incubated with a pair of pAgo proteins loaded with guides targeting the yPNA invaded strands. Lane 4 is the plasmid invaded with non-specific yPNAs targeted with specific guide DNA molecules. Lane 5 is the yPNAl and yPNA3 invaded plasmid targeted with non-specific guide DNA molecules. Lane 6 is the yPNAl and yPNA3 invaded plasmid targeted with pAgo proteins not loaded with guide DNA molecules. Lane 7 is the yPNAl invaded plasmid was incubated with a pair of pAgo proteins loaded with guides targeting the invaded strand and non-invaded strand opposite of each other. Lane 8 is the yPNA3 invaded plasmid was incubated with a pair of pAgo proteins loaded with guides targeting the invaded strand and non-invaded strand opposite of each other. Lane 9 is the yPNAl / yPNA3 invaded target plasmids incubated with a pair of pAgo proteins loaded with guide DNA targeting the displaced ssDNA molecules. SacLXmnl restricted (non-invaded) (Lane 10) sample used as size control. Lane M represents the 1Kb plus DNA ladder.

[0039] FIG. 12A and 12B shows targeting the flanking regions using the outward flanking guides. FIG. 12A is a Schematic representation of outward flanking guide 1 and 2 binding sites and the labels at the yPNAl / yPNA3 invaded region in pMRS-yPNAl / yPNA3-l-nt target. Flanking lengths represented as 0 to 20-nt, based on the guide binding region (SEQ ID NO: 404-405). FIG. 12B is a gel image showing the pAgo (Upper gel - CbAgo and lower gel - KmAgo) cleavage of yPNAl / yPNA3 invaded target using the different combinations of outward flanking guides (Lanes 1-21). Non-invaded target cleavage with pAgo (Lane 22) and SacI restricted (non-invaded) (Lane 23) samples included as controls. Lane M represents the 1Kb plus DNA ladder.

[0040] FIGs. 13A and 13B shows targeting the flanking regions using the inward flanking guides. FIG. 13A is a schematic showing the inward flanking guide 1 and 2 binding sites and the labels at the yPNAl / yPNA3 invaded region in pMRS-yPNAl / yPNA3-10-nt target. Flanking lengths represented as 0 to 10-nt, based on the guide binding region (SEQ ID NO: 406-407). FIG. 13B is a gel image showing the pAgo (Upper gel - CbAgo and lower gel - KmAgo) cleavage of yPNAl / yPNA3 invaded target using the different combinations of inward flanking guides (Lanes 1-11). Non-invaded target cleavage with pAgo (Lane 12) and SacI restricted (non-invaded) (Lane 13) samples included as controls. Lane M represents the 1Kb plus DNA ladder.

[0041] FIGs. 14A and 14B shows the effect of more guide mismatches at different positions on pAgo cleavage efficiency of BsrGI linearized plasmid DNA. FIG. 14A is a table showing the different mismatched guide 1 and 2, highlighted the region, type, and number of mismatched nucleotides (SEQ ID NO: 407-436. FIG. 14B is a gel images showing the pAgo cleavage of yPNAl / yPNA3 invaded BsrGI linearized pMRS-yPNAl / yPNA3 plasmid using different mismatched guides. Cleavage of invaded plasmid with CbAgo (upper gel) and KmAgo (lower gel) preloaded with different guide DNA containing 2-nt mismatches (Lanes 1- 5), 3-nt mismatches (Lanes 16-10), and 4-nt mismatches (Lanes 11-15) at different positions. Reactions of yPNAl / yPNA3 invaded samples with specific guides and non-specific guides were included (Lanes 16 and 17, respectively). Non-invaded but with specific guides (Lane 18), and SacI restricted (non-invaded) (Lanes 19) samples are included as control reactions. Lane M represents the 1Kb plus DNA ladder.

[0042] FIGs. 15A and 15B show pAgo cleavage tolerance assay on DNA template mismatch to yPNA molecules using the mismatch specific guides. FIG. 15A is a table showing the yPNAl and yPNA3 sequences and their mismatched target sequences. DNA target mismatches are represented as 3’ end mismatches to yPNAl and yPNA3 (1 to 11-nt mutations), central mismatches to yPNAl and yPNA3 (1 to 4-nt mutations), non-consecutive mismatches (2 to 8- nt mutations), and 5’ end mismatches to yPNAl and yPNA3 (1 to 11-nt mutations) (SEQ ID NO: 437-488). FIG. 15B is a collection of gel images showing the pAgo cleavage (Upper gel - CbAgo and lower gel - KmAgo) of yPNAl and yPNA3 invaded mismatched linear targets with mismatch specific guides. Lanes 1-8 are the cleavage of 3’ end mismatched targets, Lanes 9-12 are the cleavage of central mismatched targets, Lanes 13-16 are the cleavage of non- consecutive mismatched targets, and Lanes 17 to 24 are the cleavage of 5’ end mismatched targets using the mismatch specific guides. Lane 25 is the correct target DNA invaded with yPNAl / yPNA3 and cleavage with pAgo proteins loaded with specific guide DNA molecules. Non-invaded with specific guides cleavage with pAgo (Lane 26), and SacI restricted (noninvaded) (Lane 27) sample used as control reactions. Lane M represents the 1Kb plus DNA ladder.

[0043] FIGs. 16A and 16B shows pAgo cleavage tolerance assay on DNA template mismatch to yPNA molecules using the partial specific guides. FIG. 16A is a table showing the yPNAl and yPNA3 sequences and their mismatched target sequences. DNA target mismatches are represented as 3’ end mismatches to yPNAl and yPNA3 (1 to 11-nt mutations), central mismatches to yPNAl and yPNA3 (1 to 4-nt mutations), non-consecutive mismatches (2 to 8- nt mutations), and 5’ end mismatches to yPNAl and yPNA3 (1 to 11-nt mutations) ((SEQ ID NO: 489-541 FIG. 16B is a collection of gel images showing the pAgo cleavage (Upper gel - CbAgo and lower gel - KmAgo) of yPNAl and yPNA3 invaded mismatched linear targets with partial specific guides. Lanes 1-8 are the cleavage of 3’ end mismatched targets, Lanes 9- 12 are the cleavage of central mismatched targets, Lanes 13-16 are the cleavage of non- consecutive mismatched targets, and Lanes 17 to 24 are the cleavage of 5’ end mismatched targets using the partial specific guides. Lane 25 is the correct target DNA invaded with yPNAl / yPNA3 and cleavage with pAgo proteins loaded with specific guide DNA molecules. Non-invaded with specific guides cleavage with pAgo (Lane 26), and SacI restricted (noninvaded) (Lane 27) sample used as control reactions. Lane M represents the 1Kb plus DNA ladder.

[0044] FIG. 17 is an activity analysis of SV40-NLS fused pAgo proteins. Different CbAgo (NLS-CbAgo, NLS-CbAgo-NLS, and NLS-(dead)CbAgo-NLS) (upper gel panel) and KmAgo (NLS-KmAgo, NLS-KmAgo-NLS, and NLS-(dead)KmAgo) (lower gel panel) variants activity tested together with the native CbAgo (upper gel panel) and KmAgo (lower gel panel) on EMXl-yPNAl / EMXl-yPNA2 invaded and non-invaded target DNA using the specific guide DNA molecules. Lanes 1, 3, 5, and 7 are cleavage of EMXl-yPNAl / EMXl-yPNA2 invaded target with native Ago, NLS-Ago, NLS-Ago-NLS, and NLS-(dead)Ago-NLS proteins, respectively, loaded with specific guide DNA molecules. Lanes 2, 4, 6, and 8 are cleavage of non-invaded target with native Ago, NLS-Ago, NLS-Ago-NLS, and NLS-(dead)Ago-NLS proteins, respectively, loaded with specific guide DNA molecules. Agel restricted (noninvaded) (Lane 9) sample used as size control. Lane M represents the 1Kb plus DNA ladder.

[0045] FIG. 18A-18F are cartoons showing different gene editing methods using PNA assisted pAgo editors (PNP editors) and other potential PNA assisted nuclease editors

[0046] DETAILED DESCRIPTION OF THE INVENTION

[0047] The disclosed method and compositions can be understood more readily by reference to the following detailed description of particular embodiments and the Example included therein and to the Figures and their previous and following description.

[0048] It is to be understood that the disclosed method and compositions are not limited to specific synthetic methods, specific analytical techniques, or to particular reagents unless otherwise specified, and, as such, can vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0049] I. DEFINITIONS

[0050] A DNA sequence that “encodes” a particular RNA is a DNA nucleic acid sequence that is transcribed into RNA. A DNA polynucleotide may encode an RNA (mRNA) that is translated into protein, or a DNA polynucleotide may encode an RNA that is not translated into protein (e g. a DNA-targeting RNA; also called “non-coding” RNA or “ncRNA”).

[0051] “Hybridizable” or “complementary” or “substantially complementary” it is meant that a nucleic acid (e.g. RNA) comprises a sequence of nucleotides that enables it to non-covalently bind, i.e. form Watson-Crick base pairs and / or G / U base pairs, “anneal”, or “hybridize,” to another nucleic acid in a sequence-specific, antiparallel, manner (i.e., a nucleic acid specifically binds to a complementary nucleic acid) under the appropriate in vitro and / or in vivo conditions of temperature and solution ionic strength. As is known in the art, standard Watson-Crick base-pairing includes: adenine (A) pairing with thymidine (T), adenine (A) pairing with uracil (U), and guanine (G) pairing with cytosine (C) [DNA, RNA], In addition, it is also known in the art that for hybridization between two RNA molecules (e g., dsRNA), guanine (G) base pairs with uracil (U).

[0052] The term “subject” or “patient” refers to any mammal who is the target of administration. Thus, the subject can be a human. The subject can be a domesticated, agricultural, or wild animal. Domesticated animals include, for example, dogs, cats, rabbits, ferrets, guinea pigs, hamsters, pigs, monkeys or other primates, and gerbils. Agricultural animals include, for example, horses, cattle, pigs, sheep, rabbits, and goats. The term does not denote a particular age or sex of the subject. In some embodiments, the subject is an embryo or fetus.

[0053] A “protein coding sequence” or a sequence that encodes a particular protein or polypeptide, is a nucleic acid sequence that is transcribed into mRNA (in the case of DNA) and is translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' terminus (N-terminus) and a translation stop nonsense codon at the 3' terminus (C-terminus). A coding sequence can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and synthetic nucleic acids. A transcription termination sequence will usually be located 3' to the coding sequence.

[0054] The terms “polynucleotide” and “nucleic acid,” used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. “Oligonucleotide” generally refers to polynucleotides of between about 5 and about 100 nucleotides of single- or double-stranded DNA. However, for the purposes of this disclosure, there is no upper limit to the length of an oligonucleotide. Oligonucleotides may be isolated from genes, or chemically synthesized by methods known in the art. The terms “polynucleotide” and “nucleic acid” should be understood to include, as applicable to the embodiments being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides.

[0055] “PNP editors” as used herein, refers to PNA-assisted pAgo editing.

[0056] As used herein, “transformed” and “transfected” encompass the introduction of a nucleic acid into a cell by one of a number of techniques known in the art.

[0057] The terms “treatment”, “treating” and the like are used herein to generally mean obtaining a desired pharmacologic and / or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and / or may be therapeutic in terms of a partial or complete cure for a disease and / or adverse effect attributable to the disease. “Treatment” as used herein covers any treatment of a disease or symptom in a mammal, and includes: (a) preventing the disease or symptom from occurring in a subject which may be predisposed to acquiring the disease or symptom but has not yet been diagnosed as having it; (b) inhibiting the disease or symptom, i.e., arresting its development; or (c) relieving the disease, i.e., causing regression of the disease. The therapeutic agent may be administered before, during or after the onset of disease or injury. The treatment of ongoing disease, where the treatment stabilizes or reduces the undesirable clinical symptoms of the patient, is of particular interest. Such treatment is desirably performed prior to complete loss of function in the affected tissues. The subject therapy will desirably be administered during the symptomatic stage of the disease, and in some cases after the symptomatic stage of the disease.

[0058] “Recombination” as used herein a process of exchange of genetic information between two polynucleotides. As used herein, “homology-directed repair (HDR)” refers to the specialized form DNA repair that takes place, for example, during repair of double-strand breaks in cells. This process requires nucleotide sequence homology, uses a “donor” molecule to template repair of a “target” molecule (i.e., the one that experienced the double-strand break), and leads to the transfer of genetic information from the donor to the target. Homology- directed repair may result in an alteration of the sequence of the target molecule (e.g., insertion, deletion, mutation), if the donor polynucleotide differs from the target molecule and part or all of the sequence of the donor polynucleotide is incorporated into the target DNA. In some embodiments, the donor polynucleotide, a portion of the donor polynucleotide, a copy of the donor polynucleotide, or a portion of a copy of the donor polynucleotide integrates into the target DNA.

[0059] “Non-homologous end joining (NHEJ)” as used herein refers the repair of doublestrand breaks in DNA by direct ligation of the break ends to one another without the need for a homologous template (in contrast to homology-directed repair, which requires a homologous sequence to guide repair). NHEJ often results in the loss (deletion) of nucleotide sequence near the site of the double-strand break.

[0060] As used herein, the phrase that a molecule “specifically binds” to a target refers to a binding reaction which is determinative of the presence of the molecule in the presence of a heterogeneous population of other biologies. Thus, under designated assay conditions, a specified molecule binds preferentially to a particular target and does not bind in a significant amount to other biologies present in the sample. Specific binding between two entities can be, for example, an affinity of at least 106, 107, 108, 109, or IO10M’1. Affinities greater than 108M"1are preferred. As used herein, the term “carrier” or “excipient” refers to an organic or inorganic ingredient, natural or synthetic inactive ingredient in a formulation, with which one or more active ingredients are combined.

[0061] As used herein, the term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients.

[0062] As used herein, the terms “effective amount” or “therapeutically effective amount” means a dosage sufficient to alleviate one or more symptoms of a disorder, disease, or condition being treated, or to otherwise provide a desired pharmacologic and / or physiologic effect. The precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc ), the disease or disorder being treated, as well as the route of administration and the pharmacokinetics of the agent being administered.

[0063] A “vector” or “expression vector” is a replicon, such as plasmid, phage, virus, or cosmid, to which another DNA segment, i.e. an “insert”, may be attached so as to bring about the replication of the attached segment in a cell.

[0064] An “expression cassette” comprises a DNA coding sequence operably linked to a promoter. “Operably linked” refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression.

[0065] A cell has been “genetically modified” or “transformed” or “transfected” by exogenous DNA, e g. a recombinant expression vector, when such DNA has been introduced inside the cell. The presence of the exogenous DNA results in permanent or transient genetic change. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones that comprise a population of daughter cells containing the transforming DNA. A “clone” is a population of cells derived from a single cell or common ancestor by mitosis. A “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.

[0066] A “target DNA” as used herein is a DNA polynucleotide that comprises a “target site” or “target sequence.” The terms “target site” or “target sequence” or “target protospacer DNA” are used interchangeably herein to refer to a nucleic acid sequence present in a target DNA to which a DNA-targeting segment of a subject DNA-targeting RNA will bind provided sufficient conditions for binding exist. For example, the target site (or target sequence) 5'- GAGCATATC-3' within a target DNA is targeted by (or is bound by, or hybridizes with, or is complementary to) the RNA sequence 5'-GAUAUGCUC-3' .

[0067] By “site-directed modifying polypeptide” or “RNA-binding site-directed polypeptide” or “RNA-binding site-directed modifying polypeptide” or “site-directed polypeptide” it is meant a polypeptide that binds RNA or DNA and is targeted to a specific DNA sequence. A site-directed modifying polypeptide as described herein is targeted to a specific DNA sequence by the RNA or RNA molecule to which it is bound. The RNA molecule comprises a sequence that is complementary to a target sequence within the target DNA, thus targeting the bound polypeptide to a specific location within the target DNA (the target sequence).

[0068] “Nuclease” and “endonuclease” are used interchangeably herein to mean an enzyme which possesses catalytic activity for DNA cleavage.

[0069] As used herein “cleavage” reefers the breakage of the covalent backbone of a DNA molecule.

[0070] The RNA or DNA molecule that binds to the site-directed modifying polypeptide and targets the polypeptide to a specific location within the target DNA is referred to herein as the “DNA-targeting RNA or DNA” (also referred to herein as a “guide oligonucleotide”).

[0071] H. COMPONENTS

[0072] Features of the present disclosure include compositions, herein “PNP editors” for targeted DNA modification that (a) include site-directed modifying polypeptides, in some forms with nuclease activity, and in other forms without nuclease activity; (b) DNA-targeting RNA or DNA, herein, guide oligonucleotides and (c) a selected PNA. The DNA-targeting RNA or DNA and its site-directed modifying polypeptide (i.e., site-directed polypeptide) form a complex (i.e., bind via non-covalent interactions). The DNA-targeting RNA or DNA provides target specificity to the complex by comprising a nucleotide sequence that is complementary to a sequence of a target DNA. The site-directed modifying polypeptide of the complex provides the site-specific activity. In other words, the site-directed modifying polypeptide is guided to a target DNA sequence (e.g. a target sequence in a chromosomal nucleic acid; a target sequence in an extrachromosomal nucleic acid, e.g. an episomal nucleic acid, a minicircle, etc.; a target sequence in a mitochondrial nucleic acid; a target sequence in a chloroplast nucleic acid; a target sequence in a plasmid; etc.) by virtue of its association with the protein-binding segment of the DNA-targeting RNA. In some forms the site-directed modifying polypeptide is Argo with nuclease activity or fusions thereof, and one or more guide oligonucleotides specific for the Argo and complementary to the target sequence, region or site. In some forms, T7E1, such as mutated, catalytically inactive T7E1 fused to FokI monomer or a Cas protein is used in place of the Argo protein. FIG. 18A-F.

[0073] The PNP editors bind to a predetermined target region referred to herein as the “target sequence,” “target region,” or “target site.” The target sequence can be within the coding DNA sequence of the gene or within an intron. The target sequence can also be within DNA sequences which regulate expression of the target gene, including promoter or enhancer sequences or sites that regulate RNA splicing. .

[0074] In some forms, the compositions include a selection of PNA and Argo for PNA assisted Ago-mediated DNA modification.

[0075] In some forms, the compositions include a selection of PNA and Argo fusion protein, specifically, FokI-(d)pAgo fusion protein-mediated DNA modification.

[0076] In some forms, the compositions include a selection of PNA and Argo, for PNA assisted Argo base editing. The components include in this system are Argo fusion with Adenosine base editor (ABE), (d)pAgo-ABE, and with Cytosine Base Editor (CBE), (d)pAgo- ABE.

[0077] In some forms, the compositions include a selection of PNA and Argo fusion protein, specifically, T7E1 nuclease-(d)pAgo fusion protein-mediated DNA modification. Here the Argo protein will be dead (d) version.

[0078] In some forms, the compositions include a selection of PNA and Argo fusion protein, specifically, FokI-(d)pAgo fusion protein-mediated DNA modification.

[0079] In some forms, the compositions include a selection of 2PNA and T7E1 nuclease fusion protein, specifically, (d) T7E1 nuclease-Fokl fusion protein-mediated DNA modification. The T7E1 nuclease domain is preferably, catalytically inactive.

[0080] PNA molecules invade natural B-DNA leading to formation of unnatural distortions in the DNA helix. These structures can be recognized by mutated, catalytically inactive T7E1 fused to FokI monomer. B-DNA is the term given for the canonical right-handed DNA helix that is the most common form of DNA. Canonical B-DNA is a double helix made of two antiparallel strands that are held together via hydrogen bonding in the A*T and G*C base pairs. Hybridization of two PNA molecules with two adjacent genomic regions recruits FokI domains and induces DSB. Alternatively, PNA can be conjugated with a short DNA flap that is partially complimentary to the target site. This structure is recognized by FEN1 proteins that naturally excise DNA flaps that occur during various natural processes. It might be possible to induce DSB at targeted sites by recruiting Fokl-FENl fusion proteins in a highly specific manner, that requires two independent recognition events.

[0081] In some forms, the compositions include a selection of PNA and a CRISPR / Cas nuclease for PNA assisted CRISPR / Cas nuclease-mediated DNA modification.

[0082] In some embodiments, the compositions and methods include a potentiating factor. Accordingly, compositions and methods of increasing the efficacy of gene editing technology are provided. As used herein a “gene editing potentiating factor” or “gene editing potentiating agent” or “potentiating factor or “potentiating agent” refers a compound that increases the efficacy of editing (e.g., mutation, including insertion, deletion, substitution, etc.) of a gene, genome, or other nucleic acid) by a gene editing technology relative to use of the gene editing technology in the absence of the compound. Preferred gene editing technologies suitable for use alone or more preferably in combination with the potentiating factors are discussed in more detail below. In some embodiments, the potentiating factor is administered as a nucleic acid encoding the potentiating factor. In certain preferred embodiments, the gene editing technology preferably in a particle composition.

[0083] Potentiating factors include, for example, DNA damage or repair-stimulating or - potentiating factors. Preferably the factor is one that engages one or more endogenous high fidelity DNA repair pathways. In some embodiments, the factor is one that modulates expression of Rad51, BRCA2, or a combination thereof. In particular embodiments, the factor decreases Rad51 activity.

[0084] As discussed in more detail below, the preferred methods typically include contacting cells with an effective amount of a gene editing potentiating factor. The contacting can occur ex vivo, for example isolated cells, or in vivo following, for example, administration of the potentiating factor to a subject. Exemplary gene editing potentiating agents include receptor tyrosine kinase C-kit ligands, ATR-Chkl cell cycle checkpoint pathway inhibitors, a DNA polymerase alpha inhibitors, and heat shock protein 90 inhibitors (HSP90i).

[0085] In some embodiments, the C-kit ligand is stem cell factor protein or fragment thereof sufficient to causes dimerization of C-kit and activates its tyrosine kinase activity. The C-kit ligand can be a nucleic acid encoding a stem cell factor (SCF) protein or fragment thereof sufficient to causes dimerization of C-kit and activates its tyrosine kinase activity. The nucleic acid can be an mRNA or an expression vector. The SCF can be human SCF or a fragment or variant thereof

[0086] In some embodiments, the potentiating agent is another cytokine or growth factor such as, erythropoietin, GM-CSF, EGF (especially for epithelial cells; lung epithelia for cystic fibrosis), hepatocyte growth factor etc., could similarly serve to boost gene editing potential in bone marrow cells or in other tissues. In some embodiments, gene editing is enhanced in specific cell types using cytokines targeted to these cell types.

[0087] It will be appreciated that cytokines and growth factors including SCF can be administered to cells or a subject as protein, or as a nucleic acid encoding protein (transcribed RNA, DNA, DNA in an expression vector). For example, a sequence encoding a protein or growth factor such as SCF can be incorporated into an autonomously replicating plasmid, a virus (e.g., a retrovirus, lentivirus, adenovirus, or herpes virus), or into the genomic DNA of a prokaryote or eukaryote.

[0088] In some embodiments, the potentiating factor is a replication modulator that can, for example, manipulate replication progression and / or replication forks. For example, the ATR- Chkl cell cycle checkpoint pathway has numerous roles in protecting cells from DNA damage and stalled replication, one of the most prominent being control of the cell cycle and prevention of premature entry into mitosis (Thompson and Eastman, Br J Clin Pharmacol., 76(3): 358-369 (2013), Smith, et al., Adv Cancer Res., 108:73-112 (2010)). However, Chkl also contributes to the stabilization of stalled replication forks, the control of replication origin firing and replication fork progression, and homologous recombination. DNA polymerase alpha also known as Pol a is an enzyme complex found in eukaryotes that is involved in initiation of DNA replication. Hsp90 (heat shock protein 90) is a chaperone protein that assists other proteins to fold properly, stabilizes proteins against heat stress, and aids in protein degradation.

[0089] The potentiating factor can be a small molecule inhibitor of ATR-Chkl Cell Cycle Checkpoint Pathway Inhibitor. Such inhibitors are known in the art, and many have been tested in clinical trials for the treatment of cancer. Exemplary CHK1 inhibitors include, but are not limited to, AZD7762, SCH900776 / MK-8776, IC83 / LY2603618, LY2606368, GDC- 0425, PF-00477736, XL844, CEP-3891, SAR-020106, CCT-244747, Arry-575 (Thompson and Eastman, Br J Clin Pharmacol., 76(3): 358-369 (2013)), and SB218075. Exemplary ATR pathway inhibitors include, but are not limited to Schisandrin B, NU6027, NVP-BEZ235, VE- 821, VE-822 (VX-970), AZ20, AZD6738, MIRIN, KU5593, VE-821, NU7441, LCA, and L189 (Weber and Ryan, Pharmacology & Therapeutics, 149:124-138 (2015)).

[0090] In some embodiments, the potentiating factor is a DNA polymerase alpha inhibitor, such as aphidicolin.

[0091] In some embodiments, the potentiating factor is a heat shock protein 90 inhibitor (HSP90i) such as STA-9090 (ganetespib). Other HSP90 inhibitors are known in the art and include, but are not limited to, benzoquinone ansamycin antibiotics such as geldanamycin (GA); 17-AAG (17-Allylamino-17-demethoxy-geldanamycin); 17-DMAG (17- dimethylaminoethylamino-17-dem ethoxy -geldanamycin) (Alvespimycin); IPI-504 (Retaspimycin); and AUY922 (Tatokoro, et al., EXCLI J., 14:48-58 (2015)).

[0092] A. COMPOSITIONS FOR USE IN PNA ASSISTED pAGO MEDIATED GENOME EDITING

[0093] A composition is disclosed comprising: (i) a DNA-targeting RNA / DNA, optionally including a first segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA; and a second segment that interacts with DNA nuclease; (ii) a DNA nuclease or a polynucleotide encoding the same, the DNA nuclease comprising: (a) a RNA / DNA -binding portion that interacts with the DNA-targeting RNA / DNA; and (b) an activity portion that exhibits site-directed nuclease activity, wherein the site of enzymatic activity is determined by the DNA-targeting RNA / DNA and a PNA having a sequence that is complementary to a sequence in a target DNA.

[0094] Hybridization requires that the two nucleic acids contain complementary sequences, although mismatches between bases are possible. The conditions appropriate for hybridization between two nucleic acids depend on the length of the nucleic acids and the degree of complementation, variables well known in the art. i. Argonauts Proteins

[0095] Argonaute proteins (hereinafter, Argos) exist in all domains of life (Meister 2013; Swarts, Makarova, et al. 2014), thus, eukaryotic Argonaute (eAgo) and prokaryotic Argonaute (pAgo) proteins are known. pAgos are classified into several clades, including long pAgos, short pAgos, and PIWI-RE proteins (Koonin 2017). Several pAgo proteins have been characterized, and they belong to the long pAgo proteins and possess conserved structural features; N, PAZ (Piwi-Argonaute-Zwille), MID (middle), and PIWI (P element-induced wimpy testis) domains (Lisitskaya, Aravin, and Kulbachinskiy 2018). These domains mediate guide binding, target recognition and cleavage of DNA and RNA substrates. The PIWI domain of Argonaute is a structural homologue of the RNase H catalytic domain, and contributes to endonuclease (slicing) activity for the target strand. The MID domain consists of a Rossmann-like fold and interacts directly with the 5 '-end of the guide strand by recognition of the phosphorylated first nucleotide and base features. The PAZ domain contains a hydrophobic pocket of an oligosaccharide-binding-like fold and is involved in binding of a single oligonucleotide; the PAZ domain associates with the 3 '-end of the guide strand. Short pAgos comprise the MID and PIWI domains only; short pAgos lack the catalytic tetrad required for target cleavage, which suggests that they are catalytically inactive.

[0096] In contrast to eAgos, the majority of discovered pAgos uses small single stranded guide DNA (gDNA) molecules to target DNA targets (Olina et al. 2018). Several characterized pAgos are capable of binding DNA or RNA targets, and they can be guided by either DNA or RNA guides (L. Wang et al. 2022). Similarly, RsAgo and MpAgo proteins can also be guided by DNA and RNA guides; however, the majority of the pAgo proteins are only guided by DNA guides (Yiwei Liu et al. 2018; Lapinaite, Doudna, and Cate 2018). The pAgo protein changes conformation upon guide binding exposing the nucleotides in the seed region (2 to 8- nt) to enable target recognition. Argos recruit small (-15-30 nucleotide [nt]) single-stranded guide oligonucleotides to bind complementary single-stranded target sequences. (Koopal, et al., Cell, 185(9): 1471-1486.el9).

[0097] The Argo used in the disclosed method and systems is preferably, pAgo, with nuclease activity. Because pAgo proteins have only one catalytic site, they can cut only one strand of dsDNA substrates. Therefore, the generation of double stranded breaks (DSBs) requires the binding of two pAgo complexes, on the upper and lower strand of the DNA target sequence, using two nucleic acid (DNA / RNA) guide molecules. However, the Ago can be an eAgo. Most of the eukaryotic Agos are RNA guided RNA targeting proteins. Any DNA or RNA guided Agos lacking DNA unwinding activity and targeting ssDNA can be used for dsDNA cleavage with the help of PNAs.

[0098] The Argo preferably has catalytic activity at physiological temperature, including activities at temperatures between about 30 °C and 45 °C and high GC content on the target DNA sequence, for example. GC 13, 22, 27,31, 35, 50, and up to, 75%.

[0099] Establishing complementarity between the oligonucleotide guide (OG) in the pAgo protein and the complementary strand of the dsDNA target requires the unwinding of the dsDNA molecules (Willkomm et al. 2017). However, pAgo lack intrinsic helicase activity and are unable to unwind the DNA on their own (Lisitskaya, Aravin, and Kulbachinskiy 2018). In some forms, the disclosed methods and systems preferably do not include a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated (Cas) nuclease. In some forms, the disclosed system, methods and compositions can include a CRISPR / Cas nuclease such as Cas 12. ii. Oligonucleotide guide (OG)

[0100] The OG is a DNA or RNA molecule of defined length for example, preferably, between about 15-30 nt. The guide is designed to be complementary to the target site for cleaving, on the target DNA molecule. See FIG. ID.

[0101] In preferred embodiments, the guide is a DNA molecule which can be modified at one end. Exemplary modifications include 5 ’-hydroxylated DNA guides (5 ’-OH DNA guides), phosphorothioated guides (PT-guides), 5 ’-phosphorylated RNA guides (RNA guides), and 5’- phosphorylated DNA guides (5’P-DNA guides).

[0102] OG length is an important design consideration in the disclosed system. The guide length can vary in length from about 10 to about 20 nt, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20-nt. In some forms, when the Argo is KmAgo and / or CbAgo, the guide length can be about 14, 16, 17, or 18 nt, preferably, 16 nt.

[0103] The DNA guide strands can be divided into different sections facilitating target recognition and the subsequent catalytic activity of the pAgo proteins. The first nucleotide at the 5’ end is the anchoring nucleotide and binds to the MID domain binding pocket. Next is the seed region composed of the 8 bases from the 5 ’end of the guide, which mediate target recognition and are stabilized by the C-terminal lobe and the linker between the two lobes. The central part and the 3 ’end bind to the PAZ domain. FIG. 7A and 7B. Single nucleotide mutations were tolerated at different parts of the guide DNA sequence. FIG. 7B. For example, CbAgo and KmAgo proteins tolerated 3-nt guide mismatches at anchor, seed regions compared to the supplementary and tail region 3-nt guide mismatches. KmAgo even tolerated 4-nt mismatches at the anchor, seed regions and did not show any cleavage with 4-nt mismatches at the central, supplementary, and tail. iii. PNA

[0104] Peptide nucleic acids (PNAs) are a class of synthetic oligonucleotide analogs characterized by the replacement of the canonical sugar-phosphate backbone with neutrally charged peptide bonds (Egholm et al. 1992). As a result of its neutrally charged backbone, PNA is able to bind to complimentary DNA or RNA with markedly higher affinity and specificity, thus resulting in hybrids that are more stable than the naturally occurring nucleic acid complexes (P. E. Nielsen and Egholm 1999; Peter E. Nielsen 2014). Additionally, the modified backbone renders PNAs remarkably stable and resistant to cleavage by all known proteases or nucleases (Peter E. Nielsen 2010; P. E. Nielsen 1999). DNA and RNA have a deoxyribose and ribose sugar backbone, respectively, whereas PNA's backbone is composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. The various purine and pyrimidine bases are linked to the backbone by a methylene bridge (-CH 2-) and a carbonyl group (-(C=O)-).

[0105] The disclosed compositions preferably include a PNA capable of invading DNA substrates. Different classes of PNA molecules have been shown to efficiently invade DNA substrates, including yPNA molecules. Unlike DNA or RNA in the unhybridized state (single strand) which can adopt a helical structure through base-stacking, although highly flexible, PNA does not have a well-defined conformational folding in solution. However, a backbone modification at the " / -position of the N-(2 -aminoethyl) glycine unit can transform a randomly folded PNA into a helical structure. Dragulescu-Andrasi et al. 2006.

[0106] PNA is used in any combination when selecting PNA pairs needed for one DNA double strand break, In some forms, the PNA is ytcPNA (gamma tail clamp peptide nucleic acid).

[0107] The disclosed gene editing systems are designed to use, in some forms, one PNA molecule (when a single strand break is needed or a single nucleotide repair is needed) and in other forms, two PNA molecules (when a double strand break is desired, for example)

[0108] For example, 2 PNA molecules and two Argos (with their OG) are used to create two nicks in opposing DNA strands. Pairs of PNA molecules can be used for simultaneous double stands breads at more than one location, for example, 2, 3 4 locations etc.

[0109] In some forms two PNA molecules are designed for binding on double stranded DNA, separated by a single nucleotide spacer. The design concept depends on the PNA invasion of two DNA sequences on the opposing strands in the double-stranded DNA molecule leading to displace two strands and the formation of ssDNA sequences on opposing strands of the DNA to serve as substates of the pAgo-guide DNA complexes (FIG ID). Different types of PNA molecules can invade DNA in different ways. As an example showed in the illustration (FIG. 1H) from Brodyagin, et al., J. Org. Chem., 17: 161-1688 (2021), (A) PNA-dsDNA 1 :1 triplex; (B) PNA-DNA-PNA strand-invasion triplex; (C) the Hoogsteen and Watson-Crick parts are linked together in a bis-PNA; (D) shortening the Hoogsteen part and extending the Watson- Crick part of the bis-PNA creates a tail-clamp PNA (tcPNA); (E) and (F) single and double invasion using only Watson-Crick hydrogen bonding; (G) Janus-wedge triple helix. In a preferred embodiment, the disclosed methods employ PNA molecules where both PNA molecules bind to the target DNA via Watson-crick hydrogen bonding or Hoogsteen binding. In this embodiment, the PNA oligomer includes a Watson-crick hydrogen binding peptide nucleic acid (PNA) in FIG. IB- IE, and Hoogsteen and Watson-crick hydrogen binding peptide nucleic acid (tcPNA) in FIG. 10A-10C. .

[0110] In some forms, the PNA is a yPNA designed following the principle of design for, yPNAl (SEQ ID NO: 9), yPNA2 (SEQ ID NO: 10), yPNA3 (SEQ ID NO: 11) and yPNA4 (SEQ ID NO: 12) as described herein (for example, Gamma-alanine at all the bases, or gamma tail clamp peptide nucleic acid (See Table 2). The PNA is designed to be complementary to the target site for cleaving and in some preferred embodiments for binding to the target DNA by strong hydrogen bonding . See FIG. ID.

[0111] Thus, in some forms some or all of the PNA residues are modified at the gamma position in the polyamide backbone (yPNAs) as illustrated below (wherein “B” is a nucleobase and “R” is a substitution at the gamma position).

[0112] Substitution at the gamma position creates chirality and provides helical preorganization to the PNA oligomer, yielding substantially increased binding affinity to the target DNA (Rapireddy, et al., Biochemistry, 50(19):3913-8 (2011), He et al., “Mol. BioSyst. 6:1619-1629 (2010); and Sahu et al., “J. Org. Chem, 76:5614-5627) (2011)).

[0113] Other advantageous properties can be conferred depending on the chemical nature of the specific substitution at the gamma position (the “R” group in the illustration of the Chiral yPNA, above).

[0114] Chemical structures showing substitution at the y position of the PNA backbone. PNA oligomers have either no (PNA, left), ethylene glycol (mpyPNA, middle), or hydroxymethyl (seryPNA, right) y substitution.

[0115]

[0116] “yPNA” and “gamma PNA” as used herein can refer to individual PNA residues or PNA oligomers that are modified or substituted at the gamma position.

[0117] One class of y substitution is miniPEG, also referred to as “MPyPNA”. A MPyPNA residue is depicted above. “MiniPEG” and “MP” refer to diethylene glycol.

[0118] Another of y substitution is hydroxymethyl, also referred to as “seryPNA”. A seryPNA residue is depicted above. “Ser” refers to serine.

[0119] Additionally, any of the PNA oligomers sequences can be modified to include guanidine-G-clamp (“G-clamp”) PNA residues(s) to enhance PNA oligomer binding to a target site, wherein the G-clamp is linked to the backbone as any other nucleobase would be. yPNAs with substitution of cytosine by G-clamp (9-(2-guanidinoethoxy) phenoxazine), a cytosine analog that can form five H-bonds with guanine, and can also provide extra base stacking due to the expanded phenoxazine ring system and substantially increased binding affinity. In vitro studies indicate that a single G-clamp substitution for C can substantially enhance the binding of a PNA-DNA duplex by 23 C (Kuhn, et al., Artificial DNA, PNA & XNA, 1(1):45- 53(2010)). As a result, yPNAs containing G-clamp substitutions can have further increased activity.

[0120] The structure of a G-clamp monomer-to-G base pair (G-clamp indicated by the “X”) is illustrated below in comparison to C-G base pair.

[0121]

[0122] C«G base-pair

[0123] X-G base-pair

[0124] PNA oligomers can also include other positively charged moieties to increase the solubility of the PNA and increase the affinity of the PNA for duplex DNA. Commonly used positively charged moieties include the amino acids lysine and arginine, although other positively charged moieties may also be useful. Lysine and arginine residues can be added to a bis-PNA linker or can be added to the carboxy or the N-terminus of a PNA strand. Common modifications to PNA oligomers are discussed in Sugiyama and Kittaka, Molecules, 18:287- 310 (2013)) and Sahu, et al., J. Org. Chem., 76, 5614-5627 (2011), each of which are specifically incorporated by reference in their entireties, and include, but are not limited to, incorporation of charged amino acid residues, such as lysine at the termini or in the interior part of the oligomer; inclusion of polar groups in the backbone, a carboxymethylene bridge in the nucleobases; chiral PNA oligomers bearing substituents on the original N-(2- aminoethyl)glycine backbone; replacement of the original aminoethylglycyl backbone skeleton with a negatively -charged scaffold; conjugation of high molecular weight polyethylene glycol (PEG) to one of the termini; fusion of a PNA oligomer to DNA to generate a chimeric oligomer, redesign of the backbone architecture, conjugation of PNA to DNA or RNA. These modifications improve solubility but often result in reduced binding affinity and / or sequence specificity.

[0125] Spacer Length and guide direction

[0126] The spacer length between the two yPNA invaded strands and the orientation of two guides (5’ to 3’ ends facing inward and outward) are key in the design considerations for efficient PNA-pAgo complexes. The spacer length between the two yPNA invaded strands and the orientation of two guides (5’ to 3’ ends facing inward and outward) are key in the design considerations for efficient PNA-pAgo complexes. “Spacer” as used herein refers to the number of nucleotides on the target DNA, in between the two PNA molecule invasions. Spacer is in between the two PNA molecule invasions and it is irrespective of PNA orientation. The direction of the guide sequence is also a design consideration and the guides can be designed to face inwards or outwards, together or separately. (FIG. 4A and 4B).

[0127] The spacer lengths can vary between 1-nt to 30-nt, for example, 1, 3, 5, 6, 10, 15, 20, and 30-nt. CbAgo is active at broad spacer lengths, with a preferred spacer length of about 10 nt (when the guides are facing outward). CbAgo is preferably used with a spacer ranging from 1-nt spacer to 10-nt spacer (when the guides face inward). In some forms, the spacer length for Km Ago is preferably no more than 10 nt.

[0128] PNA and guide nucleic acid Length

[0129] PNA and guide nucleic acids can vary in length from about 10 to about 20 nt, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20-nt.

[0130] In some forms, the system uses a 20-nt long yPNAl / yPNA3 in combination with 16-nt guides and 20-nt guides and the pAgo is CbAgo and / or KmAgo.

[0131] B. PNA ASSISTED FOKI-(D)PAGO MEDIATED GENOME EDITING

[0132] This approach relies on PNA invasion of two adjacent regions in target DNA that are subsequently recognized and bound by DNA guided FokI-(d)pAgo fusion protein. DNA cleavage in this method requires dimerization of two FokI domains. This approach to induce DSB is, in principle, highly specific since it requires five events happening in close proximity, rendering non-specific activity exceedingly unlikely. First, PNAs have to recognize and invade nearby regions of dsDNA, followed by guide DNA recognition of exposed ssDNA strands. Second, FokI domains must dimerize to trigger their nuclease activity. Another advantage of this approach lies in the fact that pAgo PIWI domain is inactivated and cannot chop its expression plasmid, reducing the expression and acquisition of non-specific guides (FIG. 18B). An exemplary FOKI sequence: (GSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYR GKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRN KHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIG GEMIKAGTLTLEEVRRKFNNGEINF) (SEQ ID NO: 119) is disclosed Guilinger, J., et al., Nat Biotechnol 32, 577 -582 (2014) and can be used to fuse with (d)Argo in different orientations. C. PNA ASSISTED pAGO BASE EDITING

[0133] DNA-guided pAgo sequence recognition can be exploited to direct adenine and cytosine base editors to specific sites to elicit their activity. Current generation of base editors suffer from the requirement for PAM sequence that has to exist within a strictly defined window next to the base that is targeted for editing. Since there is, in principle, no requirement for pAgo and PNA positioning, the disclosed method can address this major obstacle facing Cas9 base editors. In addition, the presence of PNA on the opposite strand to deaminated base, might automatically bias the repair machinery to repair the non-edited strand, reducing indel generation that is featured in currently existing base editors (FIG. 18C). Different base editors such as ABE and CBE are known and are disclosed in several publications such as Li J, et al., Nat Cornmun., 12(1):2287 (2021). Koblan, L., et ai., Nat BiotechnoL, 36, 843-846 (2018). Gaudelli, N. et al., Nature, 551, 464-471 (2017). Komor, A., Nature, 533, 420-424 (2016); they can be fused with (d)Agos for base editing.

[0134] D. PNA ASSISTED T7El-(d)pAGO GENOME EDITING

[0135] PNA molecules invade natural B-DNA leading to formation of unnatural distortions in the DNA helix. These structures can be recognized by mutated, catalytically inactive T7E1 fused to FokI monomer. Hybridization of two PNA molecules with two adjacent genomic regions could recruit FokI domains and induce DSB. Alternatively, PNA can be conjugated with a short DNA flap that is partially complimentary to the target site. This structure is recognized by FEN1 proteins that naturally excise DNA flaps that occur during various natural processes. It might be possible to induce DSB at targeted sites by recruiting Fokl-FENl fusion proteins in a highly specific manner, that requires two independent recognition events (FIG. 18D). This embodiment is based on the principle that PNA induced structure may be used to recruit pAgos that are catalytically active. Alternatively, catalytically inactive pAgo are fused with other nuclease domains like T7EI can be used. Here in this modality: pAgo is used for programmable DNA binding and the T7EI will be used for the cleavage of the target sequence. The PNA will induce a structure that will be recognized by structure specific nucleases like T7EI. In some forms, the T7EI is catalytically inactive. In these embodiments, a fusion protein containing the FOKI catalytic domain fused to T7EI is used. Therefore, PNA induces the structure that is recognized by the catalytically inactive T7EI-FokI fusions and the FOKI dimerization will lead to the generation of double strand breaks. Exemplary The T7E1 mutants disclosed Declais AC, J Mol Biol. 307(4): 1145-58, (2001), can be fused with FokI protein. E. PNA ASSISTED STRUCTURE-BASED GENOME EDITING

[0136] PNA molecules invade natural B-DNA leading to formation of unnatural distortions in the DNA helix. These structures can be recognized by mutated, catalytically inactive T7E1 fused to FokI monomer. Hybridization of two PNA molecules with two adjacent genomic regions could recruit FokI domains and induce DSB. Alternatively, PNA can be conjugated with a short DNA flap that is partially complimentary to the target site. This structure is recognized by FEN1 proteins that naturally excise DNA flaps that occur during various natural processes. It might be possible to induce DSB at targeted sites by recruiting Fokl-FENl fusion proteins in a highly specific manner, that requires two independent recognition events.

[0137] F. PAM-LESS LBCAS12A GENOME EDITING

[0138] LbCasl2a is known to be active for genome editing in human cells. However, the presence of TTTV PAM sequence greatly reduces the number of targetable regions in the genome. In contrast to SpCas9 that generates PAM proximal, blunt end DSB, approximately 3 bp downstream of the PAM sequence, LbCasl2a induces PAM distal staggered DSB, that makes it possible to avoid regions invaded by PNA that would prevent nuclease activity. Moreover, PNA invasion doesn’t require a particular sequence and exposes a stretch of ssDNA that can be bound by LbCasl2 sgRNA. Since it is known that LbCasl2a is active on ssDNA without PAM requirement, this approach expands its utility beyond the conventional limitations imposed by prohibitive PAM sequence. Moreover, this technology could be expanded to include Casl2 base editors and prime editors that do not require any PAM sequences. PNA, LbCasl2a and LbCasl2a-gRNA components are required to work this system.

[0139] METHODS OF USE

[0140] The disclosed system using PNP editors can be used for targeted genome modifications, including, for example, base editing, chromatin modifications, and other types of base modifications. The therapeutic value of the disclosed PNP editor technology is valuable because the system is highly specific, and the size of the complexes is much smaller than CRISPR cargos, thereby providing improved specificity and immunogenicity and lower cellular toxicity.

[0141] Features of the present disclosure include a method of producing a modified cell in vitro or in a subject, the method comprising: (I) introducing into a target cell: (i) a DNA- targeting RNA / DNA, optionally, wherein the DNA-targeting RNA / DNA comprises: (a) a first segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA; and (b) a second segment that interacts with a site-directed DNA nuclease; and (ii) site- directed DNA modifying polypeptide such as a DNA nuclease, or a polynucleotide encoding the same, wherein the site-directed modifying polypeptide comprises: (a) an RNA / DNA - binding portion that interacts with the DNA-targeting RNA / DNA; and optionally, (b) an activity portion that exhibits nuclease activity that creates a strand break in the target DNA; wherein the site of the DNA strand break is determined by the DNA-targeting RNA / DNA, the contacting occurs under conditions that are permissive for nonhomologous end joining or homology -directed repair, and the target DNA is cleaved and rejoined to produce a modified DNA sequence; thereby producing the genetically modified cell; and (II) optionally, transplanting the genetically modified cell into a subject.

[0142] In some cases, the cell is selected from the group consisting of: an archaeal cell, a bacterial cell, a eukaryotic cell, a eukaryotic single-cell organism, a somatic cell, a germ cell, a stem cell, a plant cell, an algal cell, an animal cell, in invertebrate cell, a vertebrate cell, a fish cell, an amphibian cell, a bird cell, a mammalian cell, an ungulate cell, a rodent cell, a nonhuman primate cell, and a human cell.

[0143] However, the target cell can any type of cell may be of interest (e.g. a stem cell, e.g. an embryonic stem (ES) cell, an induced pluripotent stem (iPS) cell, a germ cell; a somatic cell, e.g. a fibroblast, a hematopoietic cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell; an in vitro or in vivo embryonic cell of an embryo at any stage, e.g., a 1-cell, 2- cell, 4-cell, 8-cell, etc. stage zebrafish embryo; etc.). Cells may be from established cell lines or they may be primary cells, where “primary cells”, “primary cell lines”, and “primary cultures” are used interchangeably herein to refer to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages, i.e. splittings, of the culture. For example, primary cultures are cultures that may have been passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, or 15 times, but not enough times go through the crisis stage. Typically, the primary cell lines of the present invention are maintained for fewer than 10 passages in vitro. Target cells are in many embodiments unicellular organisms, or are grown in culture.

[0144] The site-directed DNA modifying polypeptides disclosed herein can be delivered in the forms of DNA, mRNA, or protein.

[0145] (a) Methods of introducing a nucleic acid into a host cell

[0146] In some embodiments, the method involves introducing into a cell (or a population of cells) one or more nucleic acids comprising nucleotide sequences encoding a site-directed modifying polypeptide. In some forms the cell is in vitro. In some forms the cell is in vivo. Suitable nucleic acids comprising nucleotide sequences encoding a site-directed modifying polypeptide include expression vectors, where an expression vector comprising a nucleotide sequence encoding a site-directed modifying polypeptide is a “recombinant expression vector.”

[0147] Suitable expression vectors include, but are not limited to, viral vectors (e.g. viral vectors based on vaccinia virus; poliovirus; adenovirus (see, e.g., Li et al., Invest Opthalmol V is Sci 35:2543 2549, 1994; Borras et al., Gene Ther 6:515 524, 1999; Li and Davidson, PNAS 92:7700 7704, 1995; Sakamoto et al., H Gene Ther 5:1088 1097, 1999; WO 94 / 12649, WO 93 / 03769; WO 93 / 19191; WO 94 / 28938; WO 95 / 11984 and WO 95 / 00655); adeno-associated virus (see, e.g., Ali et al., Hum Gene Ther 9:8186, 1998, Flannery et al., PNAS 94:6916 6921, 1997; Bennett et al., Invest Opthalmol V is Sci 38:2857 2863, 1997; Jomary et al., Gene Ther 4:683 690, 1997, Rolling et al., Hum Gene Ther 10:641 648, 1999; Ali et al., Hum Mol Genet. 5:591 594, 1996; Srivastava in WO 93 / 09239, Samulski et al., I. Vir. (1989) 63:3822-3828; Mendelson et al., Virol. (1988) 166:154-165; and Flotte et al., PNAS (1993) 90:10613-10617); SV40; herpes simplex virus; human immunodeficiency virus (see, e.g., Miyoshi et al., PNAS 94:1031923, 1997; Takahashi et al., J Virol 73:7812 7816, 1999); a retroviral vector (e.g., Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, a lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus); and the like.

[0148] Numerous suitable expression vectors are known to those of skill in the art, and many are commercially available. The following vectors are provided by way of example; for eukaryotic host cells: pXTl, pSG5 (Stratagene), pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia). However, any other vector may be used so long as it is compatible with the host cell.

[0149] Depending on the host / vector system utilized, any of a number of suitable transcription and translation control elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector (see e.g., Bitter et al. (1987) Methods in Enzymology, 153:516-544).

[0150] In some embodiments, a nucleotide sequence encoding a site-directed modifying polypeptide is operably linked to a control element, e.g., a transcriptional control element, such as a promoter. The transcriptional control element may be functional in either a eukaryotic cell, e.g., a mammalian cell; or a prokaryotic cell (e g., bacterial or archaeal cell). In some embodiments, a nucleotide sequence encoding a DNA-targeting RNA and / or a site-directed modifying polypeptide is operably linked to multiple control elements that allow expression of the nucleotide sequence encoding a DNA-targeting RNA and / or a site-directed modifying polypeptide in both prokaryotic and eukaryotic cells.

[0151] Non-limiting examples of suitable eukaryotic promoters (promoters functional in a eukaryotic cell) include those from cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, early and late SV40, long terminal repeats (LTRs) from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector may also contain a ribosome binding site for translation initiation and a transcription terminator. The expression vector may also include appropriate sequences for amplifying expression. The expression vector may also include nucleotide sequences encoding protein tags (e.g., 6><His tag, hemagglutinin tag, green fluorescent protein, etc.) that are fused to the site-directed modifying polypeptide, thus resulting in a chimeric polypeptide.

[0152] In some embodiments, a nucleotide sequence encoding a DNA-targeting RNA and / or a site-directed modifying polypeptide is operably linked to an inducible promoter. In some embodiments, a nucleotide sequence encoding a DNA-targeting RNA and / or a site-directed modifying polypeptide is operably linked to a constitutive promoter.

[0153] Methods of introducing a nucleic acid such as nucleic acids encoding the disclosed site- directed DNA modifying peptides or OG into a host cell are known in the art, and any known method can be used to introduce a nucleic acid (e.g., an expression construct) into a cell. Suitable methods include e.g., viral or bacteriophage infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct micro injection, nanoparticle-mediated nucleic acid delivery (see, e.g., Panyam et., al Adv Drug Deliv Rev. 2012 Sep. 13. pii: 50169-4.

[0154] (b) Methods of polypeptides into a target cell

[0155] In some forms, the polypeptides disclosed herein are delivered into a host cell as a polypeptide. In one preferred embodiment, the site-directed modifying polypeptide and its OG are preassembled into a complex and then delivered as a complex to the host cell.

[0156] The polypeptides or their complex with OG can be delivered in a nanoparticle. Any of the disclosed compositions including, but not limited to potentiating factors, gene editing molecules, PNA, etc., can be delivered to the target cells using a nanoparticle delivery vehicle. In some embodiments, some of the compositions are packaged in nanoparticles and some are not. For example, in some embodiments, the gene editing technology and / or donor oligonucleotide is incorporated into nanoparticles while the potentiating factor is not. In some embodiments, the gene editing technology and / or donor oligonucleotide, and the potentiating factor are packaged in nanoparticles. The different compositions can be packaged in the same nanoparticles or different nanoparticles. For example, the compositions can be mixed and packaged together. In some embodiments, the different compositions are packaged separately into separate nanoparticles wherein the nanoparticles are similarly or identically composed and / or manufactured. In some embodiments, the different compositions are packaged separately into separate nanoparticles wherein the nanoparticles are differentially composed and / or manufactured.

[0157] Nanoparticles generally refers to particles in the range of between 500 nm to less than 0.5 nm, preferably having a diameter that is between 50 and 500 nm, more preferably having a diameter that is between 50 and 300 nm. Cellular internalization of polymeric particles is highly dependent upon their size, with nanoparticulate polymeric particles being internalized by cells with much higher efficiency than microparticulate polymeric particles. For example, Desai, et al. have demonstrated that about 2.5 times more nanoparticles that are 100 nm in diameter are taken up by cultured Caco-2 cells as compared to microparticles having a diameter on 1 pM (Desai, et al., Pharm. Res., 14:1568-73 (1997)). Nanoparticles also have a greater ability to diffuse deeper into tissues in vivo. i. Polymer

[0158] The polymer that forms the core of the nanoparticle may be any biodegradable or non- biodegradable synthetic or natural polymer. In a preferred embodiment, the polymer is a biodegradable polymer. Nanoparticles are ideal materials for the fabrication of gene editing delivery vehicles: 1) control over the size range of fabrication, down to 100 nm or less, an important feature for passing through biological barriers; 2) reproducible biodegradability without the addition of enzymes or cofactors; 3) capability for sustained release of encapsulated, protected nucleic acids over a period in the range of days to months by varying factors such as the monomer ratios or polymer size, for example, the ratio of lactide to glycolide monomer units in poly(lactide-co-glycolide) (PLGA); 4) well-understood fabrication methodologies that offer flexibility over the range of parameters that can be used for fabrication, including choices of the polymer material, solvent, stabilizer, and scale of production; and 5) control over surface properties facilitating the introduction of modular functionalities into the surface.

[0159] Examples of preferred biodegradable polymers include synthetic polymers that degrade by hydrolysis such as poly(hydroxy acids), such as polymers and copolymers of lactic acid and glycolic acid, other degradable polyesters, polyanhydrides, poly(ortho)esters, polyesters, polyurethanes, poly(butic acid), poly(valeric acid), poly(caprolactone), poly(hydroxyalkanoates), poly(lactide-co-caprolactone), and poly(amine-co-ester) polymers, such as those described in Zhou, et al., Nature Materials, 11:82-90 (2012) and WO 2013 / 082529, U.S. Published Application No. 2014 / 0342003, and PCT / US2015 / 061375.

[0160] Preferred natural polymers include alginate and other polysaccharides, collagen, albumin and other hydrophilic proteins, zein and other prolamines and hydrophobic proteins, copolymers and mixtures thereof. In general, these materials degrade either by enzymatic hydrolysis or exposure to water in vivo, by surface or bulk erosion.

[0161] In some embodiments, non-biodegradable polymers can be used, especially hydrophobic polymers. Examples of preferred non-biodegradable polymers include ethylene vinyl acetate, poly(meth) acrylic acid, copolymers of maleic anhydride with other unsaturated polymerizable monomers, poly(butadiene maleic anhydride), polyamides, copolymers and mixtures thereof, and dextran, cellulose and derivatives thereof.

[0162] Other suitable biodegradable and non-biodegradable polymers include, but are not limited to, polyanhydrides, polyamides, polycarbonates, polyalkylenes, polyalkylene oxides such as polyethylene glycol, polyalkylene terepthalates such as poly(ethylene terephthalate), polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyethylene, polypropylene, poly(vinyl acetate), poly vinyl chloride, polystyrene, polyvinyl halides, polyvinylpyrrolidone, polymers of acrylic and methacrylic esters, polysiloxanes, polyurethanes and copolymers thereof, modified celluloses, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxyethyl cellulose, cellulose triacetate, cellulose sulfate sodium salt, and polyacrylates such as poly(methyl methacrylate), poly(ethylmethacrylate), poly(butylmethacrylate), poly (isobutylmethacrylate), poly(hexylmethacrylate), poly(isodecylmethacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate). These materials may be used alone, as physical mixtures (blends), or as co-polymers. The polymer may be a bioadhesive polymer that is hydrophilic or hydrophobic. Hydrophilic polymers include CARBOPOL™ (a high molecular weight, crosslinked, acrylic acid-based polymers manufactured by NOVEON™), polycarbophil, cellulose esters, and dextran.

[0163] Release rate controlling polymers may be included in the polymer matrix or in the coating on the formulation. Examples of rate controlling polymers that may be used are hydroxypropylmethylcellulose (HPMC) with viscosities of either 5, 50, 100 or 4000 cps or blends of the different viscosities, ethylcellulose, methylmethacrylates, such as EUDRAGIT® RS100, EUDRAGIT® RL100, EUDRAGIT® NE 30D (supplied by Rohm America). Gastrosoluble polymers, such as EUDRAGIT® E100 or enteric polymers such as EUDRAGIT® LI 00-55D, LI 00 and SI 00 may be blended with rate controlling polymers to achieve pH dependent release kinetics. Other hydrophilic polymers such as alginate, polyethylene oxide, carboxymethylcellulose, and hydroxyethylcellulose may be used as rate controlling polymers.

[0164] These polymers can be obtained from sources such as Sigma Chemical Co., St. Louis, MO; Polysciences, Warrenton, PA; Aldrich, Milwaukee, WI; Fluka, Ronkonkoma, NY; and BioRad, Richmond, CA, or can be synthesized from monomers obtained from these or other suppliers using standard techniques.

[0165] In a preferred embodiment, the nanoparticles are formed of polymers fabricated from polylactides (PLA) and copolymers of lactide and glycolide (PLGA). These have established commercial use in humans and have a long safety record (Jiang, et al., Adv. Drug Deliv. Rev., 57(3):391-410); Aguado and Lambert, Immunobiology, 184(2-3): 113-25 (1992); Bramwell, et al., Adv. Drug Deliv. Rev., 57(9): 1247-65 (2005)). These polymers have been used to encapsulate siRNA (Yuan, et al., Jour. Nanosocience and Nanotechnology, 6:2821-8 (2006); Braden, et al., Jour. Biomed. Nanotechnology, 3:148-59 (2007); Khan, et al., Jour. Drug Target, 12:393-404 (2004); Woodrow, et al., Nature Materials, 8:526-533 (2009)). Murata, et al., J. Control. Release, 126(3):246-54 (2008) showed inhibition of tumor growth after intratumoral injection of PLGA microspheres encapsulating siRNA targeted against vascular endothelial growth factor (VEGF). However, these microspheres were too large to be endocytosed (35-45 Qn) (Conner and Schmid, Nature, 422(6927):37-44 (2003)) and required release of the anti-VEGF siRNA extracellularly as a polyplex with either polyarginine or PEI before they could be internalized by the cell. These microparticles may have limited applications because of the toxicity of the polycations and the size of the particles. Nanoparticles (100-300 nm) of PLGA can penetrate deep into tissue and are easily internalized by many cells (Conner and Schmid, Nature, 422(6927): 37-44 (2003)).

[0166] The nanoparticles can be designed to release encapsulated nucleic acids over a period of days to weeks. Factors that affect the duration of release include pH of the surrounding medium (higher rate of release at pH 5 and below due to acid catalyzed hydrolysis of PLGA) and polymer composition. Aliphatic polyesters differ in hydrophobicity, affecting degradation rate. Specifically, the hydrophobic poly (lactic acid) (PLA), more hydrophilic poly (glycolic acid) PGA and their copolymers, poly (lactide-co-glycolide) (PLGA) have various release rates. The degradation rate of these polymers, and often the corresponding drug release rate, can vary from days (PGA) to months (PLA) and is easily manipulated by varying the ratio of PLA to PGA.

[0167] Exemplary nanoparticles are described in U.S. Patent Nos. 4,883,666, 5,114,719, 5,601,835, 7,534,448, 7,534,449, 7,550,154, and 8,889,117, and U.S. Published Application Nos. 2009 / 0269397, 2009 / 0239789, 2010 / 0151436, 2011 / 0008451, 2011 / 0268810, 2014 / 0342003, 2015 / 0118311, 2015 / 0125384, 2015 / 0073041, Hubbell, et al., Science, 337:303-305 (2012), Cheng, et al., Biomaterials, 32:6194-6203 (2011), Rodriguez, et al., Science, 339:971-975 (2013), Hrkach, et al., Sci Transl Med., 4:128ral39 (2012), McNeer, et al., Mol Ther., 19:172-180 (2011), McNeer, et al., Gene Ther., 20:658-659 (2013), Babar, et al., Proc Natl Acad Sci USA, 109:E1695-E1704 (2012), Fields, et al., J Control Release 164:41-48 (2012), and Fields, et al., Advanced Healthcare Materials, 361-366 (2015). ii. Polycations

[0168] In a preferred embodiment, the nucleic acids are complexed to polycations to increase the encapsulation efficiency of the nucleic acids into the nanoparticles. The term “polycation” refers to a compound having a positive charge, preferably at least 2 positive charges, at a selected pH, preferably physiological pH. Polycationic moieties have between about 2 to about 15 positive charges, preferably between about 2 to about 12 positive charges, and more preferably between about 2 to about 8 positive charges at selected pH values.

[0169] Many polycations are known in the art. Suitable constituents of polycations include basic amino acids and their derivatives such as arginine, asparagine, glutamine, lysine and histidine; cationic dendrimers; and amino polysaccharides. Suitable polycations can be linear, such as linear tetralysine, branched or dendrimeric in structure.

[0170] Exemplary polycations include, but are not limited to, synthetic polycations based on acrylamide and 2-acrylamido-2-methylpropanetrimethylamine, poly(N-ethyl-4-vinylpyridine) or similar quartemized polypyridine, di ethyl aminoethyl polymers and dextran conjugates, polymyxin B sulfate, lipopolyamines, poly(allylamines) such as the strong polycation poly(dimethyldiallylammonium chloride), polyethyleneimine, polybrene, and polypeptides such as protamine, the histone polypeptides, polylysine, polyarginine and polyomithine.

[0171] In one embodiment, the polycation is a polyamine. Polyamines are compounds having two or more primary amine groups. In a preferred embodiment, the polyamine is a naturally occurring polyamine that is produced in prokaryotic or eukaryotic cells. Naturally occurring polyamines represent compounds with cations that are found at regularly-spaced intervals and are therefore particularly suitable for complexing with nucleic acids. Polyamines play a major role in very basic genetic processes such as DNA synthesis and gene expression. Polyamines are integral to cell migration, proliferation and differentiation in plants and animals. The metabolic levels of polyamines and amino acid precursors are critical and hence biosynthesis and degradation are tightly regulated. Suitable naturally occurring polyamines include, but are not limited to, spermine, spermidine, cadaverine and putrescine. In a preferred embodiment, the polyamine is spermidine.

[0172] In another embodiment, the polycation is a cyclic polyamine. Cyclic polyamines are known in the art and are described, for example, in U.S. Patent No. 5,698,546, WO 1993 / 012096 and WO 2002 / 010142. Exemplary cyclic polyamines include, but are not limited to, cyclen.

[0173] Spermine and spermidine are derivatives of putrescine (1,4-diaminobutane) which is produced from L-ornithine by action of ODC (ornithine decarboxylase). L-omithine is the product of L-arginine degradation by arginase. Spermidine is a triamine structure that is produced by spermidine synthase (SpdS) which catalyzes monoalkylation of putrescine (1,4- diaminobutane) with decarboxylated S-adenosylmethionine (dcAdoMet) 3 -aminopropyl donor. The formal alkylation of both amino groups of putrescine with the 3-aminopropyl donor yields the symmetrical tetraamine spermine. The biosynthesis of spermine proceeds to spermidine by the effect of spermine synthase (SpmS) in the presence of dcAdoMet. The 3-aminopropyl donor (dcAdoMet) is derived from S-adenosylmethionine by sequential transformation of L- methionine by methionine adenosyltransferase followed by decarboxylation by AdoMetDC (S- adenosylmethionine decarboxylase). Hence, putrescine, spermidine and spermine are metabolites derived from the amino acids L-arginine (L-omithine, putrescine) and L- methionine (dcAdoMet, aminopropyl donor). In some embodiments, the particles themselves are a poly cation (e.g., a blend of PLGA and poly(beta amino ester). iii. Coupling Agents or Ligands

[0174] The external surface of the polymeric nanoparticles may be modified by conjugating to, or incorporating into, the surface of the nanoparticle a coupling agent or ligand.

[0175] In a preferred embodiment, the coupling agent is present in high density on the surface of the nanoparticle. As used herein, “high density” refers to polymeric nanoparticles having a high density of ligands or coupling agents, which is preferably in the range of 1,000 to 10,000,000, more preferably 10,000-1,000,000 ligands per square micron of nanoparticle surface area. This can be measured by fluorescence staining of dissolved particles and calibrating this fluorescence to a known amount of free fluorescent molecules in solution.

[0176] Coupling agents associate with the polymeric nanoparticles and provide substrates that facilitate the modular assembly and disassembly of functional elements to the nanoparticles. Coupling agents or ligands may associate with nanoparticles through a variety of interactions including, but not limited to, hydrophobic interactions, electrostatic interactions and covalent coupling.

[0177] In a preferred embodiment, the coupling agents are molecules that match the polymer phase hydrophile-lipophile balance. Hydrophile-lipophile balances range from 1 to 15. Molecules with a low hydrophile-lipophile balance are more lipid loving and thus tend to make a water in oil emulsion while those with a high hydrophile-lipophile balance are more hydrophilic and tend to make an oil in water emulsion. Fatty acids and lipids have a low hydrophile-lipophile balance below 10.

[0178] Any amphiphilic polymer with a hydrophile-lipophile balance in the range 1-10, more preferably between 1 and 6, most preferably between 1 and up to 5, can be used as a coupling agent. Examples of coupling agents which may associate with polymeric nanoparticles via hydrophobic interactions include, but are not limited to, fatty acids, hydrophobic or amphipathic peptides or proteins, and polymers. These classes of coupling agents may also be used in any combination or ratio. In a preferred embodiment, the association of adaptor elements with nanoparticles facilitates a prolonged presentation of functional elements which can last for several weeks.

[0179] Coupling agents can also be attached to polymeric nanoparticles through covalent interactions through various functional groups. Functionality refers to conjugation of a molecule to the surface of the particle via a functional chemical group (carboxylic acids, aldehydes, amines, sulfhydryls and hydroxyls) present on the surface of the particle and present on the molecule to be attached.

[0180] Functionality may be introduced into the particles in two ways. The first is during the preparation of the nanoparticles, for example during the emulsion preparation of nanoparticles by incorporation of stablizers with functional chemical groups. Suitable stabilizers include hydrophobic or amphipathic molecules that associate with the outer surface of the nanoparticles.

[0181] A second is post-particle preparation, by direct crosslinking particles and ligands with homo- or heterobifunctional crosslinkers. This second procedure may use a suitable chemistry and a class of crosslinkers (CDI, ED AC, glutaraldehydes, etc. as discussed in more detail below) or any other crosslinker that couples ligands to the particle surface via chemical modification of the particle surface after preparation. This second class also includes a process whereby amphiphilic molecules such as fatty acids, lipids or functional stabilizers may be passively adsorbed and adhered to the particle surface, thereby introducing functional end groups for tethering to ligands.

[0182] One useful protocol involves the “activation” of hydroxyl groups on polymer chains with the agent, carbonyldiimidazole (CDI) in aprotic solvents such as DMSO, acetone, or THF. CDI forms an imidazolyl carbamate complex with the hydroxyl group which may be displaced by binding the free amino group of a molecule such as a protein. The reaction is an N- nucleophilic substitution and results in a stable N-alkylcarbamate linkage of the molecule to the polymer. The “coupling” of the molecule to the “activated” polymer matrix is maximal in the pH range of 9-10 and normally requires at least 24 hrs. The resulting molecule-polymer complex is stable and resists hydrolysis for extended periods of time.

[0183] Another coupling method involves the use of l-ethyl-3 -(3 -dimethylaminopropyl) carbodiimide (ED AC) or “water-soluble CDI” in conjunction with N- hydroxylsulfosuccinimide (sulfo NHS) to couple the exposed carboxylic groups of polymers to the free amino groups of molecules in a totally aqueous environment at the physiological pH of 7.0. Briefly, EDAC and sulfo-NHS form an activated ester with the carboxylic acid groups of the polymer which react with the amine end of a molecule to form a peptide bond. The resulting peptide bond is resistant to hydrolysis. The use of sulfo-NHS in the reaction increases the efficiency of the EDAC coupling by a factor of ten-fold and provides for exceptionally gentle conditions that ensure the viability of the molecule-polymer complex. By using either of these protocols it is possible to “activate” almost all polymers containing either hydroxyl or carboxyl groups in a suitable solvent system that will not dissolve the polymer matrix.

[0184] A useful coupling procedure for attaching molecules with free hydroxyl and carboxyl groups to polymers involves the use of the cross-linking agent, di vinyl sulfone. This method would be useful for attaching sugars or other hydroxylic compounds with bioadhesive properties to hydroxylic matrices. Briefly, the activation involves the reaction of divinylsulfone to the hydroxyl groups of the polymer, forming the vinylsulfonyl ethyl ether of the polymer. The vinyl groups will couple to alcohols, phenols and even amines. Activation and coupling take place at pH 11. The linkage is stable in the pH range from 1-8 and is suitable for transit through the intestine.

[0185] Any suitable coupling method known to those skilled in the art for the coupling of molecules and polymers with double bonds, including the use of UV crosslinking, may be used for attachment of molecules to the polymer.

[0186] In one embodiment, coupling agents can be conjugated to affinity tags. Affinity tags are any molecular species which form highly specific, noncovalent, physiochemical interactions with defined binding partners. Affinity tags which form highly specific, noncovalent, physiochemical interactions with one another are defined herein as “complementary”. Suitable affinity tag pairs are well known in the art and include epitope / antibody, biotin / avidin, biotin / streptavidin, biotin / neutravidin, glutathione-S- transferase / glutathione, maltose binding protein / amylase and maltose binding protein / maltose. Examples of suitable epitopes which may be used for epitope / antibody binding pairs include, but are not limited to, HA, FLAG, c-Myc, glutatione-S-transferase, His6, GFP, DIG, biotin and avidin. Antibodies (both monoclonal and polyclonal and antigen-binding fragments thereof) which bind to these epitopes are well known in the art.

[0187] Affinity tags that are conjugated to coupling agents allow for highly flexible, modular assembly and disassembly of functional elements which are conjugated to affinity tags which form highly specific, noncovalent, physiochemical interactions with complementary affinity tags which are conjugated to coupling agents. Adaptor elements may be conjugated with a single species of affinity tag or with any combination of affinity tag species in any ratio. The ability to vary the number of species of affinity tags and their ratios conjugated to adaptor elements allows for exquisite control over the number of functional elements which may be attached to the nanoparticles and their ratios. In another embodiment, coupling agents are coupled directly to functional elements in the absence of affinity tags, such as through direct covalent interactions. Coupling agents can be covalently coupled to at least one species of functional element. Coupling agents can be covalently coupled to a single species of functional element or with any combination of species of functional elements in any ratio.

[0188] In a preferred embodiment, coupling agents are conjugated to at least one affinity tag that provides for assembly and disassembly of modular functional elements which are conjugated to complementary affinity tags. In a more preferred embodiment, coupling agents are fatty acids that are conjugated with at least one affinity tag. In a particularly preferred embodiment, the coupling agents are fatty acids conjugated with avidin or streptavidin. Avidin / streptavidin-conjugated fatty acids allow for the attachment of a wide variety of biotin- conjugated functional elements.

[0189] The coupling agents are preferably provided on, or in the surface of, nanoparticles at a high density. This high density of coupling agents allows for coupling of the polymeric nanoparticles to a variety of species of functional elements while still allowing for the functional elements to be present in high enough numbers to be efficacious.

[0190] 1. Fatty Acids

[0191] The coupling agents may include fatty acids. Fatty acids may be of any acyl chain length and may be saturated or unsaturated. In a particularly preferred embodiment, the fatty acid is palmitic acid. Other suitable fatty acids include, but are not limited to, saturated fatty acids such as butyric, caproic, caprylic, capric, lauric, myristic, stearic, arachidic and behenic acid. Still other suitable fatty acids include, but are not limited to, unsaturated fatty acids such as oleic, linoleic, alpha-linolenic, arachidonic, eicosapentaenoic, docosahexaenoic and erucic acid.

[0192] 2. Hydrophobic or Amphipathic Peptides

[0193] The coupling agents may include hydrophobic or amphipathic peptides. Preferred peptides should be sufficiently hydrophobic to preferentially associate with the polymeric nanoparticle over the aqueous environment. Amphipathic polypeptides useful as adaptor elements may be mostly hydrophobic on one end and mostly hydrophilic on the other end. Such amphipathic peptides may associate with polymeric nanoparticles through the hydrophobic end of the peptide and be conjugated on the hydrophilic end to a functional group. 3. Hydrophobic Polymers

[0194] Coupling agents may include hydrophobic polymers. Examples of hydrophobic polymers include, but are not limited to, polyanhydrides, poly(ortho)esters, and polyesters such as polycaprolactone. iv. Functional Molecules

[0195] Functional molecules can be associated with, linked, conjugated, or otherwise attached directly or indirectly gene editing technology, potentiating agents, or nanoparticles utilized for delivery thereof. a. Targeting Molecules

[0196] One class of functional elements is targeting molecules. Targeting molecules can be associated with, linked, conjugated, or otherwise attached directly or indirectly to the gene editing molecule, or to a nanoparticle or other delivery vehicle thereof.

[0197] Targeting molecules can be proteins, peptides, nucleic acid molecules, saccharides or polysaccharides that bind to a receptor or other molecule on the surface of a targeted cell. The degree of specificity and the avidity of binding to the graft can be modulated through the selection of the targeting molecule. For example, antibodies are very specific. These can be polyclonal, monoclonal, fragments, recombinant, or single chain, many of which are commercially available or readily obtained using standard techniques.

[0198] Examples of moieties include, for example, targeting moieties which provide for the delivery of molecules to specific cells, e.g., antibodies to hematopoietic stem cells, CD34+ cells, T cells or any other preferred cell type, as well as receptor and ligands expressed on the preferred cell type. Preferably, the moieties target hematopoeitic stem cells.

[0199] Examples of molecules targeting extracellular matrix (“ECM”) include glycosaminoglycan (“GAG”) and collagen. In one embodiment, the external surface of polymer particles may be modified to enhance the ability of the particles to interact with selected cells or tissue. The method described above wherein an adaptor element conjugated to a targeting molecule is inserted into the particle is preferred. However, in another embodiment, the outer surface of a polymer micro- or nanoparticle having a carboxy terminus may be linked to targeting molecules that have a free amine terminus.

[0200] Other useful ligands attached to polymeric micro- and nanoparticles include pathogen- associated molecular patterns (PAMPs). PAMPs target Toll-like Receptors (TLRs) on the surface of the cells or tissue, or signal the cells or tissue internally, thereby potentially increasing uptake. PAMPs conjugated to the particle surface or co-encapsulated may include: unmethylated CpG DNA (bacterial), double-stranded RNA (viral), lipopolysacharride (bacterial), peptidoglycan (bacterial), lipoarabinomannin (bacterial), zymosan (yeast), mycoplasmal lipoproteins such as MALP-2 (bacterial), flagellin (bacterial) poly(inosinic- cytidylic) acid (bacterial), lipoteichoic acid (bacterial) or imidazoquinolines (synthetic).

[0201] In another embodiment, the outer surface of the particle may be treated using a mannose amine, thereby mannosylating the outer surface of the particle. This treatment may cause the particle to bind to the target cell or tissue at a mannose receptor on the antigen presenting cell surface. Alternatively, surface conjugation with an immunoglobulin molecule containing an Fc portion (targeting Fc receptor), heat shock protein moiety (HSP receptor), phosphatidylserine (scavenger receptors), and lipopolysaccharide (LPS) are additional receptor targets on cells or tissue.

[0202] Lectins that can be covalently attached to micro- and nanoparticles to render them target specific to the mucin and mucosal cell layer include lectins isolated from Abrus precatroius, Agaricus bisporus, Anguilla anguilla, Arachis hypogaea, Pandeiraea simplicifolia, Bauhinia purpurea, Caragan arobrescens, Cicer arietinum, Codium fragile, Datura stramonium, Dolichos biflorus, Erythrina corallodendron, Erythrina cristagalli, Euonymus europaeus, Glycine max, Helix aspersa, Helix pomatia, Lathyrus odoratus, Lens culinaris, Limulus polyphemus, Lysopersicon esculentum, Maclura pomifera, Momordica charantia, Mycoplasma gallisepticum, Naja mocambique, as well as the lectins Concanavalin A, SuccinyL Concanavalin A, Triticum vulgaris, Ulex europaeus I, II and III, Sambucus nigra, Maackia amurensis, Limax fluvus, Homarus americanus, Cancer antennarius, and Lotus tetragonolobus.

[0203] The choice of targeting molecule will depend on the method of administration of the nanoparticle composition and the cells or tissues to be targeted. The targeting molecule may generally increase the binding affinity of the particles for cell or tissues or may target the nanoparticle to a particular tissue in an organ or a particular cell type in a tissue. Avidin increases the ability of polymeric nanoparticles to bind to tissues. While the exact mechanism of the enhanced binding of avidin-coated particles to tissues has not been elucidated, it is hypothesized it is caused by electrostatic attraction of positively charged avidin to the negatively charged extracellular matrix of tissue. Non-specific binding of avidin, due to electrostatic interactions, has been previously documented and zeta potential measurements of avidin-coated PLGA particles revealed a positively charged surface as compared to uncoated PLGA particles. The attachment of any positively charged ligand, such as polyethyleneimine or polylysine, to any polymeric particle may improve bioadhesion due to the electrostatic attraction of the cationic groups coating the beads to the net negative charge of the mucus. The mucopolysaccharides and mucoproteins of the mucin layer, especially the sialic acid residues, are responsible for the negative charge coating. Any ligand with a high binding affinity for mucin could also be covalently linked to most particles with the appropriate chemistry and be expected to influence the binding of particles to the gut. For example, polyclonal antibodies raised against components of mucin or else intact mucin, when covalently coupled to particles, would provide for increased bioadhesion. Similarly, antibodies directed against specific cell surface receptors exposed on the lumenal surface of the intestinal tract would increase the residence time of beads, when coupled to particles using the appropriate chemistry. The ligand affinity need not be based only on electrostatic charge, but other useful physical parameters such as solubility in mucin or else specific affinity to carbohydrate groups.

[0204] The covalent attachment of any of the natural components of mucin in either pure or partially purified form to the particles would decrease the surface tension of the bead-gut interface and increase the solubility of the bead in the mucin layer. The list of useful ligands includes, but is not limited to the following: sialic acid, neuraminic acid, n-acetyl-neuraminic acid, n-glycolylneuraminic acid, 4-acetyl-n-acetylneuraminic acid, diacetyl-n-acetylneuraminic acid, glucuronic acid, iduronic acid, galactose, glucose, mannose, fucose, any of the partially purified fractions prepared by chemical treatment of naturally occurring mucin, e.g., mucoproteins, mucopolysaccharides and mucopolysaccharide-protein complexes, and antibodies immunoreactive against proteins or sugar structure on the mucosal surface.

[0205] The attachment of polyamino acids containing extra pendant carboxylic acid side groups, e.g., polyaspartic acid and polyglutamic acid, should also provide a useful means of increasing bioadhesiveness. Using polyamino acids in the 15,000 to 50,000 kDa molecular weight range yields chains of 120 to 425 amino acid residues attached to the surface of the particles. The polyamino chains increase bioadhesion by means of chain entanglement in mucin strands as well as by increased carboxylic charge.

[0206] The efficacy of the nanoparticles is determined in part by their route of administration into the body. For orally and topically administered nanoparticles, epithelial cells constitute the principal barrier that separates an organism's interior from the outside world. Epithelial cells such as those that line the gastrointestinal tract form continuous monolayers that simultaneously confront the extracellular fluid compartment and the extracorporeal space. Adherence to cells is an essential first step in crossing the epithelial barrier by any of these mechanisms. Therefore, in one embodiment, the nanoparticles disclosed herein further include epithelial cell targeting molecules. Epithelial cell targeting molecules include monoclonal or polyclonal antibodies or bioactive fragments thereof that recognize and bind to epitopes displayed on the surface of epithelial cells. Epithelial cell targeting molecules also include ligands which bind to a cell surface receptor on epithelial cells. Ligands include, but are not limited to, molecules such as polypeptides, nucleotides and polysaccharides.

[0207] A variety of receptors on epithelial cells may be targeted by epithelial cell targeting molecules. Examples of suitable receptors to be targeted include, but are not limited to, IgE Fc receptors, EpCAM, selected carbohydrate specificites, dipeptidyl peptidase, and E-cadherin. b. Protein Transduction Domains and Fusogenic Peptides

[0208] Other functional elements that can be associated with, linked, conjugated, or otherwise attached directly or indirectly to the gene editing molecule, potentiating agent, or to a nanoparticle or other delivery vehicle thereof, include protein transduction domains and fusogenic peptides.

[0209] For example, the efficiency of nanoparticle delivery systems can also be improved by the attachment of functional ligands to the NP surface. Potential ligands include, but are not limited to, small molecules, cell-penetrating peptides (CPPs), targeting peptides, antibodies or aptamers (Yu, et al., PLoS One., 6:e24077 (2011), Cu, et al., J Control Release, 156:258-264 (2011), Nie, et al., J Control Release, 138:64-70 (2009), Cruz, et al., J Control Release, 144: 118-126 (2010)). Attachment of these moieties serves a variety of different functions; such as inducing intracellular uptake, endosome disruption, and delivery of the plasmid payload to the nucleus. There have been numerous methods employed to tether ligands to the particle surface. One approach is direct covalent attachment to the functional groups on PLGA NPs (Bertram, Acta Biomater. 5:2860-2871 (2009)). Another approach utilizes amphiphilic conjugates like avidin palmitate to secure biotinylated ligands to the NP surface (Fahmy, et al., Biomaterials, 26:5727-5736 (2005), Cu, et al., Nanomedicine, 6:334-343 (2010)). This approach produces particles with enhanced uptake into cells, but reduced pDNA release and gene transfection, which is likely due to the surface modification occluding pDNA release. In a similar approach, lipid-conjugated polyethylene glycol (PEG) is used as a multivalent linker of penetratin, a CPP, or folate (Cheng, et al., Biomaterials, 32:6194-6203 (2011)).

[0210] These methods, as well as other methods discussed herein, and others methods known in the art, can be combined to tune particle function and efficacy. In some preferred embodiments, PEG is used as a linker for linking functional molecules to nanoparticles. For example, DSPE-PEG(2000)-maleimide is commercially available and can be used utilized for covalently attaching functional molecules such as CPP.

[0211] “Protein Transduction Domain” or PTD refers to a polypeptide, polynucleotide, or organic or inorganic compounds that facilitates traversing a lipid bilayer, micelle, cell membrane, organelle membrane, or vesicle membrane. A PTD attached to another molecule facilitates the molecule traversing membranes, for example going from extracellular space to intracellular space, or cytosol to within an organelle. PTA can be short basic peptide sequences such as those present in many cellular and viral proteins. Exemplary protein transduction domains that are well-known in the art include, but are not limited to, the Antennapedia PTD and the TAT (transactivator of transcription) PTD, poly-arginine, polylysine or mixtures of arginine and lysine, HIV TAT (YGRKKRRQRRR (SEQ ID NO: 116) or RKKRRQRRR (SEQ ID NO: 117), 11 arginine residues, VP22 peptide, and an ANTp peptide (RQIKIWFQNRRMKWKK) (SEQ ID NO: 118) or positively charged polypeptides or polynucleotides having 8-15 residues, preferably 9-11 residues. Short, non-peptide polymers that are rich in amines or guanidinium groups are also capable of carrying molecules crossing biological membranes. Penetratin and other derivatives of peptides derived from antennapedia (Cheng, et al., Biomaterials, 32(26):6194-203 (2011) can also be used. Results show that penetratin in which additional Args are added, further enhances uptake and endosomal escape, and IKK NBD, which has an antennapedia domain for permeation as well as a domain that blocks activation of NFkB and has been used safely in the lung for other purposes (von Bismarck, et al., Pulmonary Pharmacology & Therapeutics, 25(3):228-35 (2012), Kamei, et al., Journal Of Pharmaceutical Sciences, 102(11):3998-4008 (2013)).

[0212] A “fusogenic peptide” is any peptide with membrane destabilizing abilities. In general, fusogenic peptides have the propensity to form an amphiphilic alpha-helical structure when in the presence of a hydrophobic surface such as a membrane. The presence of a fusogenic peptide induces formation of pores in the cell membrane by disruption of the ordered packing of the membrane phospholipids. Some fusogenic peptides act to promote lipid disorder and in this way enhance the chance of merging or fusing of proximally positioned membranes of two membrane enveloped particles of various nature (e.g. cells, enveloped viruses, liposomes). Other fusogenic peptides may simultaneously attach to two membranes, causing merging of the membranes and promoting their fusion into one. Examples of fusogenic peptides include a fusion peptide from a viral envelope protein ectodomain, a membrane-destabilizing peptide of a viral envelope protein membrane-proximal domain from the cytoplasmic tails.

[0213] Other fusogenic peptides often also contain an amphiphilic-region. Examples of amphiphilic-region containing peptides include: melittin, magainins, the cytoplasmic tail of HIV1 gp41, microbial and reptilian cytotoxic peptides such as bomolitin 1, pardaxin, mastoparan, crabrolin, cecropin, entamoeba, and staphylococcal alpha -toxin; viral fusion peptides from (1) regions at the N terminus of the transmembrane (TM) domains of viral envelope proteins, e.g. HIV-1, SIV, influenza, polio, rhinovirus, and coxsackie virus; (2) regions internal to the TM ectodomain, e.g. semliki forest virus, sindbis virus, rota virus, rubella virus and the fusion peptide from sperm protein PH-30: (3) regions membrane- proximal to the cytoplasmic side of viral envelope proteins e.g. in viruses of avian leukosis (ALV), Feline immunodeficiency (FIV), Rous Sarcoma (RSV), Moloney murine leukemia virus (MoMuLV), and spleen necrosis (SNV).

[0214] In particular embodiments, a functional molecule such as a CPP is covalently linked to DSPE-PEG-maleimide functionalized nanoparticles such as PBAE / PLGA blended particles using known methods such as those described in Fields, et al., J Control Release, 164(1):41- 48 (2012). For example, DSPE-PEG-function molecule can be added to the 5.0% PVA solution during formation of the second emulsion. In some embodiments, the loading ratio is about 5 nmol / mg ligand-to-polymer ratio.

[0215] In some embodiments, the functional molecule is a CPP such as those above, or mTAT (HIV-1 (with histidine modification) HHHHRKKRRQRRRRHHHHH (SEQ ID NO: 120) (Yamano, et al., J Control Release, 152:278-285 (2011)); or bPrPp (Bovine prion) MVKSKIGSWILVLFVAMWS DVGLCKKRPKP (SEQ ID NO: 121) (Magzoub, et al., Biochem Biophys Res Commun., 348:379-385 (2006)); or MPG (Synthetic chimera: SV40 Lg T. Ant.+HIV gb41 coat) GALFLGFLGAAGSTMGAWS QPKKKRKV (SEQ ID NO: 122) (Endoh, e t al., Adv Drug Deliv Rev., 61 :704-709 (2009)).

[0216] Methods of Making nanoparticles

[0217] Methods of making nanoparticles are known in the art. For example, the nanoparticles can be formed by a double-emulsion solvent evaporation technique, such as is disclosed in U.S. Published Application No. 2011 / 0008451 or U.S. Published Application No. 2011 / 0268810, each of which is a specifically incorporated by reference in its entirety, or Fahmy, et al., Biomaterials, 26:5727-5736, (2005), or McNeer, et al., Mol. Ther. 19, 172-180 (2011)). In this technique, the nucleic acids or nucleic acid / polycation complexes are reconstituted in an aqueous solution. Nucleic acid and polycation amounts are discussed in more detail below and can be chosen, for example, based on amounts and ratios disclosed in U.S. Published Application No. 2011 / 0008451 or U.S. Published Application No. 2011 / 0268810, or used by McNeer, et al., (McNeer, et al., Mol. Ther. 19, 172-180 (2011)), or by Woodrow et al. for small interfering RNA encapsulation (Woodrow, et al., Nat Mater, 8:526-533 (2009)). This aqueous solution is then added dropwise to a polymer solution of a desired polymer dissolved in an organic solvent to form the first emulsion.

[0218] This mixture is then added dropwise to solution containing a surfactant, such as polyvinyl alcohol (PVA) and sonicated to form the double emulsion. The final emulsion is then poured into a solution containing the surfactant in an aqueous solution and stirred for a period of time to allow the dichloromethane to evaporate and the particles to harden. The concentration of the surfactant used to form the emulsion, and the sonication time and amplitude can been optimized according to principles known in the art for formulating particles with a desired diameter. The particles can be collected by centrifugation. If it is desirable to store the nanoparticles for later use, they can be rapidly frozen, and lyophilized.

[0219] In some preferred embodiments the nanoparticles are PLGA nanoparticles. In a particular exemplary protocol, nucleic acid (such as PNA, DNA, or PNA-DNA) with or without a polycation (such as spermidine) are dissolved in DNAse / RNAse free H2O. Encapsulant in H2O can be added dropwise to a polymer solution of 50:50 ester-terminated PLGA dissolved in di chloromethane (DCM), then sonicated to form the first emulsion. This emulsion can then be added dropwise to 5% polyvinyl alcohol, then sonicated to form the second emulsion. This mixture can be poured into 0.3% polyvinyl alcohol, and stirred at room temperature to form nanoparticles. Nanoparticles can then be collected and washed with, for example H2O, collected by centrifugation, and then resuspended in H2O, frozen at -80 °C, and lyophilized. Particles can be stored at -20 °C following lyophilization.

[0220] Additional techniques for encapsulating the nucleic acid and polycation complex into polymeric nanoparticles are described below.

[0221] 1. Solvent evaporation

[0222] In this method the polymer is dissolved in a volatile organic solvent, such as methylene chloride. The drug (either soluble or dispersed as fine particles) is added to the solution, and the mixture is suspended in an aqueous solution that contains a surface active agent such as poly(vinyl alcohol). The resulting emulsion is stirred until most of the organic solvent evaporated, leaving solid particles. The resulting particles are washed with water and dried overnight in a lyophilizer. Particles with different sizes (0.5-1000 microns) and morphologies can be obtained by this method. This method is useful for relatively stable polymers like polyesters and polystyrene.

[0223] However, labile polymers, such as polyanhydrides, may degrade during the fabrication process due to the presence of water. For these polymers, the following two methods, which are performed in completely anhydrous organic solvents, are more useful.

[0224] 2. Interfacial polycondensation

[0225] Interfacial polycondensation is used to microencapsulate a core material in the following manner. One monomer and the core material are dissolved in a solvent. A second monomer is dissolved in a second solvent (typically aqueous) which is immiscible with the first. An emulsion is formed by suspending the first solution through stirring in the second solution. Once the emulsion is stabilized, an initiator is added to the aqueous phase causing interfacial polymerization at the interface of each droplet of emulsion.

[0226] 3. Solvent evaporation microencapsulation

[0227] In solvent evaporation microencapsulation, the polymer is typically dissolved in a water immiscible organic solvent and the material to be encapsulated is added to the polymer solution as a suspension or solution in an organic solvent. An emulsion is formed by adding this suspension or solution to a beaker of vigorously stirring water (often containing a surface active agent, for example, polyethylene glycol or polyvinyl alcohol, to stabilize the emulsion). The organic solvent is evaporated while continuing to stir. Evaporation results in precipitation of the polymer, forming solid microcapsules containing core material.

[0228] The solvent evaporation process can be used to entrap a liquid core material in a polymer such as PLA, PLA / PGA copolymer, or PLA / PCL copolymer microcapsules. The polymer or copolymer is dissolved in a miscible mixture of solvent and nonsolvent, at a nonsolvent concentration which is immediately below the concentration which would produce phase separation (i.e., cloud point). The liquid core material is added to the solution while agitating to form an emulsion and disperse the material as droplets. Solvent and nonsolvent are vaporized, with the solvent being vaporized at a faster rate, causing the polymer or copolymer to phase separate and migrate towards the surface of the core material droplets. This phase- separated solution is then transferred into an agitated volume of nonsolvent, causing any remaining dissolved polymer or copolymer to precipitate and extracting any residual solvent from the formed membrane. The result is a microcapsule composed of polymer or copolymer shell with a core of liquid material. Solvent evaporation microencapsulation can result in the stabilization of insoluble active agent particles in a polymeric solution for a period of time ranging from 0.5 hours to several months. Stabilizing an insoluble pigment and polymer within the dispersed phase (typically a volatile organic solvent) can be useful for most methods of microencapsulation that are dependent on a dispersed phase, including film casting, solvent evaporation, solvent removal, spray drying, phase inversion, and many others.

[0229] The stabilization of insoluble active agent particles within the polymeric solution could be critical during scale-up. By stabilizing suspended active agent particles within the dispersed phase, the particles can remain homogeneously dispersed throughout the polymeric solution as well as the resulting polymer matrix that forms during the process of microencapsulation..

[0230] Solvent evaporation microencapsulation (SEM) have several advantages. SEM allows for the determination of the best polymer-solvent-insoluble particle mixture that will aid in the formation of a homogeneous suspension that can be used to encapsulate the particles. SEM stabilizes the insoluble particles or pigments within the polymeric solution, which will help during scale-up because one will be able to let suspensions of insoluble particles or pigments sit for long periods of time, making the process less time-dependent and less labor intensive. SEM allows for the creation of nanoparticles that have a more optimized release of the encapsulated material.

[0231] 4. Hot melt microencapsulation

[0232] In this method, the polymer is first melted and then mixed with the solid particles. The mixture is suspended in a non-miscible solvent (like silicon oil), and, with continuous stirring, heated to 5°C above the melting point of the polymer. Once the emulsion is stabilized, it is cooled until the polymer particles solidify. The resulting particles are washed by decantation with petroleum ether to give a free-flowing powder. Particles with sizes between 0.5 to 1000 microns are obtained with this method. The external surfaces of spheres prepared with this technique are usually smooth and dense. This procedure is used to prepare particles made of polyesters and polyanhydrides. However, this method is limited to polymers with molecular weights between 1,000-50,000.

[0233] 5. Solvent removal microencapsulation

[0234] In solvent removal microencapsulation, the polymer is typically dissolved in an oil miscible organic solvent and the material to be encapsulated is added to the polymer solution as a suspension or solution in organic solvent. Surface active agents can be added to improve the dispersion of the material to be encapsulated. An emulsion is formed by adding this suspension or solution to vigorously stirring oil, in which the oil is a nonsolvent for the polymer and the polymer / solvent solution is immiscible in the oil. The organic solvent is removed by diffusion into the oil phase while continuing to stir. Solvent removal results in precipitation of the polymer, forming solid microcapsules containing core material.

[0235] 6. Phase separation microencapsulation

[0236] In phase separation microencapsulation, the material to be encapsulated is dispersed in a polymer solution with stirring. While continually stirring to uniformly suspend the material, a nonsolvent for the polymer is slowly added to the solution to decrease the polymer's solubility. Depending on the solubility of the polymer in the solvent and nonsolvent, the polymer either precipitates or phase separates into a polymer rich and a polymer poor phase. Under proper conditions, the polymer in the polymer rich phase will migrate to the interface with the continuous phase, encapsulating the core material in a droplet with an outer polymer shell.

[0237] 7. Spontaneous emulsification

[0238] Spontaneous emulsification involves solidifying emulsified liquid polymer droplets by changing temperature, evaporating solvent, or adding chemical cross-linking agents. The physical and chemical properties of the encapsulant, and the material to be encapsulated, dictates the suitable methods of encapsulation. Factors such as hydrophobicity, molecular weight, chemical stability, and thermal stability affect encapsulation.

[0239] 8. Coacervation

[0240] Encapsulation procedures for various substances using coacervation techniques have been described in the prior art, for example, in GB-B-929406; GB-B-929401; U.S. Patent Nos. 3,266,987; 4,794,000 and 4,460,563. Coacervation is a process involving separation of colloidal solutions into two or more immiscible liquid layers (Ref. Dowben, R. General Physiology, Harper & Row, New York, 1969, pp. 142-143.). Through the process of coacervation compositions comprised of two or more phases and known as coacervates may be produced. The ingredients that comprise the two phase coacervate system are present in both phases; however, the colloid rich phase has a greater concentration of the components than the colloid poor phase.

[0241] 9. Solvent removal

[0242] This technique is primarily designed for polyanhydrides. In this method, the drug is dispersed or dissolved in a solution of the selected polymer in a volatile organic solvent like methylene chloride. This mixture is suspended by stirring in an organic oil (such as silicon oil) to form an emulsion. Unlike solvent evaporation, this method can be used to make particles from polymers with high melting points and different molecular weights. Particles that range between 1-300 microns can be obtained by this procedure. The external morphology of spheres produced with this technique is highly dependent on the type of polymer used.

[0243] 10. Spray-drying

[0244] In this method, the polymer is dissolved in organic solvent. A known amount of the active drug is suspended (insoluble drugs) or co-dissolved (soluble drugs) in the polymer solution. The solution or the dispersion is then spray-dried. Typical process parameters for a mini-spray drier (Buchi) are as follows: polymer concentration = 0.04 g / mL, inlet temperature = -24° C, outlet temperature = 13-15° C, aspirator setting = 15, pump setting = 10 mL / minute, spray flow = 600 Nl / hr, and nozzle diameter = 0.5 mm. Particles ranging between 1-10 microns are obtained with a morphology which depends on the type of polymer used.

[0245] 11. Nanoprecipitation

[0246] In nanoprecipitation, the polymer and nucleic acids are co-dissolved in a selected, water-miscible solvent, for example DMSO, acetone, ethanol, acetone, etc. In a preferred embodiment, nucleic acids and polymer are dissolved in DMSO. The solvent containing the polymer and nucleic acids is then drop-wise added to an excess volume of stirring aqueous phase containing a stabilizer (e.g., poloxamer, Pluronic®, and other stabilizers known in the art). Particles are formed and precipitated during solvent evaporation. To reduce the loss of polymer, the viscosity of the aqueous phase can be increased by using a higher concentration of the stabilizer or other thickening agents such as glycerol and others known in the art. Lastly, the entire dispersed system is centrifuged, and the nucleic acid-loaded polymer nanoparticles are collected and optionally filtered. Nanoprecipitation-based techniques are discussed in, for example, U.S. Patent No. 5,118,528.

[0247] Advantages to nanoprecipitation include: the method can significantly increase the encapsulation efficiency of drugs that are polar yet water-insoluble, compared to single or double emulsion methods (Alshamsan, Saudi Pharmaceutical Journal, 22(3):219-222 (2014)). No emulsification or high shear force step (e.g., sonication or high-speed homogenization) is involved in nanoprecipitation, therefore preserving the conformation of nucleic acids. Nanoprecipitation relies on the differences in the interfacial tension between the solvent and the nonsolvent, rather than shear stress, to produce nanoparticles. Hydrophobicity of the drug will retain it in the instantly-precipitating nanoparticles; the un-precipitated polymer due to equilibrium is “lost” and not in the precipitated nanoparticle form. A. PNA assisted pAgo mediated genome editing

[0248] This method exploits the properties of highly specific dsDNA invasion by PNA and ssDNA nicking activity of prokaryotic argonautes (FIG. 18A). Exposed ssDNA regions are recognized and nicked by pAgos resulting in DSB that can potentially be harnessed for the development of a novel genome editing platform. The advantage of this approach over existing technologies is that any DNA sequence can be targeted, in principle, without any sequence restriction. Moreover, there are two layers of specificity since DNA invasion and nicking by pAgo have to happen in close proximity in order to generate DSB.

[0249] In some forms, the method comprises: (1) introducing into a target cell: (i) a DNA- targeting RNA / DNA, optionally, wherein the DNA-targeting RNA / DNA comprises: (a) a first segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA; and (b) a second segment that interacts with a site-directed DNA nuclease; and (ii) a pAgo nuclease, or a polynucleotide encoding the same, wherein the pAgo nuclease comprises: (a) an RNA / DNA -binding portion that interacts with the DNA-targeting RNA / DNA; and optionally, (b) an activity portion that exhibits nuclease activity that creates a single strand break in the target DNA; wherein the site of the DNA strand break is determined by the DNA- targeting RNA / DNA and (2) optionally, transplanting the genetically modified cell into a subject.

[0250] The PNA- assisted localization and binding of the pAgo makes it possible to fuse a variety of functional domains to the pAgo backbones for different targeted modifications.

[0251] B. PNA assisted FokI-(d)pAgo mediated genome editing

[0252] This approach relies on PNA invasion of two adjacent regions in target DNA that are subsequently recognized and bound by DNA guided FokI-(d)pAgo fusion protein. DNA cleavage in this method requires dimerization of two FokI domains. This approach to induce DSB is, in principle, highly specific since it requires five events happening in close proximity, rendering non-specific activity exceedingly unlikely. First, PNAs have to recognize and invade nearby regions of dsDNA, followed by guide DNA recognition of exposed ssDNA strands. Second, FokI domains must dimerize to trigger their nuclease activity. Another advantage of this approach lies in the fact that pAgo PIWI domain is inactivated and cannot chop its expression plasmid, reducing the expression and acquisition of non-specific guides (FIG. 18B).

[0253] In some forms, the method comprises: (1) introducing into a target cell: (i) a DNA- targeting RNA / DNA, optionally, wherein the DNA-targeting RNA / DNA comprises: (a) a first segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA; and (b) a second segment that interacts with a site-directed DNA nuclease; and (ii) a FokI-(d)pAgo fusion protein, or a polynucleotide encoding the same, wherein the pAgo nuclease comprises: (a) an RNA / DNA -binding portion that interacts with the DNA-targeting RNA / DNA; and optionally, (b) an activity portion that exhibits nuclease activity that creates a single strand break in the target DNA; wherein the site of the DNA strand break is determined by the DNA-targeting RNA / DNA and (2) optionally, transplanting the genetically modified cell into a subject.

[0254] C. PNA assisted pAgo base editing

[0255] DNA-guided pAgo sequence recognition can be exploited to direct adenine and cytosine base editors to specific sites to elicit their activity. Current generation of base editors suffer from the requirement for PAM sequence that has to exist within a strictly defined window next to the base that is targeted for editing. Since there is, in principle, no requirement for pAgo and PNA positioning, the disclosed method can address this major obstacle facing Cas9 base editors. In addition, the presence of PNA on the opposite strand to deaminated base, might automatically bias the repair machinery to repair the non-edited strand, reducing indel generation that is featured in currently existing base editors (FIG. 18C).

[0256] Other embodiments contemplate replacing Argo protein in the disclosed embodiments, with T7E1, such as mutated, catalytically inactive T7E1 fused to FokI monomer or a Cas protein..

[0257] D. PNA assisted T7El-(d)pAgo genome editing

[0258] PNA molecules invade natural B-DNA leading to formation of unnatural distortions in the DNA helix. These structures can be recognized by mutated, catalytically inactive T7E1 fused to FokI monomer. Hybridization of two PNA molecules with two adjacent genomic regions could recruit FokI domains and induce DSB. Alternatively, PNA can be conjugated with a short DNA flap that is partially complimentary to the target site. This structure is recognized by FEN1 proteins that naturally excise DNA flaps that occur during various natural processes. It might be possible to induce DSB at targeted sites by recruiting Fokl-FENl fusion proteins in a highly specific manner, that requires two independent recognition events (FIG. 18D).

[0259] E. PAM-less LbCasl2a genome editing

[0260] LbCasl2a is known to be active for genome editing in human cells. However, the presence of TTTV PAM sequence greatly reduces the number of targetable regions in the genome. In contrast to SpCas9 that generates PAM proximal, blunt end DSB, approximately 3 bp downstream of the PAM sequence, LbCasl2a induces PAM distal staggered DSB, that makes it possible to avoid regions invaded by PNA that would prevent nuclease activity. Moreover, PNA invasion doesn’t require a particular sequence and exposes a stretch of ssDNA that can be bound by LbCasl2 sgRNA. Since it is known that LbCasl2a is active on ssDNA without PAM requirement, this approach might expand its utility beyond the conventional limitations imposed by prohibitive PAM sequence. Moreover, this technology could be expanded to include Casl2 base editors and prime editors that do not require any PAM sequences. PNA, LbCasl2a and LbCasl2a-gRNA components are required to work this system.

[0261] The disclosed methods provide alternatives to other genome editing technologies including CRISPR-mediated genome modification and may help overcome key challenges for CRISPR clinical applications. The diversity of pAgo and the practicality of PNA synthesis makes this system useful in applications for gene therapy applications and for targeted editing for diverse species.

[0262] The advantages of using PNP editors in genome editing include: PNP editors do not require any sequence motif as a prerequisite for binding, e.g., they do not require Protospacer Associated Motif (PAM) sequence. A second advantage is that PNP editors employ the pAgo enzyme, which possesses one RNAse H-like fold in the PIWI domain and can generate only a single nick. Therefore, the generation of DSBs requires the formation of two complexes. This makes PNP editors a precise genome editing tool. A third advantage is that PNP editors employs PNA and pAgo protein with small size compared with Cas9; therefore, the delivery into target cells will be much better compared with the CRISPR-Cas system. A fourth advantage of the PNP editor is programmed with PNA to mediate target invasion of the genomic DNA substrate and with DNA guides to direct the pAgo protein activity to the displaced ssDNA; therefore, PNP editors can be used to edit organellar genomes. Another advantage is their low toxicity - pAgo and PNA do not increase toxicity levels; and are therefore safe for use in gene therapy.

[0263] The present disclosure can be further understood by the following non-limiting examples.

[0264] Examples

[0265] Materials and Methods

[0266] Purification of Argonauts proteins used in in vitro experiments

[0267] CbAgo, NLS-CbAgo and NLS-CbAgo-NLS E. coli codon optimized CbAgo ( FIG. 8A;Table 1) was subcloned into the His6- TwinStrep-SUMO expression vector and transformed into the A. coli (BL21). Starter cultures were prepared by growing a single colony in LB broth containing 100 pg / mL ampicillin for 12 hours at 37°C and shaking at 180 rpm. Expression cultures consisting of Terrific Broth (IBI Scientific) containing 100 pg / mL ampicillin were inoculated with the starter culture and incubated at 37°C until ODeoo of ~0.7, placed at 4°C for 30 minutes, and induced with addition of 0.5 mM IPTG (isopropyl 13-D-l-thiogalactopyranoside). Cultures were incubated for 18 hours at 20°C with shaking at 180 rpm. Cells were harvested by centrifugation for 45 minutes at 4,000 rpm. Cells were resuspended and lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 20 mM imidazole, 1 mM TCEP [tris(2-carboxyethyl)phosphine], 5 mM MgCh, 1 mM PMSF, EDTA-free protease inhibitor [Roche]), 1.2 mg / mL lysozyme (L6876, Sigma) and Benzonase® Nuclease (Merck; E1014-5KU) for 45 minutes at 4°C. Cells were additionally lysed by sonication and clarified by centrifugation at 12,000 rpm for 60 min. Resulting 6xHis- SUMO-CbAgo protein was then applied onto the Ni-NTA column (HisTrapa HP, 5 mL GE Healthcare) and affinity chromatography was performed using AKTA Pure (GE Healthcare). Sample was washed with buffer A (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 20 mM imidazole, 1 mM TCEP) to remove unbound proteins and 6xHis-SUMO-CbAgo was eluted using buffer B (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 300 mM imidazole and 1 mM TCEP). Next, 6xHis-SUMO tag was removed by the overnight SUMO protease treatment in dialysis buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, and 5% glycerol) and applied once again onto Ni- NTA column. Tag-free protein was collected and exchanged into low salt buffer (50 mM Tris- HCl pH 7.5, 100 mM NaCl, 1 mM TCEP) and applied to cation exchange column (HiTrap® SP HP, 5 mL GE Healthcare), washed with low salt buffer and subsequently eluted with high salt buffer (50 mM Tris-HCl pH 7.5, 2M NaCl, 1 mM TCEP). Protein was collected and exchanged into size exclusion chromatography (SEC) buffer (25 mM Tris-HCl pH 7.5, 100 mM NaCl, ImM TCEP and 10% glycerol) and additionally purified by gel filtration on S200 column (GE Healthcare). Fractions containing the protein were pooled, concentrated and snap- frozen in liquid nitrogen, and stored at -80°C for downstream applications in in vitro experiments. Above protein purification protocol followed for the purification of NLS-CbAgo and NLS-CbAgo-NLS proteins (Table 1).

[0268] Table 1. Sequences of proteins used in the study

[0269] KmAgo, NLS-KmAgo, and NLS-KmAgo-NLS

[0270] KmAgo was purified from pET28a-6Xhis-HRV3C-KmAgo expression plasmid (gift from prof. Lixin Ma at Hubei University, Wuhan, China) as previously reported in Liu ¥ et al., (2021) ( FIG.8B;Table 1). Similar protein purification protocols were followed for the purification of NLS-KmAgo and NLS-KmAgo-NLS proteins (Table 1).

[0271] NLS-(dead)CbAgo-NLS and NLS-(dead)KmAgo-NLS

[0272] Gen Seri pt was custom synthesized the bacterial optimized NLS-(dead)CbAgo-NLS and

[0273] NLS-(dead)KmAgo-NLS proteins and cloned them under the 6xHis-SUMO tag sequence in pET expression vector. GenScript purified the dead versions of CbAgo and K Ago proteins ( Table 1).

[0274] Design and synthesis of different gPNA and ytcPNA molecules

[0275] Different target specific yPNA and ytcPNA molecules were designed based on the instructions from the previous reports (McNeer et al. 2015; Bahai et al. 2016; Lyu et al. 2021). All the yPNAs and ytcPNAs were y-modified with alanine molecule. All the PNA molecules employed in this study were custom synthesized by the PANAGENE company Table 2).

[0276] Table 2. PNAs (peptide nucleic acids) used in this study

[0277] Cloning of target pPNA invading regions into pMRS and pUC19 plasmids Inserts for cloning were purchased as ultramers from IDT, with overhangs corresponding to BamHI and EcoRI restriction sites in pMRS and pUC19 vectors (Table 3). All the top and bottom strands were independently phosphorylated using T4 PNK (Promega) and annealed. Plasmids were digested using BamHI-HF and EcoRI-HF in IX CutSmart buffer (NEB) for 8 hours. Phosphorylated inserts were mixed with 10 ng of digested plasmid purified from the gel in 3 : 1 molar ratio and incubated with T4 DNA Ligase (Promega) in IX T4 DNA Ligase Reaction Buffer (Promega; catalog #: Ml 801) for 3 hours at 23°C, 2 hours at 16°C and 4°C until transformation with 2 uL of the ligation reaction into E. Coli competent cells (ToplO) using heat-shock method. Transformed cells were plated on agar plates supplemented with kanamycin (pMRS) or ampicillin (pUC19). Plasmids from bacterial liquid culture were isolated using QIAprep Spin Miniprep Kit (Qiagen) and adjusted to 100 ng / mL for downstream applications. All the clones were confirmed by sanger sequencing using the primers mentioned in the Table 4.

[0278] Table 3. Oligos used for cloning target regions into pMRS or pUC19

[0279] Table 4. Primers used in the study PNA invasion and mobility shift assay

[0280] PNA invasion were performed in 10 pL reaction volume consisting of IX MOPS buffer (20 mM MOPS pH 7.0, 5 mM CH3COONa, 1 mM EDTA), 50 nM linear dsDNA target (~600bp) and 2 mM PNA. Reactions were incubated overnight at 37°C and mixed with 6X purple loading dye (NEB), and run in Novex™ 6% native TBE gel at 180V for 1 hour. Gel was stained with 1XSYBR Gold for <10 minutes and visualized using Molecular Imager Gel Doc XR+ System (BioRad). Before any experiment with PNA molecules, it is recommended to prior heat all the PNA molecules at 90°C for 20 minutes for better results. Argonaute in vitro cleavage assay of circular and linear DNA

[0281] All the circular plasmid DNA targets were linearized with desired restriction enzyme and the linear products were purified by QIAquick® Gel Extraction Kit as per the manufacturer guidelines. Prior to the pAgo protein cleavage DNA templates were incubated with the two PNA molecules for 45 minutes (for circular DNA) and overnight (for linear DNA) at 37°C for the dsDNA invasion to obtain the ssDNA. PNA invasion reaction conducted in lOpl reaction volume containing 200ng of DNA template (pMRS target; ~5.3kb), IX MOPS buffer, PNA1 (final lOOnM) and PNA2 (final lOOnM). Further, the pAgo protein mediated cleavage achieved in two steps, in the first step pAgo proteins were loaded with two different guides independently in half reaction 1 and half reaction 2 at 37°C for 15 minutes. Each half reaction contains IX final HEPES + Mn buffer (IX composition: 10 mM HEPES-NaOH pH=7.0, 100 mM NaCl, 1 mM MnCh, 5% glycerol), IpM guide (guide 1 in half reaction 1 and guide 2 in half reaction 2), I M pAgo protein, and required volume of dlLO to make up the volume of each half reaction into 16pl . In the second step after the guide loading, combine both the half reactions (8pl of each) in one tube and add 4pl of PNA invaded plasmid DNA (brings the final invaded DNA concentration to 80ng) or equal concentration (80ng) of noninvaded plasmid DNA. Total volume of the cleavage reaction will be 20pl. Incubate the cleavage reaction at 37°C for 60 minutes; lid temperature 39°C. In case of circular plasmid, add 2pl of 10X CutSmart and Ipl of appropriate restriction enzyme (10units / l pl) into the reaction and incubate at 37°C for 30 minutes. This step is not necessary for restriction enzyme linearized targets. Later, add IpL of proteinase K (Invitrogen; catalog #: 25530049) and incubate at 37°C for 30 minutes. Further, add 4pL of 6X Gel Loading Dye, Purple (NEB; catalog # B7024S) and load the sample onto 0.9% agarose gel with GelRed® for Ih and 30 minutes at 145V. Finally, visualize the gel under the FluorChemQ Gel Doc system. Conduct all the reactions setup at room temperature. This pAgo mediated DNA target cleavage protocol is same for all the cleavage experiments. However, PNA molecules, target sequences and guide sequences vary based on the type of experiment (Tables 2, 3 and 5).

[0282] Table 5. Guides used in this study pAgo cleavage site identification

[0283] For the cleavage site determination, EMXl-yPNAl / EMXl-yPNA2 binding target regions was cloned into pMRS plasmid at BamEH and EcoRI. So that the regions invaded by EMXl-yPNAl / EMXl-yPNA2 are located on the opposite strand of the primer binding site since yPNAs are known to inhibit the strand elongation. Cleavage of BsrGI linear pMRS- EMXl-yPNAl / EMXl-yPNA2 target was performed as described above and the bands were separated in 1% Agarose gel. The bands corresponding to cleavage products were excised and purified from the agarose gel using QIAquick® Gel Extraction Kit and subsequently sequenced by Sanger sequencing using the specific primers (Table 4). Cleavage sites were determined by identifying read termination sites.

[0284] Results pAgo proteins exhibit catalytic activity on PNA-invaded DNA substrates pAgo proteins lack intrinsic helicase activity, and therefore unable to unwind the DNA molecules, and expose ssDNA strands for their catalytic activity, thereby limiting their adoption in diverse biotechnological applications including genome editing. The ability of different PNA molecules to invade dsDNA in a highly specific manner prompted investigation of whether this property could be used to assist mesophilic prokaryotic Argonautes to mediate site-specific DSBs (Ishihara and Corey, 1999). Different classes of PNA molecules have been shown to efficiently invade DNA substrates, including yPNA molecules (Dragulescu-Andrasi et al., 2006). Therefore, the invasion efficiency of different yPNA molecules was tested, and the results showed that these molecules were capable of invading DNA substrates. Moreover, yPNAl and yPNA3 showed efficient DNA invasion among all (FIG. 1A-1C). Next, the engineering concept was designed based on the simultaneous use of two yPNA molecules capable of invading DNA substrates, upper and lower DNA strands, and generating ssDNA sequences available for enzymatic activity and other manipulations (FIG. ID). The formation of ssDNA molecules long enough to enable the binding of pAgo guides would enable the specific binding of pAgo proteins to these substrates and allow the catalytic activity of pAgo to cleave ssDNA substrates. The simultaneous generation of ssDNA nicks on opposing DNA strands by the two pAgo complexes will result in the generation of DSBs that can be harnessed for in vitro and in vivo diverse genome engineering applications (FIG. ID). pAgo proteins generate site-specific DSBs on DNA substrates

[0285] To test this concept, two yPNA molecules (yPNAl and yPNA3) were designed to invade into specific DNA sequences in pMRS-yPNAl / yPNA3 plasmid on opposite strands, separated by a single nucleotide spacer, to enable the generation of ssDNA sequences available for pAgo proteins activity (FIG. IE). Purified CbAgo and KmAgo proteins were expressed and used on yPNAl / yPNA3-invaded and non-invaded pMRS-yPNAl / yPNA3 plasmid substrates with single or double DNA guides at 37°C in a HEPES reaction buffer containing Magnesium 2+ (Mg 2+). The results showed that on the non-invaded pMRS-yPNAl / yPNA3 plasmid substrates, CbAgo and KmAgo proteins nicked the plasmid DNA substrates in a guide-dependent manner (FIG. IF). Intriguingly, on the yPNAl / yPNA3-invaded pMRS- yPNAl / yPNA3 plasmid DNA substrates, specific double-nicking activities in a guidedependent manner generated double-stranded breaks resulting in a release of a band with the corresponding size (Lane 7) (FIG. IF). Next, the double-nicking activity and the generation of specific DSBs on linear DNA substrates were observed. Therefore, pMRS-yPNAl / yPNA3 plasmid DNA were linearized using the BsrGI restriction enzyme and used the non-invaded and invaded linear DNA substrates for the pAgo cleavage assay. Results showed that, CbAgo and KmAgo enzymes were able to specifically bind to the yPNAl / yPNA3-invaded DNA substrates and nick the DNA molecules, double nicking, specifically resulting in the generation of a DNA band with the corresponding size (Lane 7) (FIG. 1G). Non-invaded DNA substrates did not show any DNA band release indicating the requirement of yPNA invasion and subsequent generation of ssDNA strand and the specificity of the DNA guide binding to the ssDNA to direct the activity of the pAgo enzyme (FIG. 1G).

[0286] Testing GC dependent pAgo cleavage of non-invaded circular and linear plasmids

[0287] CbAgo and KmAgo have been shown to mediate noticeable activities on plasmid DNA substrates of low GC content at physiological temperatures, indicating that strand unwinding is the limiting factor for harnessing the power of pAgo for biotechnological applications. Experiments were designed to test whether the GC content in the target sequence would affect the activity of these mesophilic pAgo proteins. The concept was tested on DNA targets of variable GC content on non-invaded DNA substrates ( GC 13, 22, 27,31, 35, 50, and 75%). The data showed that CbAgo and KmAgo exhibit catalytic activities at target sequences of low GC content. However, they do not exhibit catalytic activities at GC content of 35% or higher (FIG. 2A). For example, CbAgo exhibit catalytic activities at GC content 13 and 22% (Lanes 1-2) (FIG. 2A, upper panel). KmAgo exhibit catalytic activities at or lower than GC content of 35% (Lanes 1-4) (FIG. 2A, lower panel). However, both CbAgo and KmAgo did not show any catalytic activities on linear DNA substrate even at lower GC content (FIG. 2B). Interestingly, both CbAgo and KmAgo demonstrated robust catalytic activities at GC content of 50% or higher and on linear DNA targets, indicating that the GC content and the plasmid form are not the limiting factor in the PNP design concept which unlocked the activities of pAgo on different DNA substrates.

[0288] Effect of different yPNA combinations, different lengths of yPNAs and different types of PNAs on pAgo mediated DNA cleavage

[0289] The versatility of the PNA-assisted and pAgo-mediated activity on different DNA substrates was tested. Two additional yPNA molecules and cloned targets were designed containing yPNAl + yPNA2, yPNA3 + yPNA4, yPNA2 + yPNA4 and yPNAl + yPNA3 combinations in pUC19 vector ( FIG. 8A). pAgo cleavage reactions were performed on these targets containing different combinations of yPNA molecules. The data showed that all the yPNA combinations facilitated the pAgo-mediated site-specific generation of DSBs on circular plasmid DNA substrates, albeit with variable efficiencies that could possibly be due to variable invasion efficiencies of different yPNA molecules (Lanes 1-4) ( FIG. 8B). yPNAl + yPNA3 and yPNA3 + yPNA4 combinations are the efficient for the pAgo-mediated generation of DSBs. Intriguingly, the efficiencies of the generation of DSBs were similar between the CbAgo and KmAgo enzymes indicating that the yPNA invasion efficiency was the key variable in these assays.

[0290] The invasion efficiencies of different lengths of yPNAl / yPNA3 (10, 14, 16 and 20-nt long) were tested by pAgo cleavage using the 16-nt guides and the PNA length corresponding guides (FIGs. 9A & 9C). Linear pMRS-yPNAl / yPNA3 target were invaded with different lengths of yPNAl / yPNA3 (10, 14, 16 and 20-nt), independently. Later, cleavage of invaded pMRS-yPNAl / yPNA3 using the CbAgo and KmAgo with 16-nt guides or the yPNA length corresponding guides showed activity only on the 20-nt long yPNAl / yPNA3 invaded DNA template using the 16-nt guides and 20-nt guides (Lanes 4) ( FIGs. 9B and 9D). The shorter yPNAl / yPNA3 (10, 14 and 16-nt) with 16-nt length guides or the yPNA length corresponding guides did not show any cleavage with the CbAgo and KmAgo.

[0291] The versatility of the PNP concept was tested using the different types of PNA molecules. Here, ytcPNA (gamma tail clamp peptide nucleic acid) molecules were used to invade the DNA template and further cleave with pAgo proteins. Twp ytcPNA molecules were designed and constructed target plasmids containing complementary DNA sequences for the ytcPNA molecules. Mobility shift results showed that ytcPNAs are efficient in invading DNA templates ( FIG. 10A). Cleavage results showed an efficient cleavage of ytcPNAl / ytcPNA2 invaded DNA target in the presence of both guides using CbAgo and KmAgo proteins (Lane 7) ( FIGs. 10B and IOC). The non-invaded target did not show any cleavage activity with pAgo proteins. These results confirmed that DNA unwinding can be achieved by different types PNAs and facilitate the efficient pAgo cleavage on ssDNA template.

[0292] Multiplex PNA-assisted and pAgo-mediated site-specific DSBs on circular plasmid substrates

[0293] Next, two yPNA-pAgo complexes were used to test whether the simultaneous generation of two DSBs is possible on circular plasmid DNA substrates. A pMRS multiplexing target plasmid containing yPNAl / yPNA3 and EMXl-yPNAl / EMXl-yPNA2 binding regions was constructed (FIG. 3A). The multiplexing activities were tested using CbAgo and KmAgo and different guide combinations on non-invaded and four yPNAs invaded circular plasmid DNA. The simultaneous yPNAs invasion and two different regions in pMRS multiplexing target and pAgo activity on displaced ssDNA would lead to the generation of two DSBs releasing the 820bp GFP fragment out from the pMRS multiplexing plasmid. The results showed that 4 yPNAs invaded DNA substrate with four corresponding pAgo (CbAgo and KmAgo)-DNA guide complexes released 820bp precise DNA fragment (Lane 5) ( FIG. 3B). The non-invaded DNA template did not show any fragment release ( FIG. 3B).

[0294] Effect of spacer and guide orientation on PNA-pAgo mediated DNA cleavage

[0295] The concept depends on the PNA invasion of two DNA sequences on the opposing strands in the double-stranded DNA molecule leading to displacing of two strands and the formation of ssDNA sequences on opposing strands of the DNA to serve as sub states of the pAgo-guide DNA complexes (guides facing inward and outward) proteins ( FIGs. 4A and 4B) The spacer length between the two yPNA invaded strands and the orientation of two guides (5’ to 3’ ends facing inward and outward) are key in the designs of efficient PNA-pAgo complexes ( FIG. 4C). The effect of different spacer lengths between the two yPNA sequences and the two guides orientations on the catalytic activities of CbAgo and the KmAgo proteins were tested. Different spacer lengths starting from 1-nt to 30-nt (1, 3, 5, 6, 10, 15, 20, and 30- nt) in targets containing outward guide orientation and inward guide orientation were tested. The invasion and cleavage reactions were performed on all the spacer targets in both guide facing orientations ( FIGs. 4D and 4E). Intriguingly, CbAgo was active at broader spacer lengths with comparable efficacies and higher efficiency at spacers of 10-nt, when the guides facing outward (Lanes 1-5) (FIG. 4D, upper panel). CbAgo activity was gradually decreased from 1-nt spacer to 10-nt spacer, when the guides facing inward (Lanes 1-5) ( FIG. 4E, upper panel). However, the target plasmids with spacer lengths of 15-nt and higher in outward and inward orientations did not show any cleavage activity (FIGs.4D and 4E, upper panel). On the other hand, the KmAgo showed better cleavage efficiencies at a shorter spacer length; the optimum spacer length is 1-nt and the activity decreases to a spacer length of 10-nt and no activity with greater than 10-nt spacer length targets (FIG. 4D and 4E, lower panels). KmAgo activity on different spacer lengths was independent of the guides orientation. pAgo guide requirements to mediate efficient generation ofDSBs pAgo proteins were shown to use 5 ’-phosphorylated guide DNA molecules to direct their activity in vitro and in vivo. Here, it was tested whether the 5’ modification of the guide DNA molecules would affect the activity of the pAgo proteins on their PNA-invaded DNA substrates. Cleavage reactions were performed on invaded and non-invaded linear DNA substrates using different types of guide molecules. 5 ’-hydroxylated DNA guides (5’-OH DNA guides), phosphorothioated guides (PT-guides), 5 ’-phosphorylated RNA guides (RNA guides), and 5 ’-phosphorylated DNA guides (5’P-DNA guides) were used to load pAgo proteins, and their catalytic activities on linearized pMRS-yPNAl / yPNA3 plasmid invaded with yPNAl and yPNA3 were tested. The data showed that different 5’ modifications on the guide DNA mediated cleavage activities with CbAgo and KmAgo. However, 5’P-DNA guides and PT- guides resulted in better efficiencies compared to 5 ’-OH DNA guides and RNA guides with CbAgo and KmAgo (Lanes 7 and 9) (FIG. 5A). These results indicated that 5’P-DNA guides are superior in bringing about high levels of cleavage activities. Non-invaded DNA substrates did not show any cleavage activities, indicating the need for PNA-invasion for strand displacement and formation of ssDNA for pAgo activity. pAgo guide DNA length is a key factor in mediating robust catalytic activity. Subsequently, the optimal guide DNA length for the CbAgo and KmAgo mediated cleavage of PNA-invaded DNA substrates were determined. Variable guide lengths were used starting from 10-nt to 20-nt long guides and the catalytic activity assays on linear yPNAl / yPNA3 invaded DNA substrates were performed. The data showed that the guide length of 16-nt is optimal for the CbAgo and KmAgo catalytic activities resulting in the generation ofDSBs as evidenced by the band generated with the corresponding size (Lane 4) (5B). Interestingly, KmAgo demonstrated the robust catalytic activities with the guide lengths of 14, 16, and 18-nt (Lanes 3-5) (FIG. 5B, lower panel). Guide binding region specificities for robust pAgo cleavage

[0296] In order to test the guide specificities on the invaded DNA template, different strands (yPNA bound ssDNA and free ssDNA) and regions (non-invaded flanking regions) of the yPNAl / yPNA3 invaded pUC19-yPNAl / yPNA3 DNA target were targeted ( FIG. 11A). The results showed that, guides targeting the yPNA bound ssDNA and non-invaded flanking regions failed to show cleavage with pAgos. Whereas the CbAgo and KmAgo showed cleavage only when the guides targeting the free ssDNA of the yPNA invaded target (Lane 9) ( FIG. 11B)

[0297] Guide binding regions in the yPNA invaded DNA is important to broaden the guide designing possibilities and to find the efficient guides for the robust pAgo cleavage. To test this, guides that can target different regions in the ssDNA and also the regions spanning the ssDNA and dsDNA flanking regions outward and inward were designed. Flanking lengths of outward guide binding are represented as 0 to 20-nt, based on the guide binding region to the pMRS-yPNAl / yPNA3-l-nt spacer target ( FIG. 12A). Flanking lengths of inward guide binding were represented as 0 to 10-nt based on the guide binding region in the pMRS- yPNAl / yPNA3-10-nt spacer target ( FIG. 13A). Experiment with guides targeting the ssDNA and dsDNA flanking regions outwards showed that the CbAgo and KmAgo proteins were catalytically active until with the 11-nt flanking guides (Lanes 1-12) ( FIG. 12B). The pAgo proteins with the guides targeting greater than the 11-nt outward flanking region were catalytically not active (Lanes 13-20) ( FIG. 12B). Likewise, the experiment with guides targeting the ssDNA and dsDNA flanking regions inwards on pMRS- yPNA l / yPNA3- 10-nt spacer target showed that the CbAgo is active with guides targeting until 10-nt inward flanking region (Lanes 1-11) ( FIG. 13B, upper panel). The KmAgo was active with guides targeting until 8-nt inward flanking guides (Lanes 1-9) ( FIG. 13B, lower panel). This experiment revealed that pAgo proteins are catalytically active even the guides targeting ssDNA and certain length of flanking dsDNA in outward and inward regions.

[0298] Efficient pPNA-invasion and precision pAgo cleavage activities at different temperatures

[0299] Robust yPNA invasion and catalytic activity of the pAgo proteins at physiological temperatures are required to harness the power of this concept for genome editing and other biotechnological applications. This concept was tested on EMXl-yPNAl / EMXl-yPNA2 invaded and BsrGI linearized pMRS-EMXl-yPNAl / EMXl-yPNA2 target plasmid. EMX1- yPNAl / EMXl-yPNA2 invasions were performed at 37°C and the catalytic activities of the CbAgo and KmAgo proteins at different temperatures from 20°C to 45°C were tested. Intriguingly, both proteins mediated robust catalytic activities at different temperatures and at physiological temperatures (FIG. 6A). However, CbAgo demonstrated catalytic activities at all tested temperature but showed better activities at 30°C and higher (FIG. 6A, upper panel). KmAgo showed robust catalytic at all temperatures tested (FIG. 6A, lower panel).

[0300] PNA-invasion is a prerequisite for the pAgo activity and it is of high importance to show that yPNA invasion occurs at physiological temperatures. EMX1 -yPNAl / EMX 1 -yPNA2 invasion was performed at different temperatures (20, 25, 30, 35, 40, and 45°C) and the pAgo catalytic activity assays were conducted at 37°C. The data showed that efficient yPNA invasion occurs at greater than 25°C mediating robust CbAgo and KmAgo catalytic activities (FIG. 6B, upper and lower panels). Subsequently, both EMXl-yPNAl / EMXl-yPNA2 invasion and pAgo catalytic activity at different temperatures (20, 25, 30, 35, 40, and 45°C) were tested. The data showed that yPNA invasion and pAgo catalytic activities were efficient at 30°C or higher temperatures (Figure 6C, upper and lower panels). PNA invaded DNA target cleavage and determination of pAgo cleavage site

[0301] Previous studies have shown that pAgo proteins cleave at the canonical nucleotide 10- 11 complementary to the guide and tolerate some guide mismatches. Because the precision of the cleavage is important to harness this concept for genome engineering and other gene editing applications, the specific cleavage site was determined. Therefore, it was tested whether the CbAgo and KmAgo proteins cleave at the canonical 10-11 nucleotide of the DNA substrates (Yang Liu et al. 2021; Kuzmenko et al. 2019). EMXl-yPNAl / EMXl-yPNA2 invaded and BsrGI linearized pMRS-EMXl-yPNAl / EMXl-yPNA2 target for the cleavage site determination were used (FIG. 6D). Catalytic assays were performed on yPNA invaded DNA substrates, the released bands were gel purified, and these bands were sequences via Sanger sequencing. The results showed that both proteins cut the displaced DNA strand of the PNA- invaded DNA substrates between nucleotide 10 and 11 complementary to the guide DNA sequence of the pAgo proteins. These data show that the PNA invasion did not affect the precision of the pAgo cutting of the ssDNA and the concept could be harnessed to generate site-specific DSBs with staggered ends (FIG. 6E).

[0302] The effect of guide DNA mismatches on the activity of pAgo proteins

[0303] The DNA guide strands can be divided into different sections facilitating target recognition and the subsequent catalytic activity of the pAgo proteins. The first nucleotide at the 5’ end is the anchoring nucleotide and binds to the MID domain binding pocket. Next is the seed region composed of the 8 bases from the 5 ’end of the guide, which mediate target recognition and are stabilized by the C-terminal lobe and the linker between the two lobes. The central part and the 3’end bind to the PAZ domain. It was tested whether mismatches in these specific regions would disrupt the pAgo binding and thereby compromise the catalytic activity on the PNA-invaded DNA substrates. Perfect complementarity may be required to facilitate robust cleavage of the DNA substrate by pAgo. Several reports have shown that mismatches between the guide and the target molecules, especially in the seed region, may compromise the binding of the catalytic activity of the pAgo, mismatches at the cleavage site abolish the catalytic activity. Therefore, the impact of single and double nucleotide mutations in different parts of the guide molecule were tested, including anchor, seed, central, supplementary and tail regions (FIGs. 7A and 7B). The data showed that single nucleotide mutations were tolerated at different parts of the guide DNA sequence (FIG. 7C). However, double nucleotide mutations were not tolerated and compromised the activity of the pAgo proteins. The data showed that the central region is the most sensitive, with double mutations exerting more effect on the catalytic activity of the pAgo proteins (FIG. 7C). Besides, KmAgo catalytical activity was completely abolished with the double mutations in the central region of the guide (Lane 7) (FIG. 7C, lower panel).

[0304] Additionally, to see the maximum guide mismatch that can abolish the pAgo cleavage activity, more guide mismatches (2, 3, 4-nt) were tested at different regions (anchor, seed, central, supplementary, and tail) ( FIG. 14A). Some of the mismatches overlapped between the different regions. The results showed that CbAgo and KmAgo proteins tolerated 3-nt guide mismatches at anchor, seed regions compared to the supplementary and tail region 3-nt guide mismatches ( FIG. 14B). The cleavage activity with 3-nt guide mismatches at central region was partially tolerated by CbAgo and completely abolished using KmAgo. Furthermore, CbAgo cleavage activity was completely abolished with the 4-nt guide mismatches at all the regions. Interestingly, KmAgo even tolerated 4-nt mismatches at the anchor, seed regions and did not show any cleavage with 4-nt mismatches at the central, supplementary, and tail ( FIG. 14B)

[0305] DNA template mismatch to pPNA molecules and the pAgo cleavage tolerance assay The design concept relies on the use of PNA to mediate the double invasion of two opposing strands of DNA substrates leading to the formation of ssDNA sequences available for pAgo activity. The effect of yPNA mismatch tolerance on the activity of pAgo on DNA substrates was tested. Mismatches were introduced on DNA substrates corresponding to the 3’, 5’, and central, non-consecutive regions of the yPNA sequence, and their impact on the activity of CbAgo and KmAgo proteins were tested using mismatch specific guides and partial specific guides (FIG. 15A and 16A). yPNA 3’ mutations were introduced by using 1, 2, 3, 4, 5, 7, 9, and 11-nt mutations in the DNA substrates. The data showed that using mismatch specific guides, 1-3, and 5-nt mutations at the 3’ end of the yPNA were tolerated by the pAgo activity and the and 4, 7-11-nt mutations abrogated the pAgo activity (Lanes 1-8) ( FIG. 15B). Introducing 1, 2, 3, 4, 5, 7, 9, and 11-nt mutations at the 5’ end of the yPNA compromised the pAgo activity in 1 to 7 -nt mutations on DNA substrates with mismatch specific guides (Lanes 17-22) ( FIG. 15B). 1, 2, 3, and 4-nt mutations were introduced at the central region of the yPNA binding DNA sequence; only 1-nt mutations were tolerated by CbAgo, 2-4nt mutated targets did not show any cleavage using mismatch specific guides (Lanes 9-12) ( FIG. 15B, upper panel). Whereas, l-3nt central region mutations were tolerated by KmAgo and 4-nt central mutations abrogated the KmAgo catalytic activity using mismatch specific guides (Lanes 9-12) ( FIG. 15B, lower panel). Also tested were 2, 4, 6, and 8-nt non-consecutive mutations in the DNA template. The data showed that all the non-consecutive mutations abrogated the CbAgo cleavage activity. Besides, 2-nt non-consecutive mutation is tolerated by KmAgo and the 4-8-nt non-consecutive mutations did not show any cleavage with the mismatch specific guides (Lanes 13-16) ( FIG. 15B). These data indicate that the central and non-consecutive PNA region serves as and constitute a seed region that this sensitive to mismatches.

[0306] In the second set of experiments, cleavage assays were performed using PNA molecules with mismatches at the 3’, 5’, and central regions but with the use of gDNA that is not complementary to the DNA substrates ( FIG. 16B). The data showed that mismatches in the PNA regions and corresponding gDNA molecules compromised the activity of the CbAgo and KmAgo proteins on DNA substrates. The data indicate that PNA molecules capable of invasion of DNA substrates may tolerate some mismatches, specifically at the 5’ region of the PNA molecules. The PNA length that is sufficient to invade the DNA is the most essential prerequisite for the displacement of one strand and the formation of ssDNA strand to serve as a substrate for the pAgo activity.

[0307] Activity assay ofNLS fused pAgo proteins and pAgo variants

[0308] Activity analysis of SV40-NLS fused pAgo proteins is crucial for the in vivo studies Different versions of CbAgo (NLS-CbAgo, NLS-CbAgo-NLS, and NLS-(dead) CbAgo-NLS) and KmAgo (NLS-KmAgo, NLS-KmAgo-NLS, and NLS-(dead) KmAgo) were purified. The catalytical activities of all these proteins were tested, together with the native CbAgo and KmAgo on the EMXl-yPNAl / EMXl-yPNA2 invaded linear pMRS target. The results showed that the N-terminus and N- / C-terminus NLS fused CbAgo and KmAgo, and were catalytically active on yPNA invaded DNA template similar as native CbAgo and KmAgo (Lanes 1, 3, and 5) ( FIG. 17A). However, the dead versions of CbAgo and KmAgo are catalytically inactive (Lane 7) ( FIGs. 17A and 17Bs).

[0309] Discussion

[0310] The genome editing field has benefited from different technologies harnessing natural molecular mechanisms combined with bioengineering innovations. These technologies have their pros and cons, and there is still a massive gap in the translational potential of these genome engineering reagents due to challenges in cargo delivery, specificity, toxicity, and immunogenicity. Here, modified PNP editors were introduced, a new platform that combines the targeted DNA strand invasion ability of PNA molecules with the DNA-guided programmability of pAgos to enable programable generation of site-specific DSBs. The inability of pAgos to mediate dsDNA breaks on linear DNA at arbitrary GC content and physiological temperatures is attributed to the lack of an intrinsic helicase activity (Vaiskunaite et al. 2022). The application of various pAgos has so far been limited to manipulation of ssDNA, circular (supercoiled) dsDNA with low GC content, cleavage of circular dsDNA at elevated non-physiological temperatures, and to enhance recombination in vivo in bacterial cells (Yang Liu et al. 2021; Kuzmenko et al. 2020). An objective of the current study was to unlock the potential of pAgos for in vitro and in vivo applications, including genome editing. The pAgo activity at physiological temperatures is a prerequisite for the applications of these proteins for genome editing and other in vivo applications. Several studies have identified and used different pAgo from mesophilic bacteria and found these to be active at a broad range of temperatures from 20 to 60°C. For example, CbAgo, KmAgo, RsAgo, SeAgo, and LrAgo proteins have been identified and characterized (Kuzmenko et al. 2019; Hegge et al. 2019; Kropocheva et al. 2021; Yang Liu et al. 2021; Vaiskunaite et al. 2022). The activity of pAgo enzymes at physiological temperatures and on DNA sequences with high GC ratios disclosed here unlocks the potential of these proteins for in vitro and in vivo genome editing applications. The current study addressed the DNA strand unwinding challenge and employed PNA molecules for targeted invasion of DNA substrates, enabling the use of pAgo proteins for precision editing applications whereby sticky end cutting could be engineered in the genome. Because DNA guides can be efficiently synthesized and used for preloading the pAgo protein, this will facilitate the targeting of any genome sequences.

[0311] In the present study, the application of the PNA molecules was coupled for targeted DNA invasion to generate a displaced ssDNA sequence that can be used as a substrate for the pAgo proteins for programmable DNA binding and cleavage. Because the PNA-invaded substrates possess the localized unwinding of the DNA, it was tested whether the catalytic activities of KmAgo and CbAgo depend on the GC ratio of the PNA invaded DNA substrates. Catalytic assays were conducted using these proteins with DNA guides targeting different sites, with variable GC ratios, on different PNA invaded DNA substrates. The data showed that both proteins were capable of targeting DNA substrates irrespective of the GC content overcoming a major limitation in harnessing the power of the pAgos in genome editing. The length and types of PNA molecules were important to test. It was demonstrated that PNA lengths greater than the guide lengths provide better pAgo cleavage activities. Also, yPNA and ytcPNA molecules can efficiently invade the target DNA and showed similar pAgo catalytical activities. It was shown that the 1 to 10-nt spacer lengths between the two PNA invasions are optimal to facilitate the efficient pAgo target cleavage, this assay helps further in designing the ideal in vivo targets to achieve better editing efficiencies. One major limitation is the activity of pAgos at physiological temperatures. The present data showed that both PNA molecules and pAgo proteins are active at physiological temperatures, indicating the potential of their use for in vivo applications in genome editing. The specificity of the nicking on the two strands and the cut site of PNA invaded DNA substrates were determined. In accordance to previous data, it was shown that both proteins tested cut the ssDNA at the 10 and 11-nt complementary to the guide sequence. The in vitro data showed that some PNA mismatches could still be capable of DNA invasion.

[0312] The in vitro target and PNA specificity assays showed that target mismatches at the 3’ end (up to 3-nt), 5’ end (up to 7-nt) middle region (up to 3-nt) of the PNA and non-consecutive mismatches (up to 1-nt) are cleaved by pAgos. This showed that PNA molecules can invade somewhat non-specific target. However, the non-specific PNA invasion and cleavage activity can be overcome by using the target specific guides. Guide binding region in the PNA invaded DNA substrate plays important role for designing better guides and to target wider regions in the PNA invaded DNA targets. The assays showed that the pAgo proteins are catalytically active, even when the guides binding to the 11-nt flanking DNA outward and 8-nt flanking DNA inward. Further, guide mismatch assays revealed that 1-nt mismatches in the guide DNA are tolerated at multiple positions of the guide. However, the 2-nt mismatches in the central region are not tolerated. Moreover, increased number of mismatches (3 to 4-nt) in the guide

[0313] DNA at different regions abolished the pAgo activity. These mismatches may affect target positioning and result in a cut at a non-canonical site. Two different pAgo proteins and their

[0314] NLS fused versions were tested; all of these pAgo proteins mediated targeted cleavage of the PNA-invaded DNA substrates indicating the versatility of the technology. These data indicate the broad targetability and the promise of these proteins to target DNA substrates regardless of the GC ratio on PNA-invaded substrates.

[0315] Appendix of Additional Sequences

[0316] Expression vectors for pAgo purification used in this study

[0317] CbAgo-Twin-Strep-SUMO tttcctgtttggtcactgatgcctccgtgtaagggggatttctgttcatgggggtaatgataccgatgaaacgagagaggatgctcacgata cgggttactgatgatgaacatgcccggttactggaacgttgtgagggtaaacaactggcggtatggatgcggcgggaccagagaaaaa tcactcagggtcaatgccagcgcttcgttaatacagatgtaggtgttccacagggtagccagcagcatcctgcgatgcagatccggaaca taatggtgcagggcgctgacttccgcgtttccagactttacgaaacacggaaaccgaagaccattcatgttgttgctcaggtcgcagacgt tttgcagcagcagtcgcttcacgttcgctcgcgtatcggtgattcattctgctaaccagtaaggcaaccccgccagcctagccgggtcctc aacgacaggagcacgatcatgcgcacccgtggccaggacccaacgctgcccgagatgcgccgcgtgcggctgctggagatggcgg acgcgatggatatgttctgccaagggttggtttgcgcattcacagttctccgcaagaattgattggctccaattcttggagtggtgaatccgtt agcgaggtgccgccggcttccattcaggtcgaggtggcccggctccatgcaccgcgacgcaacgcggggaggcagacaaggtatag ggcggcgcctacaatccatgccaacccgttccatgtgctcgccgaggcggcataaatcgccgtgacgatcagcggtccaatgatcgaa gttaggctggtaagagccgcgagcgatccttgaagctgtccctgatggtcgtcatctacctgcctggacagcatggcctgcaacgcggg catcccgatgccgccggaagcgagaagaatcataatggggaaggccatccagcctcgcgtcgcgaacgccagcaagacgtagccca gcgcgtcggccgccatgccggcgataatggcctgcttctcgccgaaacgtttggtggcgggaccagtgacgaaggcttgagcgaggg cgtgcaagattccgaataccgcaagcgacaggccgatcatcgtcgcgctccagcgaaagcggtcctcgccgaaaatgacccagagcg ctgccggcacctgtcctacgagttgcatgataaagaagacagtcataagtgcggcgacgatagtcatgccccgcgcccaccggaagga gctgactgggttgaaggctctcaagggcatcggtcgagatcccggtgcctaatgagtgagctaacttacattaattgcgttgcgctcactg cccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgcca gggtggtttttcttttcaccagtgagacgggcaacagctgattgcccttcaccgcctggccctgagagagttgcagcaagcggtccacgc tggtttgccccagcaggcgaaaatcctgtttgatggtggttaacggcgggatataacatgagctgtcttcggtatcgtcgtatcccactacc gagatatccgcaccaacgcgcagcccggactcggtaatggcgcgcattgcgcccagcgccatctgatcgttggcaaccagcatcgca gtgggaacgatgccctcattcagcatttgcatggtttgttgaaaaccggacatggcactccagtcgccttcccgttccgctatcggctgaat ttgattgcgagtgagatatttatgccagccagccagacgcagacgcgccgagacagaacttaatgggcccgctaacagcgcgatttgct ggtgacccaatgcgaccagatgctccacgcccagtcgcgtaccgtcttcatgggagaaaataatactgttgatgggtgtctggtcagaga catcaagaaataacgccggaacattagtgcaggcagcttccacagcaatggcatcctggtcatccagcggatagttaatgatcagccca ctgacgcgttgcgcgagaagattgtgcaccgccgctttacaggcttcgacgccgcttcgttctaccatcgacaccaccacgctggcaccc agttgatcggcgcgagatttaatcgccgcgacaatttgcgacggcgcgtgcagggccagactggaggtggcaacgccaatcagcaac gactgtttgcccgccagttgttgtgccacgcggttgggaatgtaattcagctccgccatcgccgcttccactttttcccgcgttttcgcagaa acgtggctggcctggttcaccacgcgggaaacggtctgataagagacaccggcatactctgcgacatcgtataacgttactggtttcaca ttcaccaccctgaattgactctcttccgggcgctatcatgccataccgcgaaaggttttgcgccattcgatggtgtccgggatctcgacgct ctcccttatgcgactcctgcattaggaagcagcccagtagtaggttgaggccgttgagcaccgccgccgcaaggaatggtgcatgcaag gagatggcgcccaacagtcccccggccacggggcctgccaccatacccacgccgaaacaagcgctcatgagcccgaagtggcgag cccgatcttccccatcggtgatgtcggcgatataggcgccagcaaccgcacctgtggcgccggtgatgccggccacgatgcgtccggc gtagaggatcgagatctcgatcccgcgaaattaatacgactcactataggggaattgtgagcggataacaattcccctctagaaataatttt gtttaactttaagaaggagatataccatgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatg gctagctggagccatccgcagtttgaaaaaggtggtggtagcggtggtggttcaggtggtagtgcatggtcacaccctcagtttgagaaa atgtcggactcagaagtcaatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccga tggatcttcagagatcttcttcaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggtaaggaaatg gactccttaagattcttgtacgacggtattagaatccaagctgatcagacccctgaagatttggacatggaggataacgatattattgaggct cacagagaacagattggtggatccATGAATAACCTGACTTTTGAAGCATTTGAAGGTATCGGTCA ATTAAATGAATTAAACTTCTATAAATACCGCTTGATTGGCAAAGGGCAAATTGACA ATGTACACCAAGCAATTTGGTCCGTCAAATATAAACTGCAAGCTAACAATTTCTTC AAGCCAGTTTTTGTCAAAGGTGAAATCCTGTATAGCCTGGACGAACTTAAGGTAAT TCCCGAATTTGAAAACGTTGAGGTGATCCTTGATGGCAATATCATCCTTAGCATTT CTGAGAACACCGATATTTACAAAGATGTAATCGTTTTTTACATTAACAACGCACTG AAAAACATTAAAGACATCACTAACTACCGCAAATACATCACTAAAAATACCGACG AAATCATCTGCAAGAGCATTTTGACCACCAATTTAAAATATCAATATATGAAAAGT GAGAAAGGTTTTAAACTGCAGCGTAAATTTAAAATCTCTCCAGTTGTCTTTCGTAA TGGAAAGGTTATTCTGTATTTGAATTGTAGTTCCGATTTTAGTACCGACAAAAGTA TTTATGAAATGCTGAACAATGGCCTGGACGTAGTCGGTCTTCAAGTAAAAAACCG CTGGACAAACTCAAACGGCAACATTTTTATCGAAGAAGTGTTAGACAAGAGCATT AGCGAACCAGGAACGAGTGGAAAACTGGGCCAATCTCTCATTGACTACTACATTA ATGGAAACCAAAAATATCGTGTGGAGAAATTTACTGATGAAGATAAAAAAGCCAA AGTGATCAAAGCTAAAATTAAAAACAAAACCTATAACTACATCCCGCAGGCCCTT ACTCCCGTCATCACCCGTGAATACTTGTCACACACCGATAAAAAGTTTAGCAAACA GATTGAAAACGTTATCAAAATGGACATGAACTATCGTTACCAGACCCTGAAGTCG TTTGTCGAAGATATTGGGGTCATCAAAGAACTTAACAACTTACACTTCAAAAACCA ATACTACACGAATTTTGATTTTATGGGTTTTGAAAGCGGAATCTTAGAGGAACCTG TTCTGATGGGAGCAAACGGTAAAATTAAAGACAAAAAACAGATTTTTATTAACGG TTTTTTCAAGAACCCAAAAGAAAACGTCAAATTTGGTGTGCTCTATCCCGAAGGAT GTATGGAAAACGCCCAATCAATTGCGCGTAGCATTCTTGATTTTGCAACTGCTGGT AAATACAATAAACAGGAAAATAAATACATTTCCAAAAACCTTATGAACATCGGCT TCAAACCATCTGAATGTATCTTTGAATCTTACAAGCTGGGTGACATTACTGAGTAC AAAGCGACTGCACGTAAACTGAAAGAACACGAAAAGGTTGGGTTTGTGATTGCAG TTATCCCAGATATGAATGAATCCGAAGTCGAAAATCCATACAATCCCTTTAAGAAA GTCTGGGCCAAACTTAACATCCCGAGCCAGATGATTACGCTTAAGACAACCGAAA AATTTAAAAACATCGTGGACAAAAGTGGACTTTACTATTTGCATAATATTGCTTTG AATATCCTGGGTAAAATTGGAGGTATCCCGTGGATTATTAAAGACATGCCAGGTA ATATCGACTGTTTCATTGGCTTAGATGTCGGCACCCGCGAAAAAGGCATTCATTTC CCTGCGTGCTCTGTCCTGTTCGATAAATACGGCAAACTGATTAATTACTATAAACC CACAATTCCCCAATCTGGCGAAAAGATTGCAGAAACCATTCTTCAAGAAATCTTTG ATAACGTCCTGATTTCATATAAAGAGGAAAATGGCGAGTACCCGAAGAATATTGT AATTCACCGTGATGGATTCAGCCGTGAAAACATTGACTGGTATAAAGAGTATTTCG ACAAGAAAGGTATCAAATTCAACATCATCGAAGTCAAAAAAAATATCCCTGTTAA AATCGCTAAAGTTGTCGGCTCTAACATTTGCAATCCAATTAAAGGCTCCTATGTCC TGAAAAACGATAAAGCATTTATTGTAACCACCGATATTAAAGACGGCGTGGCCAG CCCTAACCCACTTAAAATTGAAAAAACGTACGGTGACGTGGAAATGAAATCCATC CTTGAACAAATCTACTCCCTGAGCCAGATTCACGTCGGTAGCACCAAAAGTCTCCG CTTACCCATTACCACTGGCTATGCTGATAAAATTTGCAAAGCAATCGAATATATTC CCCAAGGCGTTGTGGATAACCGCCTCTTCTTTCTGtgaGCggccgcactcgaggcccgaaaggaag ctgagttggctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggagg aactatatccggatatcccgcaagaggcccggcagtaccggcataaccaagcctatgcctacagcatccagggtgacggtgccgagg atgacgatgagcgcattgttagatttcatacacggtgcctgactgcgttagcaattaactgtgataaactaccgcattaaagcttatcgatga taagctgtcaaacatgagaattcttgaagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagac gtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataac cctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcc tgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaac agcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgt gttgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatctt acggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcgga ggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccata ccaaacgacgagcgtgacaccacgatgcctgcagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcc cggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgata aatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacga cggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaa gtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatccctt aacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttg caaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagag cgcagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgcta atcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcgg tcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatga gaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgaggga gcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggg gcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcc cctgattctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgag cgaggaagcggaagagcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcaatggtgcactctcagtacaatctg ctctgatgccgcatagttaagccagtatacactccgctatcgctacgtgactgggtcatggctgcgccccgacacccgccaacacccgct gacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggtttca ccgtcatcaccgaaacgcgcgaggcagctgcggtaaagctcatcagcgtggtcgtgaagcgattcacagatgtctgcctgttcatccgc gtccagctcgttgagtttctccagaagcgttaatgtctggcttctgataaagcgggccatgttaagggcggttt (SEQ ID NO:348) pET28a-6Xhis-HRV3C-KmAgo tggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgc cctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttaggg ttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggttttt cgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttat aagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattt caggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgaattaattcttag aaaaactcatcgagcatcaaatgaaactgcaatttattcatatcaggattatcaataccatatttttgaaaaagccgtttctgtaatgaaggag aaaactcaccgaggcagttccataggatggcaagatcctggtatcggtctgcgattccgactcgtccaacatcaatacaacctattaatttc ccctcgtcaaaaataaggttatcaagtgagaaatcaccatgagtgacgactgaatccggtgagaatggcaaaagtttatgcatttctttcca gacttgttcaacaggccagccattacgctcgtcatcaaaatcactcgcatcaaccaaaccgttattcattcgtgattgcgcctgagcgagac gaaatacgcgatcgctgttaaaaggacaattacaaacaggaatcgaatgcaaccggcgcaggaacactgccagcgcatcaacaatattt tcacctgaatcaggatattcttctaatacctggaatgctgttttcccggggatcgcagtggtgagtaaccatgcatcatcaggagtacggat aaaatgcttgatggtcggaagaggcataaattccgtcagccagttagtctgaccatctcatctgtaacatcattggcaacgctacctttgcc atgtttcagaaacaactctggcgcatcgggcttcccatacaatcgatagattgtcgcacctgattgcccgacattatcgcgagcccatttata cccatataaatcagcatccatgttggaatttaatcgcggcctagagcaagacgtttcccgttgaatatggctcataacaccccttgtattactg tttatgtaagcagacagttttattgttcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaa ggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaag agctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggccaccac ttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgg gttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaac gacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggt aagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccac ctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctgg ccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccgcctttgagtgagctgataccgctcg ccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggaagcggaagagcgcctgatgcggtattttctccttacgcatctgtgc ggtatttcacaccgcatatatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatacactccgctatcgctacgtga ctgggtcatggctgcgccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaa gctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgaggcagctgcggtaaagctcatcagc gtggtcgtgaagcgattcacagatgtctgcctgttcatccgcgtccagctcgttgagtttctccagaagcgttaatgtctggcttctgataaa gcgggccatgttaagggcggtttttcctgtttggtcactgatgcctccgtgtaagggggatttctgttcatgggggtaatgataccgatgaa acgagagaggatgctcacgatacgggttactgatgatgaacatgcccggttactggaacgttgtgagggtaaacaactggcggtatgga tgcggcgggaccagagaaaaatcactcagggtcaatgccagcgcttcgttaatacagatgtaggtgttccacagggtagccagcagcat cctgcgatgcagatccggaacataatggtgcagggcgctgacttccgcgtttccagactttacgaaacacggaaaccgaagaccattcat gttgttgctcaggtcgcagacgttttgcagcagcagtcgcttcacgttcgctcgcgtatcggtgattcattctgctaaccagtaaggcaacc ccgccagcctagccgggtcctcaacgacaggagcacgatcatgcgcacccgtggggccgccatgccggcgataatggcctgcttctc gccgaaacgtttggtggcgggaccagtgacgaaggcttgagcgagggcgtgcaagattccgaataccgcaagcgacaggccgatcat cgtcgcgctccagcgaaagcggtcctcgccgaaaatgacccagagcgctgccggcacctgtcctacgagttgcatgataaagaagac agtcataagtgcggcgacgatagtcatgccccgcgcccaccggaaggagctgactgggttgaaggctctcaagggcatcggtcgaga tcccggtgcctaatgagtgagctaacttacattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcatta atgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgccagggtggtttttcttttcaccagtgagacgggcaacagctga ttgcccttcaccgcctggccctgagagagttgcagcaagcggtccacgctggtttgccccagcaggcgaaaatcctgtttgatggtggtt aacggcgggatataacatgagctgtcttcggtatcgtcgtatcccactaccgagatatccgcaccaacgcgcagcccggactcggtaat ggcgcgcattgcgcccagcgccatctgatcgttggcaaccagcatcgcagtgggaacgatgccctcattcagcatttgcatggtttgttga aaaccggacatggcactccagtcgccttcccgttccgctatcggctgaatttgattgcgagtgagatatttatgccagccagccagacgca gacgcgccgagacagaacttaatgggcccgctaacagcgcgatttgctggtgacccaatgcgaccagatgctccacgcccagtcgcgt accgtcttcatgggagaaaataatactgttgatgggtgtctggtcagagacatcaagaaataacgccggaacattagtgcaggcagcttc cacagcaatggcatcctggtcatccagcggatagttaatgatcagcccactgacgcgttgcgcgagaagattgtgcaccgccgctttaca ggcttcgacgccgcttcgttctaccatcgacaccaccacgctggcacccagttgatcggcgcgagatttaatcgccgcgacaatttgcga cggcgcgtgcagggccagactggaggtggcaacgccaatcagcaacgactgtttgcccgccagttgttgtgccacgcggttgggaatg taattcagctccgccatcgccgcttccactttttcccgcgttttcgcagaaacgtggctggcctggttcaccacgcgggaaacggtctgata agagacaccggcatactctgcgacatcgtataacgttactggtttcacattcaccaccctgaattgactctcttccgggcgctatcatgccat accgcgaaaggttttgcgccattcgatggtgtccgggatctcgacgctctcccttatgcgactcctgcattaggaagcagcccagtagtag gttgaggccgttgagcaccgccgccgcaaggaatggtgcatgcaaggagatggcgcccaacagtcccccggccacggggcctgcca ccatacccacgccgaaacaagcgctcatgagcccgaagtggcgagcccgatcttccccatcggtgatgtcggcgatataggcgccag caaccgcacctgtggcgccggtgatgccggccacgatgcgtccggcgtagaggatcgagatctcgatcccgcgaaattaatacgactc actataggggaattgtgagcggataacaattcccctctagaaataattttgtttaactttaagaaggagatataccATGCATCACC ATCACCATCACACTAGTggctctttggaggtttgttccagggtccaGGTTCAGGCAGTggatcccgcatcag cgaattcatggaagcttacatcaccgagatggtgtccagagaaagagctaacgagttggaggtttacgtctacgtgttcccaagaaagca gtccgacaacaactacgagggtgtctaccacattatgagagcttggcaaagagccaacgacttgccattggcttacaaccagcacaccat catggctttctcaccagttagacacatgtgcggttacaccccaatggaaactcagaagagacacatcaacatcgactccccattcgagag agctttgttggagagactgatcaagaactccttgatcttcactgccgagagacacttgcatgctaagagagttggtcacgccttgagattga accaggttcagcaaatcaggcaggtcatcatctacgaggctatcgagttgtacgtcaacatcatcgagaacaggatctccatcggttcca cttgactcaccaatcgagtacgtctacaccctgcagtccatgattgagcagggtaagactatcagaccaggtatgagagtgtccactcc aacggtagacagcactacacttacaccgttgagaacgttgctacctacggtgttactgacagatgtcctttgttgcagacctccatctacca gtactacgtgagaagggtgctcagcacatcttgagaactttcaccagatccaccagagtcatccacgtaggaccaaagagcagagatt gtcctacgctgctaccttgttgaagccattgtgtaccttcgagactatgcagccacaggacgttttgaacgtttccaagtgcatcaagttgtc cgcctccaagagaatgaagtgcacctacagatggattcagcagtgagagcccagtacagacacttgactttcgccccaaatccattcac tatcgcccagaacggttacaagttggaccagttgtctaccccaaaggtccacttccatagagactacgctactgttgtctccggtatgaaga ccggtaagttgtacaaaggtggtaacatcaagatctccgtcctgttcgatgaggacttctacttgaagcaccacatcaccaagaaggatat ctaccaatcattgccgtcctgcagaagatcgctattgctcagggtgttaacatgaccatctccacctccactaagtccatcactggtaagtt caccgacgatttcttccaccacttcaccgaagaggttgaagccttgcaacctatcttcgctcagactactgttctggccttcatcacttctacc cacctgtccaacaagaaaaccaggtcctaccaattgctgaagcagtacttggtggtaagtgggacattgcttcccaggttatcaccgaaa agactatcgaggccttccaaaagatcctgcacaagcacggtctgaagaacttttacccaaacgacgagcagcactgcttgagagttattg acgtcttgaagaacgagtccttctactacaccgtcatgaacatcctgctgggtgtttacgttaagtccggtattcagccatggatcttggcta acactactcactccgactgcttcatcggtattgacgttctcacgagaacggtaactctgctgctggtatgatgaacgttatggttcccagg gtcacttgatccaacaggctccattgaacggtattttggccggtgaaaagatcgacgacaccttgttggccaatctgttgaagcagatgatc aaggcctaccacactcagttccagagattcccaaagcacatcactatccaccgtgacggtttttggagagaacacactgctttggtcgaga agatcatgtctcactacgagatcacctacgacatcgtcgagatcatcaaaaagccaaacagaaggatggccttcttcaactccgttgacaa cacttctccaccagacagggtactgtttaccagagaggtaacgaggctttcctgtgtgctacaaacccacagcaaaaggttggtatggct cagccaatcaagattcaccaggttaccaagaccttgccattctctcacattatcgaggacgtgtacaacctgtccttcttgcacattcacgcc atgaacaagatgagattgccagccactattcactacgctgacttgtctgctactgcttaccaacgtggtcaggttatgcctagatctggtaac cagaccaacctgccattcgtttaagtcgacctcgagcaccaccaccaccaccactgagatccggctgctaacaaagcccgaaaggaag ctgagttggctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggagg aactatatccggat (SEQ ID NO:349)

[0318] Target plasmids used in this study

[0319] Original pMRS plasmid used to clone all yPNA target regions between EcoRI and BamHI restriction sites (underlined) (5418 bp) tagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggc tgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatggg tggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatgg cccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgc ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgtttt ggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggt ctatataagcagagctggtttagtgaaccgtcagatccgcttgccaccatggcctcctccgaggacgtcatcaaggagttcatgcgcttca aggtgcgcatggagggctccgtgaacggccacgagttcgagatcgagggcgagggcgagggccgcccctacgagggcacccaga ccgccaagctgaaggtgaccaagggcggccccctgcccttcgcctgggacatcctgtcccctcagttccagtacggctccaaggccta cgtgaagcaccccgccgacatccccgactacttgaagctgtccttccccgagggcttcaagtgggagcgcgtgatgaacttcgaggac ggcggcgtggtgaccgtgacccaggactcctccctgcaggacggcgagttcatctacaaggtgaagctgcgcggcaccaacttcccct ccgacggccccgtaatgcagaagaagaccatgggctgggaggcctccaccgagcggatgtaccccgaggacggcgccctgaaggg cgagatcaagatgaggctgaagctgaaggacggcggccactacgacgccgaggtcaagaccacctacatggccaagaagcccgtgc agctgcccggcgcctacaagaccgacatcaagctggacatcacctcccacaacgaggactacaccatcgtggaacagtacgagcgcg ccgagggccgccactccaccggcgccgaattcCCGCTAGTGCGATGGCCTCATGGAAGCTTGATATC CAGCCAGGACAATTTACCgatCCATGAGGCCATCGCACTAGGGGggatccagtgagcaagggc gaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggc gagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggccTacActGgtTac TacATtAacAtaTggAgtCcaAtgTttTagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccg aaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccc tggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagcc acaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgc agctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccg ccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacg agctgtacaagtaagcggccgcgactctagatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctc cccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaa tttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttaaggcgtaaattgtaagcgttaatattttgt taaaattcgcgttaaatttttgttaaatcagctcattttttaaccaataggccgaaatcggcaaaatcccttataaatcaaaagaatagaccga gatagggttgagtgttgttccagtttggaacaagagtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccgtctatca gggcgatggcccactacgtgaaccatcaccctaatcaagttttttggggtcgaggtgccgtaaagcactaaatcggaaccctaaaggga gcccccgatttagagcttgacggggaaagccggcgaacgtggcgagaaaggaagggaagaaagcgaaaggagcgggcgctaggg cgctggcaagtgtagcggtcacgctgcgcgtaaccaccacacccgccgcgcttaatgcgccgctacagggcgcgtcaggtggcacttt tcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttc aataatattgaaaaaggaagagtcctgaggcggaaagaaccagctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccc cagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtat gcaaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattct ccgccccatggctgactaattttttttatttatgcagaggccgaggccgcctcggcctctgagctattccagaagtagtgaggaggctttttt ggaggcctaggcttttgcaaagatcgatcaagagacaggatgaggatcgtttcgcatgattgaacaagatggattgcacgcaggttctcc ggccgcttgggtggagaggctattcggctatgactgggcacaacagacaatcggctgctctgatgccgccgtgttccggctgtcagcgc aggggcgcccggttctttttgtcaagaccgacctgtccggtgccctgaatgaactgcaagacgaggcagcgcggctatcgtggctggcc acgacgggcgttccttgcgcagctgtgctcgacgttgtcactgaagcgggaagggactggctgctattgggcgaagtgccggggcag gatctcctgtcatctcaccttgctcctgccgagaaagtatccatcatggctgatgcaatgcggcggctgcatacgcttgatccggctacctg cccattcgaccaccaagcgaaacatcgcatcgagcgagcacgtactcggatggaagccggtcttgtcgatcaggatgatctggacgaa gagcatcaggggctcgcgccagccgaactgttcgccaggctcaaggcgagcatgcccgacggcgaggatctcgtcgtgacccatgg cgatgcctgcttgccgaatatcatggtggaaaatggccgcttttctggattcatcgactgtggccggctgggtgtggcggaccgctatcag gacatagcgttggctacccgtgatattgctgaagagcttggcggcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcccg attcgcagcgcatcgccttctatcgccttcttgacgagttcttctgagcgggactctggggttcgaaatgaccgaccaagcgacgcccaac ctgccatcacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttccgggacgccggctggatgatcctcca gcgcggggatctcatgctggagttcttcgcccaccctagggggaggctaactgaaacacggaaggagacaataccggaaggaaccc gcgctatgacggcaataaaaagacagaataaaacgcacggtgttgggtcgtttgttcataaacgcggggttcggtcccagggctggcac tctgtcgataccccaccgagaccccattggggccaatacgcccgcgtttcttccttttccccaccccaccccccaagttcgggtgaaggc ccagggctcgcagccaacgtcggggcggcaggccctgccatagcctcaggttactcatatatactttagattgatttaaaacttcatttttaa tttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtag aaaagatcaaaggatctcttgagatccttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgttt gccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagt taggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtc gtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagc ttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcgga caggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtc gggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttt tacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccgccatgcat (SEQ ID NO:350) pUC19 plasmid used to clone all yPNA target regions between EcoRI and BamHI restriction sites (underlined) (2686 bp)

[0320] TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTG TCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCG GGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAAT ACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCATTCGCCATTCAGGCTGCGCAACTG TTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGC AAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGA ATTCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCGTAATCATG GTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGC ATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGC CCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAG GCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTG CGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCA GGTGTATATATGCACAACTAATGGGTCGTACGCGCACCACACACGCGTCGCAACGGCAAGACAAATGCGACCCAAAGAGAAAATCCCGGATCAGACATACAAAGGGTCCCAGGCAGTGTGGTCGTGGCGGCAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTC CGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGC TCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCC CCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGA CTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTAC AGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTG CTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGT AGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTT TGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAG ATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGT ATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCT

[0321] GTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTA CCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAA TAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGT CTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGC CATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAAC GATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGAT CGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTT ACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAAT AGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCA GAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCT

[0322] GTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCA GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGG AAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCAT GAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGA AAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCA CGAGGCCCTTTCGTC (SEQ ID NO:351)

[0323] References

[0324] Anzalone, et al., 2020. Nature Biotechnology 38 (7): 824-44.

[0325] Bahai, et al. 2016. Nature Communications 7 (October): 13304.

[0326] Bahai, et al. 2013. Artificial DNA, PNA & XNA 4 (2): 49-57.

[0327] Bibikova, et al. 2001. Molecular and Cellular Biology 21 (1): 289-97.

[0328] Boch, et al. 2009. \Science 326 (5959): 1509-12.

[0329] Braun, et al. 2002. Journal of Molecular Biology 318 (2): 237-43.

[0330] Cutrona, et al. 2000. Nature Biotechnology 18 (3): 300-303.

[0331] Dragulescu-Andrasi, et al. 2006. Journal of the American Chemical Society 128 (31): 10258-67.

[0332] Economos, et al. 2020. Molecules 25 (3). https: / / doi.org / 10.3390 / molecules25030735.

[0333] Egholm, et al. 1992. “Peptide Nucleic Acids (PNA). Journal of the American Chemical Society 114 (5): 1895-97.

[0334] Faruqi, et al. 1998.” PNAS, 95 (4): 1398-1403.

[0335] Gupta, et al. 2017. Molecular Therapy. Nucleic Acids 9 (December): 111-19.

[0336] Hegge, et al. 2019. Nucleic Acids Research 47 (11): 5809-21. Ho, et al. 2021. PNAS of the United States of America 118 (45). https: / / doi.org / 10.1073 / pnas.2109175118.

[0337] Ishihara, et al. 1999. Nucleic Acids Symposium Series. https: / / doi.Org / 10.1093 / nass / 42.l.141.

[0338] Koonin, Eugene V. 2017. “Evolution of RNA- and DNA-Guided Antivirus Defense Systems in Prokaryotes and Eukaryotes: Common Ancestry vs Convergence.” Biology Direct 12 (1): 5.

[0339] Koopal, et al., Cell, 185(9): 1471-1486.el9

[0340] Kropocheva, et al. 2021. Nucleic Acids Research 49 (7): 4054-65.

[0341] Kuzmenko, et al. 2020. Nature 587 (7835): 632-37.

[0342] Kuzmenko, et al. 2019. Nucleic Acids Research 47 (11): 5822-36.

[0343] Lapinaite, et al. 2018. PNAS, 115 (13): 3368-73.

[0344] Lee, et al. 2021. Nucleic Acids Research 49 (17): 9926-37.

[0345] Lisitskaya, et al. 2018. Nature Communications 9 (1): 5165.

[0346] Liu, et al. 2021. Nucleic Acids Research 49 (3): 1597-1608.

[0347] Liu, et al. 2018. Cell Reports 24 (2): 453-62.

[0348] Lonkar, et al. 2009. Nucleic Acids Research, https: / / doi.org / 10.1093 / nar / gkp217.

[0349] Lyu, et al. 2021. Journal of the American Chemical Society 143 (26): 9724-28.

[0350] McNeer, et al. 2015. Nature Communications 6 (April): 6952.

[0351] Meister, 2013. Nature Reviews. Genetics 14 (7): 447-59.

[0352] Nielsen, 1999. Current Opinion in Biotechnology 10 (1): 71-75.

[0353] Nielsen, et al. 1999. Current Issues in Molecular Biology 1 (1-2): 89-104.

[0354] Olina, et al.. 2018. Biochemistry. Biokhimiia 83 (5): 483-97.

[0355] Ricciardi, et al. 2018. Molecules 23 (3). https: / / doi.org / 10.3390 / molecules23030632.

[0356] Shiraishi, et al. 2014. Methods in Molecular Biology 1050: 193-205.

[0357] Swarts, et al. 2014. Nature 507 (7491): 258-61.

[0358] Swarts, et al. 2014. Nature Structural & Molecular Biology 21 (9): 743-53.

[0359] Vaiskunaite, et al. 2022. Nucleic Acids Research 50 (8): 4616-29.

[0360] Wang, et al. 2016. Annual Review of Biochemistry 85 (June): 227-64.

[0361] Wang, et al. 2022. Cell Reports 41 (4): 111533.

[0362] Willkomm, et al. 2017. Nature Microbiology 2 (March): 17035. Xu, et al. 1999. “Peptide Nucleic Acid (PNA) Binding-Mediated Induction of Human y-Globin Gene Expression.” Nucleic Acids, https: / / academic.oup.com / nar / article- abstract / 27 / 13 / 2806 / 2378218.

[0363] Zheng, et al. 2022. Nucleic Acids Research 50 (13): 7529-44. It is understood that the disclosed method and compositions are not limited to the particular methodology, protocols, and reagents described as these can vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the method and compositions described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

CLAIMS1. A DNA composition comprising: a. a complex comprising: i. at least a first and a second prokaryotic Argonaute protein (pAgo) or fusion protein complex comprising a first and a second oligonucleotide guide (OG) and ii. a first and a second PNA oligomer comprising a spacer, wherein each PNA molecule can invade and unwind double stranded DNA; and b. a target nucleic acid comprising a first and a second strand, wherein the first PNA oligomer is complementary to a first target site on a first DNA strand of a double stranded DNA and the second PNA oligomer is complementary to a second target site the second strand of the double stranded DNA; and wherein the first OG is complementary the first target site on the first DNA strand of the double stranded DNA and the second OG is complementary the second target site on the second DNA strand of the double stranded DNA and wherein the optional spacer comprises 1 to 10 nt.

2. The composition of claim 1, wherein the first and second PNA oligomers bind to the target DNA via Hoogsteen hydrogen bonding.

3. The composition of claim 1 or 2, wherein the PNA wherein the PNA oligomer comprises gamma (y) modifications in the PNA residues.

4. The composition of any one of claims 1-3, wherein the first and second PNA oligomer is a yPNA or a gamma tail clamp PNA.

5. The composition any one of claims 1-4, wherein the first or second PNA oligomer comprises one or more substitutions or modifications selected from the group consisting of ethylene glycol (mpyPNA, middle), hydroxymethyl (seryPNA, right) y substitution, and miniPEG.

6. The composition of any one of claims 1-4 wherein the y modification is serine.

7. The composition of any one of claims 1-5, wherein the second Argonaute protein of fusion protein comprises a FokI domain.

8. The composition of any one of claims 1-7, wherein the first or second pAgo show at least activity at physiological temperature, and / or activity at high target GC content of over 50% and optionally, is CbAgo or KmAgo.

10. A nanoparticulate composition comprising: i. at least a first and a second Argonaute protein or fusion protein complex comprising a first and a second guide sequence and ii. a first and a second PNA oligomer optionally comprising a spacer, wherein each PNA molecule can invade and unwind double stranded DNA via Hoogsteen hydrogen bonding; wherein the first PNA oligomer is complementary to a first target site on a first DNA strand of a double stranded DNA and the second PNA oligomer is complementary to a second target site the second strand of the double stranded DNA, and wherein the first OG is complementary the first target site on the first DNA strand of the double stranded DNA and the second OG is complementary the second target site on the second DNA strand of the double stranded DNA and wherein the optional spacer comprises 1 to 10 nt.

11. The composition of claim 9, wherein the first and second PNA oligomers bind to the target DNA via Hoogsteen hydrogen bonding.

12. The composition of claim 9 or 10, wherein the PNA wherein the PNA oligomer comprises gamma (y) modifications in the PNA residues.

13. The composition of any one of claims 9-11, wherein the first and second PNA oligomer is a yPNA or a gamma tail clamp PNA.

14. The composition any one of claims 9-12, wherein the first or second PNA oligomer comprises one or more substitutions or modifications selected from the group consisting of ethylene glycol (mpyPNA, middle), hydroxymethyl (seryPNA, right) y substitution, and miniPEG.

15. The composition of any one of claims 9-13 wherein the y modification is serine.

16. The composition of any one of claims 9-14, wherein the second Argonaute protein of fusion protein comprises a FokI domain.

17. A modified cell comprising the composition of any one of claims 1-15.

18. The modified cell of claim 16, wherein the cell is selected from the group consisting of: an archaeal cell, a bacterial cell, a eukaryotic cell, a eukaryotic single-cell organism, a somatic cell, a germ cell, a stem cell, a plant cell, an algal cell, an animal cell, in invertebrate cell, a vertebrate cell, a fish cell, an amphibian cell, a bird cell, a mammalian cell, an ungulate cell, a rodent cell, a non-human primate cell, and a human cell.

19. A method comprising:(a) introducing into a target or host cells:(i) a DNA-targeting RNA / DNA, optionally, wherein the DNA-targeting RNA / DNA comprises: a first segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA; and a second segment that interacts with a site-directed DNA nuclease; and(ii) a pAgo nuclease or fusion protein thereof, or a polynucleotide encoding the same, wherein the pAgo nuclease comprises: an RNA / DNA -binding portion that interacts with the DNA-targeting RNA / DNA; and optionally, an activity portion that exhibits nuclease activity that creates a single strand break in the target DNA; wherein the site of the DNA strand break is determined by the DNA-targeting RNA / DNA and(b) optionally, transplanting the genetically modified cell into a subject.

20. The method of claim 17 wherein the contacting occurs in vitro, ex vivo, or in vivo.

21. The method of claim 18 or 19, comprising contacting the cell with the nanoparticulate composition of any one of claims 9-15.

22. The method of any one of claims 18-20, wherein the first and second PNA oligomers bind to the target DNA via Hoogsteen hydrogen bonding.

23. The method of any one of claims 18-21, wherein the PNA wherein the PNA oligomer comprises gamma (y) modifications in the PNA residues.

24. The method of any one of claims 18-22, wherein the first and second PNA oligomer is a yPNA or a gamma tail clamp PNA.

25. The method of any one of claims 18-23, wherein the first or second PNA oligomer comprises one or more substitutions or modifications selected from the group consisting of ethylene glycol (mpyPNA, middle), hydroxymethyl (seryPNA, right) y substitution, and miniPEG.

26. The method of any one of claims 18-24, wherein the y modification is serine.

27. The method of any one of claims 18-25, wherein the second Argonaute protein of fusion protein comprises a FokI domain.

28. The method of any one of claims 18-26, wherein the first or second pAgo is CbAgo or KmAgo.

29. The method of any one of claims 18-27, wherein the cell is selected from the group consisting of: an archaeal cell, a bacterial cell, a eukaryotic cell, a eukaryotic single-cellorganism, a somatic cell, a germ cell, a stem cell, a plant cell, an algal cell, an animal cell, in invertebrate cell, a vertebrate cell, a fish cell, an amphibian cell, a bird cell, a mammalian cell, an ungulate cell, a rodent cell, a non-human primate cell, and a human cell.

29. The method of claim 28, wherein the contacting occurs ex vivo, the cells are autologous cells to a subject, and the cells are administered to the subject in an effective amount.

30. The method of any one of claims 18-29 further comprising contacting the cells with an effective amount of a potentiating agent to increase the frequency of recombination of the donor oligonucleotide at a target site in the genome of the cells.

31. The compositions or methods of any one of claims 1-30, wherein the yPNA is about 20-nt, the OG is about 16-nt or about 20-nt and the pAgo is CbAgo and / or KmAgo.

32. The method of any one of claims 18-29, wherein the pAgo nuclease or fusion protein thereof is transcribed from a vector comprising a nucleotide sequence encoding the pAgo nuclease or fusion protein thereof.

33. The method of claim 32 the nucleotide sequence is operably linked to a control element operable in a desired cell type.

34. The method of claim 32 or 33, wherein the vector is selected from the group consisting of plasmids, cosmids, minicircles, phage, and viral vectors.

35. The method of claim 34, wherein the viral vector is selected from the group consisting of retroviral, lentiviral, adenoviral, adeno-associated, and herpes simplex virus vectors.

Citation Information

Patent Citations

  • Encapsulated emulsions and processes for their preparation

    GB929401A

  • A process for the production of encapsulated material

    GB929406A

  • Methods of treatment with drug loaded polymeric materials

    US20090239789A1

  • Targeted and high density drug loaded polymeric materials

    US20090269397A1

  • Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles

    US20100151436A1